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The etiology of autism spectrum disorder (ASD) remains largely undiscovered. Common genetic 
variants are increasingly being realized, but the functional biology implicated by these SNPs has 
yet to be elucidated. Integrating epigenetic data, particularly DNA methylation (DNAm), with 
ASD SNP data is warranted, given its success in schizophrenia and bipolar disorder and the 
evidence for an epigenetic basis to ASD. Given that DNAm is tissue-specific, it is of interest to 
consider DNAm from brain, the main tissue of interest for ASD, and peripheral tissues 
simultaneously so that SNP and CpG-based insights can be compared across tissues. One 
peripheral tissue, the placenta, is understudied in an ASD context, despite being the critical organ 
regulating the gestational period, a key window of interest for ASD etiology. Given this role, the 
placenta also “programs” early and later life phenotypes, and sex-biased ratios in many 
phenotypes, including ASD, may be driven by sex-specific placenta functions. In Chapter 1, we 
first describe the current literature on ASD etiology, and then review placenta structure and 
function, role in fetal brain development, and known differences by fetal sex. Next we use 
DNAm data across tissues in conjunction with paired genotype data to find that, across blood and 
brain, ASD-associated SNPs are enriched for methylation quantitative trait loci (meQTLs), or 
SNPs that are associated with DNAm, and that the DNAm sites controlled by ASD-related SNPs 
are engaged in immune response pathways (Chapter 2). We then focus on studies of the 
placenta, first demonstrating the additional enrichment of ASD-associated SNPs with placenta 
meQTLs (Chapter 3), and conducting queries for differentially methylated regions (DMRs) and 
global methylation differences related to ASD (Chapter 4). Finally, we discover a genome-wide 
significant DMR for fetal sex in placenta near ZNF300. DNAm levels in this region are related to 
placenta morphology, demonstrating a mechanism by which sex-specific placenta structure, and 





contributes to our understanding of how epigenetics mechanisms, particularly acting in 
conjunction with genetic variation, contributes to understanding of ASD etiology across tissues, 
and govern placental functions to create sex-specific gestational environments. 
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CHAPTER 1: INTRODUCTION 
1.1 Autism spectrum disorder 
1.1.1  Definition 
Autism spectrum disorder (ASD) is characterized by social, behavioral, and communication 
deficits and, as of 2012, it affects 1 in 68 children in the US. Estimated prevalence is higher in 
males (23.6 per 1,000 individuals) than females (5.3 per 1,000 individuals) (Christensen et al., 
2016). There is also a high degree of phenotypic heterogeneity in ASD, underscored by various 
comorbid conditions relating to intellectual development, language ability, and attention deficit 
hyperactivity disorder, among other traits (Gillberg & Fernell, 2014). 
Prevalence for ASD has increased rapidly worldwide in recent decades, though the most recent 
estimate provided by the Autism and Developmental Disabilities Monitoring Network remained 
the same from the estimate of two years prior (Christensen et al., 2016). A recent Danish-registry 
based study attempted to find the attributable fraction of this prevalence increase to improved 
diagnosis and reporting practices vs. etiologic factors. This study concluded that the majority 
(60%) of the increase in reported ASD prevalence can be attributed to both changing in 
diagnostic criteria and the inclusion of outpatient controls (Hansen, Schendel, & Parner, 2015). 
Thus, a substantial fraction of the ASD prevalence increase in not explained by secular and 
diagnostic trends and likely represents a true increase in the disease prevalence. Studies are 
needed to understand the etiology of ASD and identify risk factors that can be intervened on to 
reduce the burden of disease. 
1.1.2  ASD heritability estimates 
Early estimates of ASD from twin or family-based studies have varied greatly, ranging from 





Rijsdijk, 2016). A recent Swedish registry-based analysis sought to determine the relative 
contribution of common and rare genetic variation to overall liability. They estimated the SNP-
based heritability, or that due to common variation at roughly 49%, and a total genetic 
contribution (i.e. including rare inherited and de novo variants, and non-additive genetic factors) 
of about 60% (Gaugler et al., 2014), thus, leaving approximately 40% of ASD liability being 
attributable to environmental factors. 
1.1.3 Environmental risk factors associated with ASD 
Several demographic factors have been linked to ASD. Strong evidence indicates that advanced 
maternal and paternal age is a risk factor for ASD (Wu et al., 2017). Also, it has been 
consistently reported that there is a higher prevalence of ASD in males than females, and that 
males are particularly over-represented in higher-functioning cases. Male-female ratios of ASD 
tend to equilibrate when limiting to individuals who have comorbid intellectual disability. 
Overall, research has increasingly indicated that ascertainment biases may exaggerate the 
frequently stated 4:1 male to female ratio, but that true sexual dimorphism in ASD exists 
biologically (Halladay et al., 2015; Werling & Geschwind, 2013). It has been hypothesized that 
there exists a “female protective effect” in ASD such that females tend to accumulate a higher 
number of ASD risk factors before reaching a diagnostic threshold (Robinson, Lichtenstein, 
Anckarsäter, Happé, & Ronald, 2013). Genetic studies showing a higher burden of ASD-related 
genetic variants in females support this notion (Jacquemont et al., 2014). However, still the 
mechanism of sex differences in ASD is not completely understood. In Chapter 5, we query for 
epigenetic signatures related to sex in placenta, in an effort to understand sex differences in the 





There has also been more recent focus on the contribution of environmental factors to ASD 
etiology after recent, more rigorous, studies have shown the initial very high (~90%) heritability 
estimates were overestimates, thus supporting the notion of a stronger environmental risk 
component than initially thought (Hallmayer et al., 2011; Sandin et al., 2014). Evidence supports 
the prenatal period as a critical window of environmental exposure risk for autism (Lyall, 
Schmidt, & Hertz-Picciotto, 2014). Therefore, many maternal lifestyle factors have been 
examined for their potential role in contributing to ASD. Reduced interpregnancy interval has 
been shown to be associated with ASD (Cheslack-Postava, Liu, & Bearman, 2011). Prenatal 
vitamin intake has been associated with a decreased risk for ASD particularly if taken before or 
near conception (Schmidt et al., 2011), as has folic acid intake (Schmidt et al., 2012; Surén et al., 
2013; Wang, Li, Zhao, & Li, 2017). However, a recent study has suggested that very high 
maternal folate levels at birth are associated with a 2.5 times greater risk for ASD compared to 
folate levels at the 80th percentile, finding similar relationships with maternal Vitamin B12 levels 
and self-reported maternal multi-vitamin intake (Raghavan et al., 2018). Vitamin D and fish oil 
intake has been investigated for associations with ASD as well but no relationships have been 
identified (Lyall, Munger, O’Reilly, Santangelo, & Ascherio, 2013; Surén et al., 2013). Perhaps 
the most investigated maternal lifestyle factor is smoking, but with very mixed findings overall. 
Many studies have identified no association between maternal smoking and ASD (Kalkbrenner 
et al., 2012; H. J. Larsson et al., 2005; Lee et al., 2012; Maimburg & Vaeth, 2006; Tran et al., 
2013), with some studies also identifying no association but trends in a protective direction 
(Bilder, Pinborough-Zimmerman, Miller, & McMahon, 2009; Burstyn, Sithole, & Zwaigenbaum, 





smoking (Hultman, Sparén, & Cnattingius, 2002; Hvidtjørn et al., 2011; M. Larsson, Weiss, 
Janson, Sundell, & Bornehag, 2009; Ronald, Happé, Dworzynski, Bolton, & Plomin, 2010; 
Visser et al., 2013). Finally, a much less studied risk factor has been alcohol exposure; 2 
previous studies have reported no association with ASD (Eliasen et al., 2010; Singer et al., 2017) 
but lower maternal alcohol consumption in mothers of ASD children compared to controls has 
also been reported in two studies (Singer et al., 2017; Visser et al., 2013). 
Maternal infections and autoimmune disorders have been among the more studied risk factors for 
ASD. Several studies based in European or US populations have demonstrated an association 
between viral or bacterial maternal infection during pregnancy and increased ASD risk 
(Atladóttir et al., 2010; Lee et al., 2015; Zerbo et al., 2015). A recent meta-analysis of 15 studies 
confirmed this association and noted an enhanced risk for infections requiring hospitalization 
(Jiang et al., 2016).  Finally, a recent study in a habitually under-studied minority population of 
African ancestry demonstrated increased risk for ASD due to prenatal exposure to maternal fever 
(Brucato et al., 2017).  
In addition, many environmental chemicals have also been investigated for their roles in ASD. 
Air pollution is perhaps one of the most robust factors positively associated with ASD. This 
broad category includes metals and solvents (Kalkbrenner et al., 2010; Roberts et al., 2013; 
Windham, Zhang, Gunier, Croen, & Grether, 2006), as well as particles, ozone, and nitrous 
oxides (Becerra, Wilhelm, Olsen, Cockburn, & Ritz, 2013; Kalkbrenner et al., 2010; Volk, 
Hertz-Picciotto, Delwiche, Lurmann, & McConnell, 2011; Volk, Lurmann, Penfold, Hertz-
Picciotto, & McConnell, 2013; Windham et al., 2006).  





To date, most genetic factors associated with ASD risk have been rare de novo variants. For 
example, one landmark study utilized whole exome sequencing in more than 2,500 simplex 
families to find that de novo mutations (including both single nucleotide and copy number 
variants) account for 30% of all simplex cases and 45% of female cases of ASD, including likely 
gene disrupting (LGD) and missense events. Examination of the impact of LGD mutations on IQ 
level revealed a 5 point drop in IQ among males and a 20 point drop in IQ for recurrent LGD de 
novo mutations. Autism associated de novo mutations were also shown to be enriched in the gene 
classes of FMRP target genes, chromatin modifiers, and embryonically expressed genes (Iossifov 
et al., 2014). Studies have also demonstrated an increased burden of copy number variants 
(CNVs), including rare de novo CNVs, among individuals with autism (Sanders et al., 2015). In 
addition, a few studies have localized rare autism-associated CNVs and found the loci are also 
associated with developmental delay and schizophrenia (Sanders et al., 2015). Despite the 
differing locations and specific rare variants associated with ASD, the findings have been shown 
to converge on three biological pathways: Wnt signaling, chromatin remodeling, and synaptic 
function (Krumm, O’Roak, Shendure, & Eichler, 2014; Pinto et al., 2014).  
As samples sizes for autism genome-wide association studies (GWAS) are starting to approach 
the numbers needed to achieve genome-wide significance, common risk variants for autism are 
beginning to emerge. The Psychiatric Genomics Consortium AUT workgroup has spearheaded 
the largest GWAS of autism to date. The first wave of results from the PGC-AUT group 
included 7,387 cases and 8,567 controls; they identified one genome-wide significant locus near 
PITX3, which is known to be involved in neuronal differentiation, and CUEDC2, previously 





Genomics Consortium, 2017). These results also confirmed previous finding showing a strong 
degree of genetic correlation between ASD and schizophrenia (Cross-Disorder Group of the 
Psychiatric Genomics Consortium et al., 2013). The next wave of the PGC-AUT analysis 
included 18,381 ASD cases and 27,969 controls; five genome-wide significant loci were 
identified and results have recently been published as a preprint (Grove et al., 2017). As sample 
sizes continue to increase, more common variants as expected to be identified, as has been 
demonstrated in other psychiatric disorder GWAS (Schizophrenia Psychiatric Genome-Wide 
Association Study (GWAS) Consortium, 2011; Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2014).  
Given that common variant findings for ASD are only now emerging, the functional biology 
implicated by these variants is not well understood. Moreover, many GWAS findings in general 
are often in inter-genic and/or non-coding areas of the genome, and thus lack an obvious 
functional consequence (Schierding, Cutfield, & O’Sullivan, 2014). This dissertation aims to 
elucidate the potential functional impact of implicated ASD common variation by integrating 
ASD GWAS results with epigenetic, specifically DNA methylation, data (Chapter 2 and 
Chapter 3).  
1.2 Epigenetics and ASD 
1.2.1  Description of epigenetics 
Epigenetics is the study of reversible, mitotically heritable molecular information that does not 
include the DNA sequence itself. Epigenetic marks regulate transcription, imprinting, organismal 
development and tissue differentiation, and nuclear organization; they include histone 





easily measured and thus most well studied epigenetic mark: DNA methylation (DNAm). This 
term is used to describe the covalent addition of a methyl or hydroxymethyl group to cytosine 
bases, and is a phenomenon that primarily occurs at CG dinucleotides in the mammalian 
genome, or CpG sites. CpG islands are characterized by dense clusters of CpG sites. They tend 
to by unmethylated and to be located in gene promoters. In general, most but not all, increases in 
CpG island methylation are associated with gene silencing (Illingworth & Bird, 2009). Unlike 
promoter and CpG island regions of the genome, DNA methylation located within the body of 
genes tends to be directly related to the expression of that gene, e.g. increased methylation is 
related to increased gene expression (Lou et al., 2014). DNAm at locations proximal (roughly a 2 
Kb window) to CpG islands, known as CpG island shores, is often characterized by sites that are 
differentially methylated by tissue type and adverse health outcomes (Irizarry et al., 2009).  
1.2.2  The relevance of epigenetics in ASD etiology 
There is compelling evidence suggesting that the etiology of ASD involves epigenetic 
mechanisms. First, certain disorders that overlap with ASD phenotypically such as Rett, 
Angelman, and Fragile X syndromes all have an epigenetic basis (Budimirovic & Kaufmann, 
2011; Jedele, 2007; Mount, Charman, Hastings, Reilly, & Cass, 2003). Second, one of the major 
pathways on which rare variant findings for ASD converge is that of chromatin regulation or 
remodeling (Krumm et al., 2014; Pinto et al., 2014; Sanders et al., 2015). Most previous studies 
of ASD and epigenetic factors have examined DNAm, the most well understood and easily 
measured epigenetic mark. 
A large proportion of prior human epigenetic studies of autism have examined DNAm 





implicated various genes, such as TSAPN32/C11orf21, ZFP57, PRRT1, and SDHAP3 (C. Ladd-
Acosta et al., 2014; Nardone et al., 2014), while candidate gene approaches have found 
associations with the MeCP2, OXTR, EN-2, and SHANK3 genes (Gregory et al., 2009; James, 
Shpyleva, Melnyk, Pavliv, & Pogribny, 2013; Nagarajan, Hogart, Gwye, Martin, & LaSalle, 
2006; Zhu et al., 2014). Another recent brain-based study interrogated, on a genome-wide scale, 
another type of epigenetic mark, histone acetylation. Specifically analyzing the acetylation mark 
H3K27ac, the authors discovered large scale dysregulation of histone acetylation in the ASD 
cerebral cortex among a subset of all ASD cases they examined (Sun et al., 2016). Many studies 
on peripheral blood-based DNAm have also been conducted on a genome-wide scale – often 
using measurement platforms with less genomic coverage than used in the brain – and on a 
candidate gene scale as well. These analyses have also implicated various genes such as NFYC, 
PTPRCAP, and MBD4 (Aldinger, Plummer, & Levitt, 2013; Gregory et al., 2009; Nguyen, 
Rauch, Pfeifer, & Hu, 2010; Wong et al., 2014). A recent preprint meta-analyzed blood-based 
DNAm from neonatal and early life blood samples, allowing for the largest EWAS for ASD to 
be performed to date. No genome-wide significant loci were found, though 45 loci passed a 
suggestive threshold for significance of 5E-5. Interestingly, the authors did discover significant 
associations between increased polygenic burden for ASD and two CpG sites near an ASD 
GWAS signal (Hannon et al., 2017).  
Finally, there have been other peripheral tissues analyzed for DNAm relationships to ASD. One 
study used DNAm from buccal epithelium cells in ASD cases and controls all born to mothers at 
least 35 years of age. 15 DMRs in 14 genes were identified, many of which had been previously 





pathways (Berko et al., 2014). Another study using DNAm measured in sperm of fathers with a 
previously diagnosed ASD child identified 193 differentially methylated regions associated with 
the Autism Observational Score for Infants metric obtained at 12 months of age. These regions 
tended to cluster in genes involved in developmental processes (Feinberg et al., 2015).    
1.2.3  Framework for understanding epigenetic involvement in ASD 
There are several pathways in which epigenetic mechanisms can be associated with ASD 
(Figure 1.1). Mechanistically, epigenetics can mediate genetic and/or environmental risk factors 
associated with ASD. In addition, epigenetics can illuminate gene-environment interactions. 
Environmental insults result in epigenetic changes, which, in turn, can provide different contexts 
in which genotype effects on phenotype may differ. Conversely, genotype can create different 
epigenetic states, which can dictate or influence how an environmental insult leads to disease. 
These constructs can inform disease etiology and intervention targets. It is also possible that 
epigenetic changes are a consequence of ASD as opposed to cause. If so, understanding these 
epigenetic changes could still be useful because they can serve as biomarkers of disease, which 
can help with disease diagnosis or treatment, and identification of at risk populations (Christine 
Ladd-Acosta & Fallin, 2016).  
1.2.4 Challenges with studying epigenetics in autism: tissue availability 
While the most etiologically relevant tissue for mechanistic studies in ASD is brain tissue, we 
cannot measure brain methylation in living individuals. Therefore, analysis of this tissue type is 
limited to post-mortem samples which is not ideal because DNAm signatures to be analyzed may 
have only manifested after ASD onset (limiting etiologic inferences). Although organized efforts 





autism brain samples available at this time, further limiting our ability to examine the ASD brain 
epigenome. More accessible tissues that can be examined in a large number of living individuals 
include cord blood, placenta, saliva and buccal swabs, and peripheral blood tissues. However, it 
is unclear whether these accessible tissue sources can provide etiologically relevant results 
(Bakulski, Halladay, Hu, Mill, & Fallin, 2016). The degree to which blood can serve as a 
surrogate tissue for brain or other tissues is still being explored; while high levels of cross-tissue 
DNAm correlation at specific sites is not frequently observed, when concordance is observed, it 
is likely due to genetic influences (Davies et al., 2012; Hannon, Lunnon, Schalkwyk, & Mill, 
2015). 
This dissertation aims to understand the extent which these peripheral tissues can be used for 
DNAm studies of ASD, specifically focusing on DNAm sites that are associated with ASD-
related SNPs. We integrate ASD GWAS findings with DNAm data from fetal brain, and 
compare SNP- and CpG-based inferences to the same integration from peripheral tissue such as 
cord blood and early-life peripheral blood (Chapter 2) and placenta (Chapter 3).  
1.2.5 Challenges in studying epigenetics in autism: measurement platforms 
The advent of commercially available, affordable, high-throughput, genome-wide array 
measurements for DNA methylation, such as the Illumina HumanMethylation450 BeadChip 
(450k Array), have led to the emergence of epigenome-wide association studies (EWAS). The 
450k Array allows for the interrogation of roughly 485,000 CpG sites in the human genome, 
covering 99% of RefSeq genes and 96% of CpG islands (Bibikova et al., 2011). And, more 
recently, the next iteration of the 450k Array was released, known as the EPIC Array. This 





expands coverage to roughly 850,000 CpG sites, including more than 90% of those sites covered 
on the 450k Array. A main focus of this newer technology is the improved coverage of enhancer 
regions (Moran, Arribas, & Esteller, 2016; Pidsley et al., 2016). While array-based technologies 
continue to be necessary for methylome interrogation of epidemiologic-scale cohorts, they do 
suffer from a lack of comprehensive coverage of loci. Roughly 28 million CpG sites exist in the 
human genome; even the most comprehensive Illumina array platform only covers about 4% of 
methylation loci (Clark et al., 2012). Although the arrays are enriched for high value content and 
disease-relevant regions of the genome, it is still possible that disease-associated loci are not 
present on arrays and, thus, could be missed. An alternative methylation profiling technique 
known as whole genome bisulfite sequencing (WGBS) offers comprehensive, unbiased coverage 
of the epigenome. WGBS undoubtedly offers the greatest coverage compared to the widely used 
array technologies but is cost-prohibitive on large numbers of samples (Yong, Hsu, & Chen, 
2016). This dissertation makes use of a unique collection of WGBS placenta samples to be able 
to perform an unbiased, comprehensive query of the DNA methylome for signatures related to 
ASD diagnosis. This study offers an examination of genome wide, sequencing-based DNAm and 
ASD, which has rarely been performed previously. However, sample sizes for individual, sex-
stratified comparisons were limited. This dissertation also makes use of 450K-based DNAm 
from peripheral blood and cord blood samples to generate maps of methylation quantitative trait 
loci. While these data are inherently limited to the genomic regions queried by the 450K, they 
are produced via large numbers of samples and thus offer high confidence findings.   





Genetic control of methylation has been demonstrated both in local (cis, SNP and CpG site on 
same chromosome) and more distant (trans, SNP and CpG site on different chromosomes) 
contexts. MeQTLs share properties of expression quantitative trait loci (eQTLs), though they are 
not perfectly overlapping. In fact, while meQTLs are enriched for eQTLs, only about 10% of 
eQTL relationships are completely mediated by DNAm. This reflects the fact that while DNAm 
plays a role in gene expression, other factors such as transcription factors (TFs), chromatin state, 
and nucleosome positioning are important contributors as well (Bell et al., 2011). MeQTLs have 
been shown to be enriched in various regulatory elements of the genome such as TFBS and 
DNase hypersensitive sites, across various tissue types (Hannon et al., 2016; McClay et al., 
2015; Shi et al., 2014). Stronger SNP to CpG associations have been observed at smaller 
distances between SNP and CpG sites relative to associations at increasing distance (Hannon et 
al., 2016; Shi et al., 2014).  
Recently, several studies have illustrated the potential for meQTLs to inform etiology of bipolar 
disorder (Gamazon et al., 2013) and schizophrenia (Hannon et al., 2016; van Eijk et al., 2015). 
These studies described an integration of meQTLs with GWAS summary statistics in what can 
be described as a “genotype-first” approach and a “methylation-first approach”. In the 
“genotype-first” approach, disorder-associated SNPs are tested for their enrichment for meQTLs. 
This question aims to prove a global role for disorder-associated common variation with DNAm. 
The “methylation-first” approach undertaken by these studies is more centered on individual 
loci. The location of CpG site targets of disorder-associated SNPs can be used to expand SNP-
based loci beyond the locations identified by SNPs alone. These expanded loci can then indicate 





phenotype (Hannon et al., 2016; van Eijk et al., 2015). Given the success of these techniques in 
bipolar disorder and schizophrenia, which have well-established genetic overlap with autism 
spectrum disorder (ASD), and the emerging evidence for an epigenetic basis to ASD, integration 
of genetic and epigenetic data in an ASD context is warranted. We exploit these same 
methodologies, adding an additional “methylation-first” approach that seeks to understand the 
biological pathways enumerated by ASD SNP-controlled CpG sites. Our studies are undertaken 
across fetal brain, cord blood, peripheral childhood blood, and placenta tissues to provide cross-
tissue insights into ASD SNP-methylation relationships and etiology (Chapter 2 and Chapter 
3). 
 
1.3 The placenta 
1.3.1 General structure and function 
The placenta is a unique structure formed during pregnancy that consists of a maternal 
contribution (known as the basal plate) and a fetal contribution (chorionic plate).  The placenta 
acts as a maternal-fetal interface that allows for nutrient uptake, waste elimination, and gas 
exchange. The basal plate, derived from the endometrium, consists of a layer of epithelial cells 
and blood vessels that extend from the uterine wall. The chorionic plate, derived from the 
chorionic sac, is anchored by the umbilical cord that extends from the fetus. The umbilical cord 
contains two arteries, which take deoxygenated blood away from the fetus, and one vein which 
brings oxygenated blood towards the fetus. These blood vessels protrude towards the maternal 
side in what is known as the intervillous space, and branch out in structures known as villi (to 





spiral endometrial arteries and constantly bathe the villous structures to promote maternal-fetal 
nutrient exchange and waste elimination (Gude, Roberts, Kalionis, & King, 2004).  
The growth and maintenance of placenta function during pregnancy involves a highly dynamic 
but tightly regulated process of cellular differentiation. Placental cytotrophoblasts can be broadly 
dichotomized into those that differentiate towards the villous and the extravillous pathways. The 
placental villi contain an inner cytotrophoblasts layer and an outer syncytiotrophoblast layer, 
which is a continuous, multinucleated mass of cells that is the only actual fetal portion of the 
placenta that makes contact with maternal blood. Another group of cytotrophoblasts operate 
outside of the villous structures and serve other functions, such as the remodeling of uterine 
arteries and tunneling of the uterine wall.  
1.3.2.  The role of the placenta in fetal brain development 
The current framework linking placenta function to increased susceptibility to 
neurodevelopmental disorders involves the placenta’s role in regulating maternal-fetal 
interactions. Maternal insults such as immune activation, malnutrition, or stress, are thought to 
lead to altered placenta status in the state of cytokines, hormones and endocrine factors, and gene 
expression. These altered states then disrupt placental processes such as immune tolerance, the 
growth of the placenta, invasion into the uterine wall, and the production of neuroactive 
molecules. Finally, these affected processes result in several adverse events linked to the prenatal 
programming of disease, such as immune dysfunction, intrauterine growth restriction or 
malnutrition, hypoxia, ischemia, and altered neuronal development and circuit formation, each of 
which contribute to an increased susceptibility to neurodevelopmental disorders (Hsiao & 





There has been a wave of recent work relating placenta epigenetic features to 
neurodevelopmental outcomes, broadly. There has been one previous study specifically 
examining the ASD phenotype for distinguishing placenta DNAm profiles. This study was 
successful in identifying one autosomal differentially methylated region in DLL1 (Schroeder et 
al., 2016). Numerous other studies, most via a candidate gene approach but two via a genome-
wide approach, have investigated infant-based neurobehavioral outcomes with placenta DNAm 
(Lester & Marsit, 2018). For example, one of the genome-wide studies found 2 genome-wide 
significant loci associated with infant attention harbored in FHIT and ANKRD11. The authors 
examined 4 domains of infant behavior in addition to attention: arousal, lethargy, and quality of 
movement, finding that suggestively associated CpG sites were almost always unique to each 
outcome. However, at a gene level, 51 genes were differentially methylated (again at suggestive 
levels of significance) to some extent in all 4 outcomes; gene ontology analyses indicated that 
these genes were involved in pathways such as cellular adhesion and nervous system 
development (Paquette et al., 2016).  
In addition, altered placenta structure and/or function has also been directly linked to ASD. One 
study based in the prospective, enriched risk birth cohort Markers of Autism Risk in Babies – 
Learning Early Signs (MARBLES), demonstrated that mothers with a previous child with 
diagnosed ASD had an 8-fold greater odds of having placentas (from a subsequent pregnancy) 
with two or more trophoblast inclusions compared to control mothers (Walker et al., 2013). 
Trophoblast inclusions are a hallmark of abnormal growth, and are characterized by the typically 
inner cytotrophoblast cell layer enveloping the typically outer syncytiotrophoblast layer (Adler, 





in utero, which itself is independently linked to ASD (Mulder et al., 2004), leads to increased 
cytotrophoblast proliferation, which then in turn can lead to trophoblast inclusions (Fecteau & 
Eiler, 2001; Walker et al., 2013). The MARBLES-based study also identified mothers with ASD 
as having a 5.5-fold higher odds of having a calcified trophoblast inclusion compared to control 
mothers; calcification in trophoblast inclusions is thought to be a mark of age and impede blood 
flow (Walker et al., 2013). In addition to this study examining pregnancies subsequent to the 
ASD-affected child, similar relationships demonstrating an association between trophoblast 
inclusions and ASD have also come in directly comparing placentas from children who went on 
to develop ASD to those from control children (Anderson, Jacobs-Stannard, Chawarska, 
Volkmar, & Kliman, 2007). Another more recent study also linked various aspects of placenta 
histopathology to ASD. Specifically, acute placenta inflammation, chronic uteroplacental 
vasculitis, the fetal inflammatory response in the chorionic plate, and maternal vascular 
malperfusion pathology were all associated with placentas from children who went on to develop 
ASD compared to those from matched controls (Straughen et al., 2017). Finally, another paper 
demonstrated the utility of random forest-based classification of placenta chorionic surface 
vascular network structure to distinguish between placentas from high risk ASD pregnancies (i.e. 
those from mothers with a child previously diagnosed with ASD) and population-based controls 
(Chang et al., 2017). 
1.3.3. Differences in disease prevalence by sex and sexual dimorphism in the placenta 
It is well established that there are sex biases in phenotypes across the life course. For example, 
males are 20% more likely to have a poorer outcome in pregnancies complicated by 





2004). And later in life, males are more likely to be diagnosed with autism spectrum disorder 
(ASD) (Christensen et al., 2016), schizophrenia (Aleman, Kahn, & Selten, 2003), and 
cardiovascular outcomes (Bots, Peters, & Woodward, 2017), while females are more likely to be 
diagnosed with autoimmune disorders such as systemic lupus erythematosus, Sjogren’s 
syndrome, and rheumatoid arthritis (Ngo, Steyn, & McCombe, 2014). Moreover, it is 
increasingly appreciated that the developmental and/or gestational period is critical to the 
programming of disease late in life – the “developmental origins of health and disease” construct 
(Wadhwa, Buss, Entringer, & Swanson, 2009). The placenta is the key organ at play during fetal 
development, providing a critical interface between the mother and fetus and through regulating 
the transfer of nutrients, waste, and oxygen (Gude et al., 2004). Taken together, these notions 
suggest that there are sex-specific placental functions that can ultimately contribute to skewed 
sex ratios for adverse health outcomes early and later in life.  
Male-female differences have been demonstrated during the gestational period, particularly in 
their adaptations to adverse insults or environments (Clifton, 2010). For example, female growth 
has been shown to be reduced in the presence of mild maternal asthma; growth can be returned 
to normal levels with use of inhaled steroids, however (Murphy et al., 2003). Alternatively males 
continue normal growth in the presence of maternal asthma and only exhibit signs of affected 
growth when the asthma reaches acute levels (Murphy, Gibson, Talbot, & Clifton, 2005). 
Similarly, female fetuses in pregnancies complicated by preeclampsia have shown to exhibit 
reduced growth, while males tend to grow normally (Stark, Clifton, & Wright, 2009). Such 
findings have led to hypotheses regarding the differential nature of responses to perturbations 





insult, leaving less reserve capacity to handle an additional adverse event. In contrast, females 
reduce growth in the presence of a poor intrauterine environment, allowing for increased ability 
to address further adverse events (Clifton, 2010).  It is also postulated that females tend to be 
more at risk for adverse outcomes when perturbations occur in the peri-conception or early 
gestational periods, affecting trophoblast differentiation. In contrast, male fetuses are more 
vulnerable in mid-to late gestation, when exposures will affect expansion and function of the 
definitive placenta and affect nutrient transport (Kalisch-Smith, Simmons, Dickinson, & Moritz, 
2017). Finally, placenta immune function displays evidence for sex-specific effects as well; for 
example mouse studies have shown maternal obesity to be linked to placenta inflammation in 
late gestation, with males displaying greater inflammation and macrophage activation than 
females (Kim, Young, Grattan, & Jasoni, 2014; Tarrade, Panchenko, Junien, & Gabory, 2015).  
However, little is understood with respect to the mechanism of sex differences in the placenta. 
Some gene expression studies have been conducted; for example a study investigating sorted 
placenta cell types found pathways such as graft vs. host disease, immune function, and 
inflammation to be enriched in genes differentially expressed by sex (Cvitic et al., 2013). 
Another meta-analysis of placenta microarray data discovered pathways such as cell growth, 
proliferation, and hormonal function (Buckberry, Bianco-Miotto, Bent, Dekker, & Roberts, 
2014). Sex-related mechanisms may be additionally illuminated through the placenta methylome. 
Specifically, understanding the mechanisms of placenta structural or functional differences by 
sex can thus shed light on the mechanisms leading to highly sex-biased phenotypes such as ASD.  





The placental epigenome is of increasing area of interest both in the context of normal 
development and disease states. A seminal paper characterizing the placenta methylome 
demonstrated its unique tendency to contain partially methylated domains (PMDs), which are 
associated with gene repression and inactive chromatin. The authors discovered some additional 
features such as the fact that genes within placenta PMDs have tissue-specific functions, and that 
in regulatory regions, methylation levels in promoter CpG islands are higher for genes within 
PMDs. Additionally, PMDs are broadly of interest outside of the context of the placenta 
specifically. For example, the authors found that genes harbored in regions that are PMDs in 
placenta, SH-SY5Y (neuronal), and IMR90 (lung fibroblast), are enriched for pathways such as 
sensory perception of smell, neurological system processes, cell surface receptor signals, and 
keratinization. Finally, PMDs contain many neuronal development genes, making their 
investigation in an ASD context a promising endeavor (Schroeder et al., 2013). This study was 
carried out by the same authors some years later (see ‘Epigenetics of ASD’), with good success 
(Schroeder et al., 2016).   
There have been many other successful studies identifying placental DNAm changes associated 
with many other phenotypes such as preeclampsia (Kulkarni, Chavan-Gautam, Mehendale, 
Yadav, & Joshi, 2011; Yuen, Peñaherrera, von Dadelszen, McFadden, & Robinson, 2010) and 
IUGR (Roifman et al., 2016). Another branch of studies has established the sensitivity of the 
placenta methylome to various environmental exposures. For example two previous studies, both 
using an early iteration of the Illumina methylation array technology (27K Array), have 
identified CpG sites significantly associated with prenatal smoking (Maccani, Koestler, 





later iteration of Illumina methylation arrays (450K Array), also identified placenta methylation 
sites significantly associated with mercury (Maccani et al., 2015) and cadmium (Mohanty et al., 
2015). The degree of genetic control of placenta methylation signals has not been investigated on 
a genome-wide scale. Chapter 3 of this dissertation addresses this gap by defining, to our 
knowledge, the first comprehensive meQTL map in placenta tissue and using this map to provide 
insights into ASD biology. Another key feature of the placenta methylome is its dynamic nature 
across the gestational period. Specifically, it has been demonstrated that global methylation 
levels tend to rise with increasing gestational age (Novakovic et al., 2011). Therefore, 
association analyses must consider gestational age as a potential confounding factor, as 
gestational age can be linked to various phenotypes as well. Moreover, studies from term 
placenta samples must take caution to claim functional implications of any significant findings, 
as the identified DNAm signatures may not be reflective of the DNAm state during the 
gestational period.  
Finally, two previous studies have investigated the placenta methylome in the context of sexual 
dimorphism. These efforts are buoyed by many successful efforts to identify autosomal sex-
specific DNAm differences in tissues such as peripheral blood (Inoshita et al., 2015; Price et al., 
2013; Singmann et al., 2015; Suderman et al., 2017), cord blood (Yousefi et al., 2015), and 
prefrontal cortex (Xu et al., 2014). One the previous placenta studies successfully identified 91 
significant autosomal sites related to fetal sex in a small for gestational age cohort, implicating 
similar pathways to those found by gene expression studies such as immune function, 
growth/transcription factor signaling, and transport across cell membranes. However, this 





While the standard measurement tool for DNAm studies, this platform is still limited in its 
coverage of the DNA methylome. The second placenta study addressed these concerns by 
measuring placenta DNAm via WGBS. This study identified many sex chromosome DNAm 
differences by sex, which is expected, but also one autosomal differentially methylated region in 
the gene body of CSMD1. The authors also failed to identify this sex DMR in 8 other tissues, 
suggesting that it is placenta-specific. One limitation of this study was that sample sizes were 
limited to 2 male and female samples each (Gong et al., 2018). In Chapter 5 of this dissertation, 
we extend this area of research by conducting a whole-genome bisulfite study for sex-specific 
DNAm patterns in placenta tissue from a substantial number of samples (Nmales = 17, Nfemales = 
20). 
1.4. Focus of this dissertation 
This dissertation is centered on gaining etiologic insights towards ASD and sexual dimorphism 
during pregnancy through epigenetic data, particularly through its integration with genotype 
data, across tissue types. With respect to ASD, this work can aid our understanding of the genetic 
and epigenetic dysregulation characteristic of ASD, provide intervention targets, and provide 
mechanistic insights to observed genetic associations. Moreover, this work can shed light on 
specific placental functions that differ in normal development according to fetal sex, allowing for 
an understanding of how the gestational period can program sex-biased phenotypes, like ASD, 
throughout the life course.  
Our first goal is to better characterize the functional biology of common variants that are 
increasingly being identified in ASD. Given the growing evidence for an epigenetic basis to 





with ASD GWAS association data. To simultaneously investigate the utility of peripheral tissues 
for DNAm-based insights into a brain-based disease such as ASD, we conduct these genotype-
epigenotype integrations using DNAm data from fetal brain, peripheral blood, and cord blood 
(Chapter 2), and additionally placenta (Chapter 3). Specifically, we determined whether ASD 
associated SNPs were enriched for meQTLs and also whether particular pathways were enriched 
in the methylation targets of ASD SNPs. We compare SNP and CpG-based insights from 
peripheral tissues to those from brain, to better understand the suitability of various tissues for 
etiologic insights into ASD. These insights can also reveal tissue-specific functionality of GWAS 
SNPs that better characterizes how their effect on ASD is context-dependent.  
Our next goal is to search for ASD-related signatures of placenta DNAm. Most previous studies 
of ASD and DNAm have taken place using brain samples and peripheral tissues such as blood. 
While brain-based DNAm is of most interest for etiologic insights into a neurodevelopmental 
disorder such as ASD, accessibility is limited to post-mortem samples. Peripheral tissues are 
inherently more accessible from brain, but are less useful for identifying mechanistic etiologic 
insights into ASD. The placenta is a unique peripheral tissue in an ASD context because it is 
similarly accessible, but more connected to ASD etiology. Specifically, genetic factors and 
environmental insults during pregnancy can act through placenta DNAm to influence placenta 
structure and function, which in turn influences fetal brain development. Despite this compelling 
framework and rationale for placenta DNAm and ASD, only one previous study has examined 
this relationship. Therefore, we undertake a study searching for differentially methylated regions 





Finally, the role of placenta DNAm in contributing to phenotype is one in which genetic and 
environmental insults shape DNAm, which in turn effects placenta structure and function, which 
then leads to health outcomes. This framework fits squarely within the realm of the 
developmental origins of health and disease construct, which suggest that early life factors 
program disease later in life (Bianco-Miotto, Craig, Gasser, van Dijk, & Ozanne, 2017). Taken 
together with the fact that certain phenotypes, such as ASD, maintain a highly sex-biased 
prevalence, it follows logically that this placenta framework itself is sex-specific. Indeed, 
evidence exists for the differential response of the male and female fetus to certain insults during 
the gestational period, such as asthma (Murphy et al., 2003, 2005). But little is known with 
respect to the mechanisms of these sex-specific placental responses and functions. Therefore, we 
perform an epigenome-wide association study searching for differentially methylated regions 
associated with fetal sex. Additional follow-up analyses of a fetal sex-related region incorporate 
data from other tissue types to assess placental tissue specificity, and integrate genotype data to 
assess epigenetic mediation of genetic variation, at both the local and distal level, on placenta 
morphological features (Chapter 5). 
The work presented in this dissertation demonstrates the utility of integrating genetic and 
epigenetic data across tissue types to extend research on the genetic and epigenetic etiology of 
ASD, and for uncovering the mechanisms of sex-specific placental function and the potential 
programming of sex-biased disease later in life. 
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Integration of emerging epigenetic information with Autism Spectrum Disorder (ASD) genetic 
results may elucidate functional insights not possible via either type of information in isolation. 
Here, we use genotype and DNA methylation (DNAm) data from cord blood and peripheral 
blood to identify SNPs associated with DNA methylation (meQTL lists). Additionally, we use 
publicly available fetal brain and lung meQTL lists to assess enrichment of ASD GWAS results 
for tissue-specific meQTLs. ASD-associated SNPs are enriched for fetal brain (OR = 3.55; P < 
0.001) and peripheral blood meQTLs (OR = 1.58; P < 0.001). The CpG targets of ASD meQTLs 
across cord, blood, and brain tissues are enriched for immune-related pathways, consistent with 
other expression and DNAm results in ASD, and reveal pathways not implicated by genetic 
findings. This joint analysis of genotype and DNAm demonstrates the potential of both brain and 













2.2 Introduction  
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by 
deficits in social communication and interaction as well as restricted repetitive behavior(Rapin, 
1997). ASD has a strong genetic basis(Colvert et al., 2015; Sandin et al., 2014), and most 
findings to date have been rare variants, including inherited and de novo mutations as well as 
copy number variations(Iossifov et al., 2014; O’Roak et al., 2014; Sanders et al., 2015). 
Although rare variants explain a relatively small proportion of all ASD cases(Gaugler et al., 
2014), they provide converging evidence for three key biological processes implicated in ASD, 
including epigenetic regulation (Krumm, O’Roak, Shendure, & Eichler, 2014; Pinto et al., 2014; 
Sanders et al., 2015).  Other lines of evidence also implicate epigenetic mechanisms in 
ASD(Abdolmaleky, Zhou, & Thiagalingam, 2015; Amir et al., 1999; Horsthemke & Wagstaff, 
2008; Loke, Hannan, & Craig, 2015; Oberlé et al., 1991). Common genetic variation also plays a 
role, similar to other complex psychiatric diseases(Cross-Disorder Group of the Psychiatric 
Genomics Consortium, 2013; Cross-Disorder Group of the Psychiatric Genomics Consortium et 
al., 2013; Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), and 
mega-analysis GWAS results from the Psychiatric Genomics Consortium ASD workgroup 
(PGC-AUT)(Autism Spectrum Disorders Working Group of The Psychiatric Genomics 
Consortium, 2017) are only recently available, and thorough examination of the biology 
implicated by common variants has not yet been fully pursued.  Previous studies of 
neuropsychiatric disorders(Davis et al., 2012; Gamazon et al., 2013; van Eijk et al., 2015) have 
demonstrated the enrichment of GWAS results for expression quantitative trait loci (eQTLs), 





confer some risk through regulatory mechanisms. Given the implications of epigenetic regulation 
in ASD, a similar approach exploring enrichment of SNPs controlling epigenetic marks, such as 
DNA methylation, may be fruitful, assuming similarly that ASD genetic risk may act in part 
through epigenetic regulation. As with expression loci, genetic variation contributes to DNAm 
levels locally and distally(Hannon et al., 2016; Shi et al., 2014) and thus integration of 
methylation quantitative trait loci (meQTLs), or SNPs that are highly associated with DNAm, 
and autism-associated GWAS results may inform our understanding of autism GWAS findings. 
Moreover, meQTLs are enriched in top hits for bipolar disorder(Gamazon et al., 2013) and 
schizophrenia(Hannon et al., 2016; van Eijk et al., 2015), which have well-established genetic 
overlap with ASD(Cross-Disorder Group of the Psychiatric Genomics Consortium et al., 2013).  
Epigenetic patterns necessarily differ across tissue types, given their role in cell differentiation 
and expression. For brain-related conditions like ASD, careful consideration of tissue source for 
epigenetic analyses is warranted(Bakulski, Halladay, Hu, Mill, & Fallin, 2016).  This must be 
balanced by consideration of tissue availability, which is limited for ASD brain tissue.  We and 
others have shown blood-based epigenetic biomarkers are useful in psychiatric conditions, 
including ASD(Montano et al., 2016; Wong et al., 2014), while recognizing the limitations and 
need for comparison to brain-derived data wherever possible(Bakulski et al., 2016; Davies et al., 
2012; Hannon, Lunnon, Schalkwyk, & Mill, 2015). ASD-related epigenetic differences have also 
been observed in buccal(Berko et al., 2014), lymphoblastoid cell line(Nguyen, Rauch, Pfeifer, & 
Hu, 2010), and postmortem brain samples(James, Shpyleva, Melnyk, Pavliv, & Pogribny, 2014; 
Ladd-Acosta et al., 2014; Nardone et al., 2014), as well as in the sperm from fathers of children 





observed high correlation of DNAm levels at specific sites across tissues; however, when such 
concordance is observed, it is likely due to genetic influences(Davies et al., 2012; Hannon et al., 
2015). meQTL signals overlap in adult brain and blood tissues(Smith et al., 2014), suggesting 
blood-derived meQTLs may also reflect SNP-DNAm relationships in brain tissue, though this 
relationship has rarely been tested. 
This study used lists and locations of meQTLs and their CpG targets, termed meQTL maps, from 
cord blood, peripheral blood, and fetal brain tissues to characterize and prioritize ASD GWAS 
SNPs and the CpG sites under their control.  We created such meQTL maps from our own data 
for infant cord and childhood peripheral blood tissues, and used publicly available meQTL maps 
for brain and lung tissues to examine cross-tissue meQTLs.  We find that ASD GWAS signals 
are enriched for meQTLs in peripheral blood and fetal brain. The CpG site targets controlled by 
ASD-associated SNPs are enriched for immune response pathways, and can implicate new genes 
not directly identified by GWAS results alone. Finally, we extend the characterization of SNP-
controlled CpG sites to neuropsychiatric disease more generally, and discover their enrichment 
for specific regulatory features within and across tissue type. Our work demonstrates the utility 
of jointly analyzing GWAS and DNAm data for insights into ASD and neuropsychiatric disease.   
2.3 Methods 
2.3.1 Cord blood samples 
Cord blood DNA was obtained from newborn participants of the Early Autism Risk Longitudinal 
Risk Investigation (EARLI), an enriched-risk prospective birth cohort described in detail 
elsewhere(Newschaffer et al., 2012). The EARLI study was approved by Human Subjects 





Drexel University, University of California Davis, and Kaiser Permanente). Informed consent 
was obtained from all participating families.  The 232 mothers with a subsequent child born 
through this study had births between November 2009 and March 2012.  Infants were followed 
with extensive neurophenotyping until age three, including ASD diagnostics. 
2.3.2 Cord blood DNA methylation 
Cord blood biospecimens were collected and archived at 175 births.  DNA was extracted using 
the DNA Midi kit (Qiagen, Valencia, CA) and samples were bisulfite treated and cleaned using 
the EZ DNA methylation gold kit (Zymo Research, Irvine, CA).  DNA was plated randomly and 
assayed on the Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA), or 
“450k”, at the Center for Inherited Disease Research (CIDR, Johns Hopkins University).  
Methylation control gradients and between-plate repeated tissue controls (n=68) were 
used(Feinberg et al., 2015). 
The minfi library (version 1.12)(Aryee et al., 2014) in R (version 3.1) was used to process raw 
Illumina image files with the background correcting and dye-bias equalization method: normal-
exponential using out-of-band probe (Noob)(Fortin et al., 2014; Triche, Weisenberger, Van Den 
Berg, Laird, & Siegmund, 2013). Probes with failed detection P-value (>0.01) in >10% of 
samples were removed (n=661), as were probes annotated as cross-reactive (n=29,233)(Chen et 
al., 2013) and those mapping to sex chromosomes (n=11,648).  All cord samples passed sample-
based filters (sex matching, detection P-values > 0.01 in greater than 1% of sites). Pre-processed 
data were adjusted for batch effects related to hybridization date and array position using the 





3.9.1)(“sva,” n.d.).  Methylation data were available from 175 cord blood samples at 445,241 
probes.  
2.3.3 Cord blood genotyping 
Overlapping cord blood DNA methylation and corresponding SNP data was available on 171 
EARLI cord blood samples. Genotype data were generated for 841 EARLI family biosamples 
and 18 HapMap control samples run on the Omni5 plus exome (Illumina, San Diego, CA) 
genotyping array at CIDR (Johns Hopkins University), generating data on 4,641,218 SNPs.  The 
duplicated HapMap sample concordance rate was 99.72% and the concordance rate among five 
EARLI samples with blind duplicates was 99.9%. Samples were removed if they were HapMap 
controls (n=18), technical duplicates (n=5; selected by frequency of missing genotypes), or re-
enrolled families/other relatedness errors (n=9). No samples met the following additional criteria 
for exclusion: missing genotypes at >3% of probes, or excess heterozygosity or homozygosity (4 
SD). Probes were removed for CIDR technical problems (n=94,712), missing genomic location 
information (n=8,124). Among probes with high minor allele frequencies (>5%), SNPs with a 
missing rate > 5% were excluded (n=8,902) and among probes with low minor allele frequencies 
(<5%) SNPs with a missing rate >1% were excluded (n=65,855). There were 827 samples and 
4,463,625 probes at this stage and SNPs out of Hardy-Weinberg equilibrium (χ2 test P< 10-7) 
were flagged (n=2,170).  Samples were merged with the 1,000 genomes project (1000GP, 
version 5) data(1000 Genomes Project Consortium et al., 2012) and EARLI ancestries were 
projected into four categories (White, Black, Asian, Hispanic). EARLI measured genotype data 
was phased using SHAPEIT(Delaneau, Zagury, & Marchini, 2013) and imputed to the 1000GP 
data using Minimac3(Howie, Fuchsberger, Stephens, Marchini, & Abecasis, 2012). SNPs with 





2.3.4 Peripheral blood samples 
Samples were obtained from the Study to Explore Early Development (SEED), a multi-site, 
national case-control study of children aged 3-5 years with and without ASD. Overall, 2,800 
families were recruited and classified into 3 groups according to the status of the child: the ASD 
group, the general population control group, and the (non-ASD) developmental delay 
group(Schendel et al., 2012). This study was approved as an exemption from the Johns Hopkins 
Institutional Review Board (IRB) under approval 00000011. Informed consent was obtained 
from all participants as part of the parent SEED study. SEED recruitment was approved by the 
IRBs of each recruitment site: Institutional Review Board (IRB)-C, CDC Human Research 
Protection Office; Kaiser Foundation Research Institute (KFRI) Kaiser Permanente Northern 
California IRB, Colorado Multiple IRB, Emory University IRB, Georgia Department of Public 
Health IRB, Maryland Department of Health and Mental Hygiene IRB, Johns Hopkins 
Bloomberg School of Public Health Review Board, University of North Carolina IRB and Office 
of Human Research Ethics, IRB of The Children's Hospital of Philadelphia, and IRB of the 
University of Pennsylvania. All enrolled families provided written consent for participation. 
2.3.5 Peripheral blood DNA methylation 
Genomic DNA was isolated from whole blood samples using the QIAsumphonia midi kit 
(Qiagen, Valencia, CA).  For each a subset of case and control samples (n = 630), bisulfite 
treatment was performed using the 96-well EZ DNA methylation kit (Zymo Research, Irvine, 
CA). Samples were randomized within and across plates to minimize batch and position effects. 
The minfi R package (version 1.16.1) was used to process Illumina .idat files generated from the 
array(Aryee et al., 2014). Control samples (n=14) were removed and quantile normalization 





failed detection P-value (>0.01) in >10% of samples were removed (n=772), as were probes 
annotated as cross-reactive (n=29,233)(Chen et al., 2013), and probes on sex chromosomes 
(n=11,648).  Samples were excluded if reported sex did not match predicted sex (minfi function 
getSex()) (n=0),  detection P-values > 0.01 in greater than 1% of sites (n=2), low overall intensity 
(median methylated or unmethylated intensity < 11; n=2), and if they were duplicates (n=8). 
Successive filtering according to these criteria resulted in 445,154 probes and 604 samples.  
2.3.6 Peripheral blood genotyping 
Of the SEED samples with DNAm data, 590 had whole-genome genotyping data available, 
measured using the Illumina HumanOmni1-Quad BeadChip (Illumina, San Diego, CA). 
Standard quality control measures were applied: removing samples with < 95% SNP call rate, 
sex discrepancies, relatedness (Pi-hat > 0.2), or excess hetero- or homozygosity; removing 
markers with < 98.5% call rate, or monomorphic. Phasing was performed using 
SHAPEIT(Delaneau et al., 2013) followed by SNP imputation via the IMPUTE2 
software(Howie et al., 2012), with all individuals in the 1000 Genomes Project as a reference. 
Genetic ancestry was determined using EigenStrat program(Price et al., 2006). A total of 
4,948,723 SNPs were available post imputation at MAF > 1%. 
2.3.7 Normal lung tissue meQTLs 
A list of meQTLs identified in a recent characterization of normal lung tissue(Shi et al., 2014) as 
well as the total list of SNPs (n = 569,753) and 450k CpG sites (n = 338,730) tested for meQTL 
identification (i.e. passed filtering and QC done in that study) was obtained from the study 
authors.  





Fetal brain meQTLs were identified via imputed genotypes in a recent study examining meQTLs 
in the context of schizophrenia(Hannon et al., 2016).  The total list of SNPs (n = 5,159,699) and 
450k CpG sites (n = 314,554) that were tested (i.e. passed filtering and QC done in that study) 
was obtained from the study authors. For all analyses, only fetal brain meQTLs within a SNP to 
CpG distance of 1 Mb, were included, in order to improve comparability to the other 3 meQTL 
lists, where distant (trans) meQTL relationships were not explored (peripheral blood, cord blood) 
or used (lung). 
2.3.9 meQTL identification parameters 
There are three main parameters of interest in a meQTL query: the SNP minor allele frequency 
(MAF) threshold for inclusion, the definition of standard deviation cutoff that dictates a CpG site 
is variably methylated, and the maximum physical distance between a SNP and CpG site to be 
queried, often referred to as the window size. These 3 factors contribute to the total number of 
CpG to SNP linear regression tests that are performed. Our available sample sizes (and thus 
statistical power, at fixed effect size) for the joint DNAm and genotype data differed for 
peripheral blood (n = 339) and cord blood (n = 121) analyses after limiting both to samples of 
European descent identified via principle components analysis of SNP data. Thus, the ideal 
combination of these parameters should differ between the two study populations for them to be 
comparable.  
For each tissue sample set, we computed the total number of CpG to SNP linear regression tests 
at various combinations of the 3 main parameters of interest to a meQTL query. We then used 
the genetic power calculator Quanto(Gauderman, 2002) to determine the most permissive set of 





addition of the minor allele, at the lowest allowed MAF. We computed this power calculation at 
a Bonferroni-based significance level derived from the total number of CpG to SNP linear 
regression tests. We defined ‘most permissive’ in a hierarchical manner that first prioritized the 
inclusion of the most methylation sites (lowest sd cutoff), then the inclusion of the most number 
of SNPs (lowest MAF threshold), and then the use of the largest window size. This procedure 
resulted in study-specific MAF thresholds for the SNP data, standard deviation cutoffs for the 
methylation data, and window sizes that were tailored to the number of samples available.  
2.3.10 meQTL identification procedure 
Pairwise associations between each SNP and CpG site were estimated via the R package 
MatrixEQTL(Shabalin, 2012), with percent methylation (termed ‘Beta value’, ranging from 0 to 
100) regressed onto genotype assuming an additive model, adjusting for the first two principal 
components of ancestry and sex. Models did not adjust for age given the very narrow age ranges 
in each tissue type.  
False discovery rate (FDR) was controlled via permutation(Shi et al., 2014). Briefly, the total 
number of CpG sites (Nobs) under genetic control was obtained for a meQTL P-value of po. 
Genome-wide meQTL query was performed for each of 100 permuted sets of the genotype data 
(scrambling sample IDs, to retain genotype correlation structure). In each set, we retained the 
total number of CpG sites under genetic control (Nnull) at the same P-value po. The FDR was 
defined as the mean(Nnull)/ Nobs. Finally we determined the value of po to control the FDR at 
values of 10%, 5%, and 1%. Both the meQTL discovery and FDR determination were performed 
in each tissue or study sample. 





We tested for enrichment of meQTLs from four tissue types among ASD GWAS SNPs. ASD 
SNPs were assigned from the PGC-AUT analysis (downloaded February 2016), based on 5,305 
cases and 5,305 pseudocontrols(“Psychiatric Genomics Consortium,” n.d.). The PGC provides 
results for 9,499,589 SNPs; 11,749 SNPs exceeded an ASD P-value threshold of 1e-03, and 
1,094 SNPs exceeded an ASD P-value threshold of 1e-04. For each tissue, we included only 
SNPs available in both the PGC-AUT analysis and our meQTL analysis, either via direct or 
proxy (r2 > 0.8 within 500Kb window in CEU 1KG) overlap as defined via the SNAP 
software(A. D. Johnson et al., 2008).  
To estimate the proportion of meQTLs among ASD SNPs versus among all SNPs (or a sample of 
null SNPs), we recognized three important factors that could differ between null SNP sets and 
the ASD SNP set: LD structure, MAF distribution, and number of CpG sites per window size in 
the meQTL screen. We designed a comparison process to address each of these. First, we 
performed LD pruning ‘supervised’ by PGC ASD P-value (so as to not prune away all ASD 
SNPs) using PriorityPruner (v0.1.2)(“PriorityPruner,” n.d.), removing SNPs at r2 > 0.7 within a 
sliding 500Kb window. For the peripheral blood and cord blood datasets this pruning was done 
with the study-specific genotype data, and for the fetal brain and lung datasets this pruning was 
done with 1000 Genomes CEU samples. Second, we grouped remaining SNPs into MAF bins of 
5%. Third, we characterized each SNP according to the number of CpGs within the meQTL 
discovery window size to allow for differential opportunity to have been identified as a meQTL. 
We then collapsed this number into categories of 0-49, 50-99, etc. to reflect the same concept. 
We defined 1,000 null SNP sets by finding, for each SNP in the ASD set, a random SNP in the 





enrichment fold statistic as the proportion of meQTLs in the ASD SNP set divided by the mean 
proportion of meQTLs across null sets; and a P-value as the total number of null set proportions 
as or more extreme than in the ASD set. To evaluate the robustness of our results, we used two 
PGC AUT P-value cutoffs (1e-03, 1e-04) and three meQTL P-value cutoffs (FDR 10%, 5%, 1%) 
for peripheral blood and cord blood. However, based on available information for lung and fetal 
brain, we were limited to assess our results at FDR 5% for lung, and P<1e-08 for fetal brain for 
meQTL P-value.  
2.3.12 Gene ontology analysis of meQTL targets 
We further assessed which biological pathways are implicated by the location of CpG targets of 
ASD SNPs acting as meQTLs.  To do this, we identified CpG sites associated with ASD SNPs 
(ASD-related meQTL targets) among all CpG sites controlled by SNPs (all meQTL targets). We 
then examined Gene Ontology (GO) terms specific to these ASD-related meQTL targets, in 
order to enumerate biological pathways engaged specifically by ASD SNPs.  
Specifically, we first filtered the full list of CpG sites associated with any meQTL to only those 
sites associated with an ASD SNP (PGC Wald P < 1e-04; N=1,094) or their proxies (r2 > 0.8 
within 500kb window in CEU 1KG as defined via the SNAP software(A. D. Johnson et al., 
2008)). We used thresholds of FDR ≤ 5% for peripheral and cord blood meQTL lists, and Wald 
P < 1e-08 for the fetal brain list. We only examined CpG sites that did not overlap with SNPs 
within 10bp of the CpG site or at the single base extension(Bibikova et al., 2011), as it has been 
previously demonstrated that these CpG sites may strongly influence functional-type enrichment 
analysis of CpG sites(McClay et al., 2015), and these CpG sites were not examined in the fetal 





package(“missMethyl,” n.d.), which maps 450k DNAm sites to their nearest gene, and corrects 
for bias due to non-uniform coverage of genes on the 450k. We further ran nominally significant 
(hypergeometric test P< 0.05) results for the category “biological processes” through the 
REVIGO tool to avoid reporting GO terms with a greater than 70% overlap in gene lists(Supek, 
Bošnjak, Škunca, & Šmuc, 2011). Finally, we determined the set of terms in these lists that 
overlapped at least two tissues, and prioritized them by summing the scaled, enrichment P-value-
based rank in each tissue. This scaling was done by dividing the raw rank for the term in the list 
for that tissue by the total number of nominally significant, post-REVIGO terms for that tissue.  
We also ran analogous GO analyses comparing all meQTL targets to all CpGs to explore 
functional implications for meQTL targets versus CpGs not under strong genetic control. This 
allowed for comparison of ASD SNP-specific functional pathways engaged through methylation 
versus general SNP functional pathways engaged through methylation.  
2.3.13 Identifying novel genes via ASD meQTL target locations 
Defining ASD SNPs as those with PGC Wald P < 1e-04, meQTL relationships as in the GO 
analysis, and RefSeq genes from the UCSC Genome Browser(Karolchik et al., 2004), we 
annotated gene overlap (if any) via findOverlaps() in the GenomicRanges R package for all ASD 
SNPs and their associated CpG sites (if any). We filtered out long intergenic non-coding RNAs, 
long non-coding RNAs, microRNAs, and small associated RNAs from the RefSeq gene list. We 
further collapsed SNPs into bins by LD block. Blocks were defined using recombination hot spot 
data from 1000 Genomes(1000 Genomes Project Consortium et al., 2012).  





To quantify the propensity of regulatory features to overlap with meQTL targets within and 
across tissue type, we first compared regulatory feature overlap of all meQTL targets to non-
meQTL targets. We next compared meQTL targets of psychiatric condition-related SNPs to 
meQTL targets of SNPs unrelated to psychiatric conditions. SNPs associated with psychiatric 
conditions were obtained from the PGC cross-disorder analysis(Cross-Disorder Group of the 
Psychiatric Genomics Consortium, 2013) (PGC Wald P < 1e-04) and their proxies. We used 
these SNPs in order to analyze a greater total number of meQTL targets than associated with 
ASD SNPs only (and thus ensure a well-powered analysis), and to make functional insights that 
could be applied to psychiatric disease more broadly. Our results are still relevant to ASD in 
light of known cross-disorder GWAS consistency(Cross-Disorder Group of the Psychiatric 
Genomics Consortium et al., 2013).  
We performed both comparisons for unique and overlapping tissue categories (n =7): peripheral 
blood, cord blood, fetal brain, lung, intersection of peripheral blood and cord blood, intersection 
of peripheral blood and fetal brain, and intersection of peripheral blood and lung. For each 
intersection, we conducted a new meQTL discovery screen in which the peripheral blood was 
down sampled to the sample size of the other tissue, and run at the same parameters used to 
identify meQTLs in that tissue. This increases comparability with respect to power and meQTL 
query parameters. For the peripheral blood overlaps with cord blood and lung, we also computed 
the meQTL P-value to control the FDR at 5%, since this FDR threshold was available for each of 
those tissue types(Shi et al., 2014). However, we only computed the FDR P-values using data 
from the first 6 chromosomes, as we found empirically that FDR P-value estimates stabilized by 





peripheral blood that passed a meQTL P-value of 1E-8, as reported from the fetal brain 
study(Hannon et al., 2016).   
Regulatory feature information came from several sources. General DHSs were defined as those 
CpG probes experimentally determined to be within a DHS, as determined by the manifest for 
the 450k array(“IlluminaHumanMethylation450kmanifest,” n.d.). In addition, tissue-specific 
DHS data were tested for enrichment. Brain DHSs were downloaded from GEO(Edgar, 
Domrachev, & Lash, 2002) for three brain regions: Frontal Cortex [GEO Sample ID: 
GSM1008566], Cerebellum [GSM1008583], and Cerebrum [GSM1008578]). Two blood 
(CD14+ Monocytes; ‘wgEncodeOpenChromDnaseMonocd14’ and CD4+ cells; 
‘wgEncodeUwDnaseCd4naivewb78495824PkRep1’) and one lung-derived (IMR90; 
‘wgEncodeOpenChromDnaseImr90Pk’) data sets were additionally downloaded from the UCSC 
Genome Browser(Karolchik et al., 2004).  
Tissue-specific histone data were compiled from the Roadmap Epigenomics Project(Roadmap 
Epigenomics Consortium et al., 2015) for five different marks: H3K27me3, H3K36me3, 
H3K4me1, H3K4me3, and H3K9me3.  As Epigenome Roadmap Project data were often 
generated across a number of individuals, for those cases in which data were generated in more 
than one Caucasian individual, the overlap across individual samples was utilized in downstream 
analyses. Overlap was calculated using the UCSC Genome Browser’s ‘intersect’ function for 
those samples indicated in Table 2.4. Regions with any overlap were included in functional 





Finally, TFBS information from ChIP-Seq experiments carried out by the ENCODE 
project(ENCODE Project Consortium, 2012) were extracted for 161 transcription factors from 
the UCSC Genome Browser (‘wgEncodeRegTfbsClusteredV3’)(Karolchik et al., 2004). 
Significant feature overlap was assessed via two-sided Fisher’s 2x2 exact test, with Bonferroni 
correction (P< 0.05 / (181 regulatory features * 7 categories) = 3.95e-05). Odds ratio and P-
value were recorded for each test in each unique and overlapping tissue category.  
2.4 Results 
2.4.1 Creating meQTL maps 
We identified meQTL SNPs using combined GWAS and 450K methylation array data available 
on both peripheral blood and cord blood samples. For these analyses, we defined study-specific 
parameters that were optimal for each dataset and determined the P-value (Wald test) to control 
the FDR at 10%, 5%, and 1%. In peripheral blood, we identified 1,878,577 meQTLs controlling 
DNAm at 85,250 CpGs; in cord blood, we found 1,252,498 meQTLs controlling DNAm at 
35,905 CpGs, both at FDR = 5%. Peripheral blood and cord blood meQTLs, on average, were 
associated with 4.83 and 2.56 CpG sites respectively.  Statistical significance was inversely 
related to distance between SNP and CpG site (Supplementary Figure I-1). We have provided a 
full list of all identified peripheral and cord blood meQTLs and their associated CpG sites at 
FDR = 5% (Supplementary Data II-1 and II-2).  
We used publicly available lung(Shi et al., 2014) (to include a likely non ASD-related tissue) and 
fetal brain(Hannon et al., 2016) meQTL lists and the P-value cutoffs stated in those respective 





there were a total of 299,992 meQTLs controlling 7,863 CpGs, and in lung there were 22,866 
meQTLs controlling 34,304 CpG sites. Dataset characteristics, meQTL parameters, and P-values 
used are summarized in Table 2.1. In all tissues, meQTL targets (CpG sites controlled by 
meQTLs) implicate additional genes that are not accounted for by their corresponding meQTLs 
(Supplementary Table I-1).  
There were 2,704,013 overlapping SNPs considered for meQTL discovery across peripheral 
blood, cord blood, and fetal brain analyses.  Of these, 125,869 (4.65%) were identified as 
meQTLs in all three tissues, 407,722 (15.08%) were meQTLs only in peripheral and cord blood, 
30,691 (1.14%) were meQTLs only in peripheral blood and fetal brain, and 528 (0.02%) were 
meQTLs only in cord blood and fetal brain (Supplementary Table I-2).  
2.4.2 Enrichment of meQTLs in ASD GWAS SNPs across 4 tissue types 
We observed enrichment of fetal brain meQTLs at both the more liberal GWAS SNP P-value 
threshold (enrichment fold = 1.70, permutation Penrichment < 1e-03 at Wald PGWAS < 1e-03), and at 
a more stringent GWAS P-value threshold (3.55, permutation Penrichment < 1e-03 at Wald PGWAS < 
1e-04) (Table 2.2).  There was no association with lung meQTLs at either the more liberal (1.09, 
permutation Penrichment = 0.343) or more stringent (0.80, permutation Penrichment = 0.301) 
threshold.  
In peripheral and cord blood, we considered multiple GWAS SNP P-value thresholds as well as 
multiple meQTL discovery thresholds (the latter not available in brain and lung public data). 
There was significant meQTL enrichment for all GWAS and meQTL thresholds considered 





1e-03; Table 2.2). However, in cord blood, meQTL enrichment was only observed for a liberal 
GWAS SNP threshold (range = 1.14 – 1.21, permutation Penrichment = 0.011 – 0.032 at Wald 
PGWAS < 1e-03). This was not statistically significant after considering a Bonferonni correction to 
account for the 16 enrichment tests performed.  
2.4.3 Gene Ontology enrichment analyses of meQTL targets 
We examined the biological functions of meQTL targets of ASD SNPs specifically compared to 
meQTL targets generally. We identified 210, 66, and 53 meQTL targets associated with ASD 
SNPs in peripheral blood, cord blood, and fetal brain respectively. After mapping these CpG 
sites to genes, performing GO enrichment analyses, and removing overlapping GO terms, there 
were a total 95, 76, and 47 nominally significant (hypergeometric test P < 0.05) biological 
processes, respectively. 
A total of 37 biological processes were present across either two or three tissues (Table 2.3, 
Supplementary Data II-3 to II-5), many of them relating to immune system function. Of these, 
3 terms overlapped across all three tissues, 12 processes were enriched in cord blood and fetal 
brain but not peripheral blood, and 22 processes were present in both the peripheral and cord 
blood but not in fetal brain.  
To test whether our findings were unique to ASD meQTL targets, we performed the same 
analysis comparing all meQTL targets to all CpG sites. (Supplementary Figures I-2 to I-4). 
Though there were some immune-related pathways discovered for fetal brain ASD meQTL 






2.4.4 Expansion of ASD GWAS loci via ASD meQTL target locations 
The location of CpG targets for particular meQTL associations can further elucidate genes or 
regions relevant to ASD risk beyond the genomic location of the associated SNP variant. Of the 
1,094 ASD-associated PGC SNPs (Wald P < 1e-04), five (0.46%) were detected as meQTLs 
across peripheral blood, cord blood, and fetal brain tissues (Supplementary Table I-3, 
Supplementary Data II-6). Consideration of the CpG DNAm targets of these SNPs implicates 
genes not directly annotated to the SNPs themselves. For example, ASD SNPs in XKR6 target 
CpGs in TDH in both peripheral blood and fetal brain, and target CpGs in SOX7 in peripheral 
blood and cord blood (Figure 2.1A).  A similar result can be seen for ASD SNPs in PPFIA3 
with meQTL target CpGs that implicate HRC (Figure 2.1B).   
2.4.5 Characterizing meQTL targets for regulatory feature overlap 
We sought to quantify the propensity of regulatory features to overlap with meQTL targets 
within and across tissue type, and particularly whether meQTL targets of SNPs associated with 
psychiatric conditions have specific regulatory features.  Individual and overlapping tissue 
meQTL target lists were compared for regulatory feature annotation.  First, among psychiatric 
condition associated SNPs (via the PGC cross-disorder analysis(Cross-Disorder Group of the 
Psychiatric Genomics Consortium, 2013)), their meQTL targets were significantly enriched for 
DNaseI hypersensitive sites (DHSs) in peripheral blood (OR = 1.22, Fisher’s exact P = 0.014), 
fetal brain (OR = 2.23, Fisher’s exact P = 3.5e-03), and peripheral blood-fetal brain overlap lists 
(OR = 2.22, Fisher’s exact P = 0.018; black font and boxes, Figure 2.2), compared to meQTL 
targets of SNPs not associated with psychiatric conditions. Further, there was marginally 





Supplementary Data II-7) in the peripheral blood-fetal brain list. Few chromatin marks met 
Bonferroni significance (Fisher’s exact P ≤ 3.95e-05) defined by the 181 tests of regulatory 
features performed in all 7 lists of meQTL targets, though numerous marginally significant 
enrichment associations were observed for blood H3K36me3 (active) and blood H3K27me3 
(repressive).  Transcription factor binding sites (TFBSs) with observed enrichment include 
(Supplementary Data II-7) STAT1 for fetal brain (OR = 4.32, Fisher’s exact P = 2.66e-05) and 
peripheral blood (OR = 2.24, Fisher’s exact P = 3.56e-08), TAF1 for peripheral blood (OR = 
1.53, Fisher’s exact P = 2.24e-06), cord blood (OR = 2.24, Fisher’s exact P = 4.01e-06), and 
fetal brain (OR = 3.2, Fisher’s exact P = 4.40e-06), and POL2RA for peripheral blood (OR = 
1.38, Fisher’s exact P = 1.14e-06), cord blood (OR = 2.28, Fisher’s exact P = 3.54e-08), and 
their overlap (OR = 2.20, Fisher’s exact P = 9.63e-09). 
When considering meQTL targets generally (regardless of their status of being downstream of 
PGC SNPs), compared to non-meQTL-target CpGs, enrichment was observed for DHSs for all 7 
meQTL target lists, with the largest effect sizes among the peripheral blood-cord blood overlap 
list and the peripheral blood-fetal brain overlap list (gray font and boxes, Figure 2.2). In fact, a 
large number of regulatory features were significantly enriched among meQTL targets for each 
tissue, including lung, given the very large sample size of CpG sites (Supplementary Data II-
8). However, these were typically small effects. Larger, but still moderate enrichment effects 
were primarily seen for cross-tissue overlap meQTL lists, particularly for the peripheral blood-






This first study integrating ASD GWAS results and meQTL maps provides novel insights about 
ASD etiology using data within and across tissue types. First, using blood samples from birth 
and early life, we identify meQTL maps and compare them to previously reported fetal brain 
tissue meQTLs, showing a subset of SNPs that are meQTLs across all three tissues. , The highest 
percent overlap is between peripheral and cord blood meQTL maps, as is expected given their 
tissue similarity.  When examining enrichment among ASD GWAS results, we observe 
enrichment of peripheral blood (1.20 ≤ OR ≤ 1.58; permutation P < 0.001) and fetal brain (OR = 
1.70 and 3.55; permutation P < 0.001) meQTLs.  When considering the biological processes 
annotated to ASD meQTL targets, we see enrichment for immune-related pathways using all 
three tissue meQTL maps.  Further, specific ASD meQTL targets may suggest novel regions for 
functional follow-up of ASD genetic associations. Finally, we identify several regulatory 
elements that preferentially overlap with meQTL targets associated with known SNPs for 
neuropsychiatric disease generally. Our results demonstrate the utility of meQTLs and their CpG 
targets for insights into ASD and neuropsychiatric disease overall.  
Comparison of meQTL lists across tissues presents several challenges for interpretation of 
results. First, each set of samples came from a different study source, reflecting different sets of 
individuals and different sampling strategies, as well as differences in sample size and in 
genotyping and methylation array platforms. For example, we expected and observed 
considerable overlap between cord and peripheral blood meQTL signals, and less overlap with 
brain.  The lack of further cross-tissue concordance with brain and blood could be due to 
differential statistical power between studies, lack of SNP or CpG overlap on arrays, or 





frequency, etc.).  In our functional characterization of meQTL targets, we used down sampling of 
peripheral blood results to make them comparable to the sample size and meQTL query pipeline 
decisions  of the tissue to which it was being compared. While this is likely an incomplete 
solution, it is a step toward harmonization that has not been carried out in other studies.   
We demonstrate that joint analysis of SNP and DNAm data can reveal novel insights towards 
ASD etiology not apparent when looking at either type of data alone.  It is important to examine 
the biological implications of the genes implicated by SNPs, as well as the genes and regulatory 
functions implicated by DNAm. When considering the ASD SNPs, we found enrichment of fetal 
brain and peripheral blood meQTLs. The enrichment was stronger at increasingly stringent 
meQTL P-value and ASD P-value thresholds, bolstering confidence in these findings. These 
results are also concordant with similar studies of schizophrenia, a disorder with known genetic 
overlap to ASD(Cross-Disorder Group of the Psychiatric Genomics Consortium et al., 2013), 
that have demonstrated enrichment in fetal brain meQTLs(Hannon et al., 2016) and peripheral 
blood meQTLs(van Eijk et al., 2015). A previous study examining enrichment of eQTLs in ASD 
GWAS SNPs observed enrichment in parietal and cerebellar eQTLs but not lymphoblastoid cell 
line eQTLs(Davis et al., 2012), though the GWAS results in that report likely differ greatly from 
those of the larger PGC-AUT mega-analysis. Crucially, we did not observe enrichment of lung 
meQTLs, supporting the specificity of fetal brain and peripheral blood results. However, we also 
did not observe an enrichment of cord blood meQTLs, suggesting the role of ASD-related 
DNAm marks in peripheral tissues may be developmentally regulated or a function of age.  
Additional insights may be gained through examination of specific CpG targets of the ASD-





immune response-related pathways, using brain, peripheral blood, or cord blood meQTL lists.  
This immune enrichment was not seen when considering CpG targets of all meQTLs in blood 
(not just the ASD SNPs), suggesting specificity to ASD.  However, such enrichment was seen 
for all meQTL targets in fetal brain. This may be a consequence of the complications during 
pregnancy that resulted in fetal tissue collection (56-166 days post conception(Hannon et al., 
2016)). Though many immune-related disorders are known to be comorbid with ASD(Estes & 
McAllister, 2015), previous enrichment-type analysis for genetic variants alone have not 
highlighted immune-related pathways, instead implicating chromatin regulation, synaptic 
function, and Wnt signaling(Krumm et al., 2014; Sanders et al., 2015), particularly for genes 
implicated via rare variants.  However, several gene expression and epigenetic studies of ASD 
have implicated immune function in both brain tissue(Ander, Barger, Stamova, Sharp, & 
Schumann, 2015; Gupta et al., 2014; Nardone et al., 2014; Voineagu et al., 2011) and peripheral 
blood(Jalbrzikowski et al., 2015; Kong et al., 2013). Our results are concordant with these 
expression and epigenetic studies but still suggest a role for genetic variation in contributing to 
immune dysregulation in ASD, through SNP control of DNAm.  
Beyond genome and epigenome enrichment analyses, specific meQTL targets also helped to 
“expand” ASD GWAS-implicated regions to include CpG sites, and their associated genes. 
While this does not increase or decrease statistical support for a particular GWAS SNP finding, 
better characterization of the functional architecture of the region can inform follow-up analyses 
of these hits. Two GWAS loci displayed evidence of meQTLs in peripheral blood, cord blood, 
and fetal brain, and many more loci displayed evidence of meQTLs in at least one tissue. These 





GWAS) analyses, since the sequence itself does not show ASD-related variability in these areas. 
Insights emerge only through the integration of SNP and DNAm data.  Current PGC-AUT 
GWAS results are likely underpowered to provide reliable genome-wide hits. As larger GWAS 
of ASD emerge with higher-confidence findings, this cross-tissue meQTL mapping approach 
should be used to expand regions for follow-up, as recently demonstrated for schizophrenia in 
fetal brain(Hannon et al., 2016).   
Finally, we sought to understand the propensity of meQTL targets, both generally and those 
controlled by psychiatric disorder-related SNPs, to overlap with regions of known functional 
activity. MeQTL targets of psychiatric SNPs in peripheral blood, fetal brain, and their 
intersection significantly overlapped with DHS sites, a result that is concordant with our 
observation of meQTL enrichment among ASD SNPs limited to peripheral blood and fetal brain. 
We also identified specific TFBSs enriched in psychiatric disorder meQTL targets such as TAF1 
and STAT1. Recently, a study of nine families demonstrated both de novo and maternally 
inherited single nucleotide changes in TAF1 to be associated with intellectual disability, facial 
dysmorphology, and neurological manifestations(O’Rawe et al., 2015). Our finding that binding 
sites for the TAF1 transcription factor overlap meQTL targets of psychiatric SNPs could serve a 
basis for future functional studies examining the link between TAF1 mutations and adverse 
neurological phenotypes. Lastly, mutations in STAT1 have been linked to early life combined 
immunodeficiency(Baris et al., 2016). The significant overlap with STAT1 TFBSs could thus 
serve as a starting point for functional work looking to understand the role of immune disorders 





We also considered regulatory feature overlap with meQTL targets in general, for comparison to 
results for psychiatric meQTLs. Given the very large number of meQTL targets when not 
restricting to those downstream of psychiatric GWAS SNPs, many cell type specific DHS sites 
and chromatin marks showed significant enrichment for meQTLs in general. Among within-
tissue analyses, the effect sizes were small. However, enrichment seen in meQTL targets that 
overlapped peripheral blood and cord blood, and meQTL targets that overlapped peripheral 
blood and fetal brain was of larger effect size (though still moderate).  This is consistent with the 
idea that genetically controlled CpGs are more likely to have common function across tissues 
(given they all share genomic sequence) compared to those less under direct genetic control.  For 
example, one study has demonstrated that cross-tissue meQTLs (the SNPs, rather than meQTL 
CpG targets) are enriched for miRNA binding sites(Smith et al., 2014). We have not found 
literature examining cross-tissue meQTL targets themselves. This finding suggests an important 
area for future research, that could give greater context to our and future investigations of cross-
tissue meQTL targets in a disease context specifically. 
In summary, our work is the first genome-wide study of meQTLs in the context of ASD to date. 
The results point to the utility of both brain and blood tissues in studies of ASD that integrate 
epigenetic data to enhance current GWAS findings for ASD. We show the utility of examining 
the meQTL targets of ASD SNPs in providing novel insights into functional roles like immune 
system processes that would not be apparent via genotype-based analysis in isolation.  Our work 
suggests that genetic and epigenetic data integration, from a variety of tissues, will continue to 
provide ASD-related functional insights as GWAS findings and meQTL mapping across a 
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# of meQTLs identified 





166 NA 5% 1 Mb 1.0e-08f 299,992f 7,863f 
Peripheral 
Blood 






















Lunga  210 NA 3% 500 Kb 4.0e-05h 22,866h 34,304h 
aPublicly available data. bThe probe standard deviation across samples that was used as an inclusion criterion for CpG sites in the 
meQTL query (blood datasets only). cThe MAF cutoff used as an inclusion criterion for SNPs in the meQTL query. dThe maximum 
distance between the SNP and CpG site used in the meQTL query for the peripheral blood, cord blood, and lung datasets, and the 
value at which results for filtered in the fetal brain results. eSNP to CpG association P-values considered in subsequent analyses. fFDR 












Table 2.2: Enrichment statistics for meQTLs derived from 4 tissue types in ASD GWAS SNPs 
  ASD P-value = 1e-03 ASD P-value = 1e-04 
  meQTL P-value = 1e-08 meQTL P-value = 1e-08 
Fetal 
Brain1 
1.70 (<0.001) 3.55 (<0.001) 
  
meQTL  
FDR = 10% 
meQTL  
FDR = 5% 
meQTL  
FDR = 1% 
meQTL  
FDR = 10% 
meQTL  
FDR = 5% 
meQTL  
FDR = 1% 
Peripheral 
Blood2 
1.22 (< 0.001) 1.20 (< 0.001) 1.23 (< 0.001) 1.31 (0.001) 1.40 (< 0.001) 1.58 (< 0.001) 
Cord 
Blood2 
1.14 (0.032) 1.21 (0.011) 1.20 (0.023) 1.13 (0.299) 1.10 (0.392) 1.10 (0.406) 
Lung1  - 1.09 (0.343) - - 0.80 (0.301) - 
Enrichment fold statistics and P-values based on 1,000 permutations. 1LD pruning performed with 1000 Genomes CEU samples. 2LD 












Table 2.3: Gene Ontology terms significantly enriched in multiple tissue types in 











response to interferon-gamma 0.14 0.11 0.11 
positive regulation of relaxation of cardiac muscle 0.20 0.46 0.30 
production of molecular mediator of immune response 0.65 0.22 0.28 
cellular response to interferon-gamma NA 0.07 0.09 
detection of bacterium NA 0.18 0.06 
detection of biotic stimulus NA 0.26 0.04 
T-helper 1 type immune response NA 0.08 0.34 
regulation of interleukin-10 secretion NA 0.09 0.43 
interferon-gamma production NA 0.57 0.19 
regulation of interleukin-4 production NA 0.24 0.62 
interleukin-4 production NA 0.29 0.60 
interleukin-10 production NA 0.25 0.74 
tongue development NA 0.68 0.32 
inflammatory response to antigenic stimulus NA 0.32 0.81 
endochondral bone growth NA 0.71 0.53 
antigen processing and presentation of peptide or 
polysaccharide antigen via MHC class II 
0.01 0.05 NA 
T cell costimulation 0.05 0.01 NA 
positive regulation of hormone secretion 0.09 0.04 NA 
antigen receptor-mediated signaling pathway 0.08 0.13 NA 
immunoglobulin production involved in immunoglobulin 
mediated immune response 
0.24 0.03 NA 
single organismal cell-cell adhesion 0.23 0.12 NA 
single organism cell adhesion 0.34 0.16 NA 
negative regulation of nonmotile primary cilium assembly 0.16 0.39 NA 
antigen processing and presentation of polysaccharide antigen 
via MHC class II 
0.02 0.58 NA 
polysaccharide assembly with MHC class II protein complex 0.03 0.59 NA 
protein-carbohydrate complex subunit organization 0.04 0.61 NA 
microtubule sliding 0.29 0.38 NA 
MHC protein complex assembly 0.06 0.75 NA 
negative regulation of serine-type peptidase activity 0.41 0.41 NA 
regulation of satellite cell activation involved in skeletal muscle 
regeneration 
0.39 0.45 NA 
protein repair 0.43 0.43 NA 





protein localization to basolateral plasma membrane 0.46 0.55 NA 
lymphocyte migration into lymphoid organs 0.47 0.62 NA 
Peyer's patch morphogenesis 0.60 0.70 NA 
regulation of homeostatic process 0.45 0.92 NA 
skeletal muscle satellite cell activation 0.88 0.63 NA 
1 Scaled rank refers to enrichment P-value based rank divided by the number of marginally 
significant terms post REVIGO filtering for that tissue (peripheral blood: 95, cord blood: 76, 
fetal brain: 47). ‘NA’ shown for terms that did not appear in these lists for that tissue. Terms are 
lumped into sections based on cross-tissue overlap: Section 1 – all three tissues, Section 2 – cord 
blood and fetal brain, Section 3 – peripheral blood and cord blood. Within each of these sections, 






Table 2.4: Samples downloaded from Roadmap Epigenomics Project for 5 different histone 
modifications. 
   H3K27me3 H3K36me3 H3K4me1 H3K4me3 H3K9me3 
Adult 
Lung 
NA  GSM1059437 GSM1059443 GSM1227065 GSM1120355 
GSM1220283 GSM956014 GSM910572 GSM915336 GSM906411 
           
Fetal 
Brain 
GSM621393 GSM621410 GSM706850 GSM621457 GSM621427 
GSM916061       GSM916054 
            
Peripheral 
Blood 
GSM1127130 GSM1127131 GSM1127143 GSM1127126 GSM1127133 








Figure 2.1: ‘Expansion’ of ASD loci through meQTL mapping in peripheral blood, cord 
blood, and fetal brain  Each tissue-specific panel presents, from bottom to top: genomic 
location, gene annotations, SNP locations, SNP-CpG associations, CpG locations. Light gray 
meQTL association lines denote all SNP to CpG associations in that tissue type; Dark meQTL 
association lines denote SNP-CpG associations for ASD-associated SNPs in PGC (P-value <= 
1e-04).   Panel A) Locus at chr8; Panel B) Locus at chr19. Data are presented for meQTL maps 
for fetal brain (top); cord blood meQTLs (middle), and peripheral blood meQTLs (bottom).  
Please note locus coordinates differ from those in Supplementary Data II-6 because in this 













Figure 2.2: Enrichment of meQTL target CpG sites in DNaseI hypersensitive sites We 
identified the meQTL targets (at FDR 5% in peripheral blood, cord blood, and lung and past 1e-
08 P-value threshold in fetal brain results) in peripheral blood, cord blood, fetal brain and lung as 
well those meQTL targets that were present in the overlap of peripheral blood with the other 
three tissues. Odds ratio and P-value in gray text represent enrichment fold statistic and P-value 
from Fisher’s exact tests examining the tendency of meQTL targets to overlap with DHS sites 
compared to CpG sites that were not meQTL targets. Odds ratio and P-value in black text 
represent enrichment fold statistic and P-value from Fisher’s exact tests examining the tendency 
of meQTL targets of significant (P-value <= 1e-04) SNPs from the PGC cross-disorder results or 
their proxies (r2 >= 0.8) to overlap with DHS sites compared to CpG sites that were not meQTL 
targets of the same SNPs. A full list of enrichment statistics and P-value for both tests against a 
total of 181 cell-type specific DHS sites, cell-type specific chromatin marks, and transcription 








CHAPTER 3: FUNCTIONAL ANNOTATION OF GWAS FINDINGS, 
ACROSS AFFECTED AND SURROGATE TISSUE TYPES, TO PROVIDE 
MECHANISTIC INSIGHT IN AUTISM SPECTRUM DISORDER  
3.1 Abstract 
Background: Common variant GWAS discovery studies for autism spectrum disorder (ASD) 
have begun to realize their potential with recent substantial increases in sample size through the 
Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH) initiative and 
Psychiatric Genomics Consortium ASD workgroup (PGC-AUT). Genome-wide significant 
common variants have been identified as well as a number of loci with suggestive significance. 
However, the downstream functional biology impacted by ASD associated common variants 
remains elusive. A separate but growing literature supports epigenetic involvement in the 
etiology of ASD. Thus, studies that integrate genome-wide association study (GWAS) findings 
for ASD and epigenetics provide a fruitful avenue for furthering our understanding of altered 
biologic mechanisms in ASD. In fact, we recently demonstrated the utility of meQTL maps for 
uncovering ASD biology that otherwise would not have been implicated by GWAS findings 
alone. Here, we extend this framework and assess meQTLs in a new tissue relevant to ASD – 
placenta – to uncover downstream biology related to the most recent PGC-AUT GWAS results. 
Objectives: This study aims to expand upon our previous study that integrated genetic and 
epigenetic data to inform our understanding of biological mechanisms in ASD by using GWAS 
summary statistics from the largest ASD GWAS to date, nearly tripling the number of samples as 
the previous largest GWAS, and by generating new meQTL maps for placenta tissue. We then 
use the new GWAS results and placenta meQTL maps to: A) determine whether ASD associated 





controlled by ASD SNPs. We perform these analyses in tissues thought to be affected (e.g. fetal 
brain) as well as surrogate tissues (e.g. blood) in ASD. 
Results: ASD-related SNPs (PGWAS < 1E-5) were enriched for placenta (fold enrichment = 1.25, 
PEnrichment = 0.011) meQTLs, as well as fetal brain (FE = 4.53, PEnrichment < 0.001), peripheral 
blood (FE = 1.39, PEnrichment = 0.011), and cord blood (FE = 2.16, PEnrichment < 0.001) meQTLs but 
not adipose tissue meQTLs (FE = 1.41, PEnrichment = 0.317). Gene ontology analysis revealed both 
tissue-specific pathways targeted by ASD SNPs, such as glial cell development in fetal brain and 
virus-host interaction in placenta, as well as endopeptidase activity and mitochondrion transport 
pathways that were commonly engaged by ASD SNPs across fetal brain, placenta, cord blood, 
and peripheral blood tissue types. Finally, all loci containing the five genome-wide significant 
ASD GWAS SNPSs contain meQTLs in placenta, including two that are also contain peripheral 
blood meQTLs. Mapping the locations of their downstream CpG site targets identified additional 
putative ASD candidate genes in specific tissue types.  
Conclusion: Integration of ASD GWAS summary statistics and tissue-specific meQTL maps 
provide insights into ASD biology as well as into the utility of surrogate tissues for ASD etiology 
based research. SNP-based enrichment analyses show the broad function of ASD SNPs through 
DNAm across brain and peripheral tissue types, and CpG-based enrichment analyses illuminate 
the biological pathways through which these SNPs function, demonstrating their downstream 
impact. Thus our study provides needed characterization of functional biology impacted by ASD 
SNPs and adds further evidence for the epigenetic basis to ASD. Future studies of epigenetics in 






Autism spectrum disorder (ASD) is characterized by social, behavioral, and communication 
deficits and, as of 2012, affects 1 in 68 children in the US (Christensen et al., 2016). ASD is 
known to have a strong genetic basis (Colvert et al., 2015; Gaugler et al., 2014; Sandin et al., 
2014). Most genetic studies of ASD to date have aimed to identify rare variants, including 
inherited and de novo single nucleotide and copy number variants (CNVs), associated with the 
disorder (Iossifov et al., 2014; O’Roak et al., 2014; Sanders et al., 2015). Common variant 
findings are increasingly being realized through the Psychiatric Genomics Consortium ASD 
working group (PGC-AUT). The most recent meta-analysis results nearly tripled the number of 
samples analyzed and resulted in the identification of 5 genome-wide significant SNPs (Grove et 
al., 2017). However, the functional biology implicated by common variation in ASD is not well 
understood. Previous studies of neuropsychiatric phenotypes have sought to elucidate these 
mechanisms by integrating disorder-specific GWAS results along with data for expression 
quantitative trait loci, or eQTLs (Davis et al., 2012; Gamazon et al., 2013; van Eijk et al., 2015). 
Epigenetic factors, such as DNA methylation (DNAm), can be integrated with GWAS data in a 
similar manner, given that SNPs can control DNAm levels locally and distally as with expression 
loci (Bell et al., 2011). These studies have been undertaken in bipolar disorder (Gamazon et al., 
2013) and schizophrenia (Hannon et al., 2016; van Eijk et al., 2015), specifically demonstrating 
an enrichment of methylation quantitative trait loci (meQTLs), or SNPs that control DNAm, in 
disorder-associated SNPs.  
The evidence for a role of epigenetic factors such as DNAm in the etiology of ASD is 
increasingly developing. ASD epigenetic studies are founded upon the fact that epigenetic 





Eichler, 2014; Pinto et al., 2014; Sanders et al., 2015), and that many disorders (Rett, Angelman, 
Fragile X) that overlap with ASD phenotypically have an epigenetic basis (Budimirovic & 
Kaufmann, 2011; Jedele, 2007; Mount, Charman, Hastings, Reilly, & Cass, 2003). Studies in 
postmortem brain samples have shown ASD-based changes in DNAm (Gregory et al., 2009; 
James, Shpyleva, Melnyk, Pavliv, & Pogribny, 2013; Ladd-Acosta et al., 2014; Nagarajan, 
Hogart, Gwye, Martin, & LaSalle, 2006; Nardone et al., 2014; Zhu et al., 2014) and histone 
acetylation (Sun et al., 2016). Brain-based samples have limited accessibility. Therefore, many 
peripheral tissues have been examined in this context as well including peripheral blood 
(Aldinger, Plummer, & Levitt, 2013; Gregory et al., 2009; Wong et al., 2014), buccal epithelium 
(Berko et al., 2014), lymphoblastoid cell lines (Nguyen, Rauch, Pfeifer, & Hu, 2010), the sperm 
of fathers of children with ASD (Feinberg et al., 2015), and placenta (Schroeder et al., 2016). 
Therefore, there is evidence to suggest epigenetics may be involved in ASD etiology and that 
changes related to ASD may be detected in both affected and accessible tissue sources. 
We recently integrated genetic and epigenetic data to better characterize the biology of disease 
associated common variants and DNAm in ASD (see Chapter 2 and (Andrews et al., 2017)). This 
work was based on results from the initial, considerably smaller, PGC-AUT GWAS that did not 
reach genome-wide significance (Autism Spectrum Disorders Working Group of The Psychiatric 
Genomics Consortium, 2017). A unique aspect of our approach was to leverage DNAm 
information from both affected and peripheral surrogate tissue types which enabled us to 
understand whether ASD meQTL biology was specific to brain tissue or whether some could 
also be detected in surrogate tissues. Here, we applied the same approach using the most recent 





determine: (1) whether ASD-associated SNPs are enriched for meQTLs, (2) what methylation 
loci are controlled by the 5 genome-wide significant SNP and, thus, provide novel candidate 
genes and loci for follow-up functional work, and (3) identify pathways enriched in the 
methylation targets of ASD meQTLs. In addition, we expand upon our previous work in blood 
and brain tissues (Andrews et al., 2017) by generating and using new meQTL maps in a fourth 
tissue - placenta – that is relevant to ASD (see details in Chapter 1).  
3.3 Methods 
3.3.1 EARLI Study Description 
The Early Autism Risk Longitudinal Investigation (EARLI) is a prospective, enriched-risk birth 
cohort that has been described in detail elsewhere (Newschaffer et al., 2012). The EARLI study 
was approved by Human Subjects Institutional Review Boards (IRBs) from each of the four 
study sites (Johns Hopkins University, Drexel University, University of California Davis, and 
Kaiser Permanente). Informed consent was obtained from all participating families. The 232 
mothers with a subsequent child born through this study had births between November 2009 and 
March 2012. Placental biopsy samples were collected after delivery at each clinical lab site using 
Baby Tischler Punch Biopsy Forceps. Samples were stored at ambient temperature in RNAlater 
vials (Qiagen, Cat. No. 76154) and shipped same-day to the Johns Hopkins Biological 
Repository (JHBR) in Baltimore, Maryland, for storage at -190°C until processing. After biopsy, 
the placentas were then placed flat in a bag with 10% formalin at a volume roughly equivalent to 
the size of the placenta. 





Genomic DNA (gDNA) from biopsy punches was extracted at JHBR using a QIAgen 
QIAsymphony automated workstation with the Blood 1000 protocol of the DSP DNA Midi kit 
(Cat. No. 937255) as per manufacturer’s instructions. 250ng gDNA was bisulfite treated using 
the Zymo EZ-96 DNA Methylation Kit (Cat. No. D5004), and sequencing libraries were made 
with the NEBNext Ultra DNA Library Prep Kit for Illumina. Library preparation was performed 
at the Center for Epigenetics and libraries were sequenced at ~4x coverage at the High 
Throughput Sequencing Center at the Johns Hopkins University School of Medicine using the 3 
Illumina HiSeq 2500 instruments. Initially 133 placenta samples were run on 16 flow cells; two 
samples failed due to a fluidics error and were re-run using a 17th flow cell.  
Raw .fastq files were aligned the human reference genome (hg38) downloaded from Ensembl 
(Aken et al., 2017) via Bismark (v0.16.3) (Krueger & Andrews, 2011) using the default 
arguments for paired-end sequencing data. M-bias plots (Hansen, Langmead, & Irizarry, 2012) 
were used to inform the trimming of the 5 bp of both the first and second reads, and methylation 
status was called using the Bismark methylation extractor function. All subsequent analyses used 
R (version 3.4.2) and the R package bsseq (version 1.13.6) (“bsseq,” n.d.). The bsseq function 
read.bismark() was used to read in Bismark output files (“cytosine report” format) and obtain 
DNAm measurements on a per-CpG site basis. A total of 29,091,077 CpG sites were measured 
with at least 1 read in 1 sample out of the total 133. Next methylation levels were smoothed 
using the BSmooth algorithm that has been previously described (Hansen et al., 2012). Briefly, 
this technique employs a local-likelihood smoothing algorithm to recapitulate higher coverage 





local correlation structure in DNAm data. We used the BSmooth() function in the bsseq R 
package with the default arguments.    
3.3.3 Genotype data and methylation quantitative trait loci query 
Measurement, quality control, and imputation for the EARLI placenta genotype samples were 
described previously for their matched cord blood samples (Andrews et al., 2017). Overall, 
10,773,289 SNPs were available on 121 out of 133 samples on which we had WGBS DNAm 
data. After imposing a 5% MAF threshold, 7,187,552 SNPs remained. Finally, we used the 
liftOver (Hinrichs et al., 2006) tool to convert the hg19 SNP positions into hg38 positions, to 
match the genome build to which the WGBS data were aligned. 5,155 SNPs failed this 
conversion process, leaving a final total of 7,182,397 SNPs on the 121 samples.  
We took two steps to prepare the DNAm data for the meQTL query. First, in the total dataset of 
29,091,077 CpG sites and 133 samples, we filtered out sites with standard deviations less than 
the 15th percentile of the total vector of standard deviations calculated at every sample. This step 
was done to reduce computational burden by removing sites of low variability at which we are 
underpowered to discover meQTLs and/or meQTL targets. This step limited the number of 
available CpG sites to 24,727,415 sites. Next we imposed similar coverage filtering as done for 
the previous analyses. Specifically we limited the remaining data to retain sites with ≥ 2 reads in 
more than two-thirds of the total number of samples, leaving 22,710,938 DNAm sites. 
Pairwise associations between all SNPs and CpG sites within a distance of 1 Mb from each other 
were estimated via the MatrixEQTL R package (Shabalin, 2012). Percent methylation was 
regressed onto genotype using an additive model, adjusting for the first two principal 





weighting, implemented via the IHW R package. This method assigns p-value weights according 
to an informative covariate and increases power over typical FDR control methods (Ignatiadis, 
Klaus, Zaugg, & Huber, 2016). We used distance between SNP and CpG site as our specified 
covariate, as suggestive by the IHW authors and given previous evidence for its strong role in 
dictating meQTL associations (Andrews et al., 2017; Hannon et al., 2016; Shi et al., 2014).  
3.3.4 Additional meQTL datasets 
We used the peripheral blood, cord blood and fetal brain meQTL (Hannon et al., 2016) lists from 
our previous ASD meQTL study (Andrews et al., 2017). We also utilized a list of cis-meQTLs 
from a previous adipose tissue study (Volkov et al., 2016) and obtained a list of SNPs that passed 
QC (N = 592,794) and CpG sites that passed QC (N = 477,891) from the study authors. These 
meQTL results were used in an analogous manner as the lung tissue meQTLs from our previous 
study (Andrews et al., 2017); they were included as a negative control given that adipose tissue is 
likely a non-ASD-related tissue.  
3.3.5 Enrichment of meQTLs in ASD-associated SNPs 
We tested for enrichment of meQTL from five tissue types among ASD GWAS SNPs. ASD 
SNPs were obtained from the latest iteration of the PGC-AUT analysis based on 18,381 cases 
and 27,696 controls (Grove et al., 2017). This list consisted of a total of 9,112,386 SNPs, with 
8,209 SNPs having an ASD association p-value < 1E-4, and 4,027 SNPs with p-value < 1E-5. 
We implemented an identical SNP enrichment pipeline to our previous analysis (Andrews et al., 
2017). This pipeline proceeds in the following steps: 1) Determination of SNP overlap between 
those used in the meQTL query and those used in the PGC analysis via direct or proxy overlap as 





ASD p-value via the PriorityPruner software (v0.1.2) (“PriorityPruner,” n.d.), 3) Running 1000 
permutations employing matching of null SNP sets in equal number to the ASD SNP set on bins 
of MAF and the number of CpG sites in the meQTL discovery window. Full details on 
parameters used for each pipeline step can be found in our previous paper (Andrews et al., 2017). 
Finally, to explore the sensitivity of our results to definitions of a meQTL and an ASD-related 
SNP, we evaluated enrichment at two PGC-AUT p-value cutoffs (1E-4, 1E-5) and two meQTL 
p-value cutoffs (FDR = 5% and FDR = 1%) for peripheral blood, cord blood, and placenta. For 
the publically available adipose tissue and fetal brain meQTL lists were limited to the available 
information; therefore we only assessed our results at P < 1E-8 for fetal brain and P < 4.8E-10 
for adipose tissue.  
The LD pruning steps were conducted with sample-specific genotype data for in house data 
(peripheral blood, cord blood, placenta) and with 1000 Genomes CEU samples (1000 Genomes 
Project Consortium et al., 2012) when using the publically available fetal brain and adipose 
tissue meQTL lists.  
3.3.6 Gene ontology analysis of meQTL targets 
We next sought to assess which biological pathways are implicate via the location of meQTL 
targets of ASD-related SNPs. Therefore, we identified meQTL targets of ASD SNPs (and their 
proxies) and conducted a gene ontology analysis in which we compared these CpG sites against 
a background of meQTL targets as whole. The choice of this background set, rather than 
measured CpG sites, was so that we could enumerate the pathways specifically engaged by ASD 





For all of the tissues in which DNAm data was measured via the 450K Array (peripheral blood, 
cord blood, fetal brain) we implemented an identical meQTL target enrichment pipeline as in our 
previous analysis (Andrews et al., 2017). First we filtered the list of meQTL targets to those 
associated with an ASD SNP (defined as GWAS p-value < 1E-5) or their proxies (defined as r2 > 
0.8 within 500 kb window in CEU 1KG as defined via the SNAP software). Only meQTLs 
passing the respective meQTL FDR = 1% thresholds in peripheral blood and cord blood and p < 
1E-8 in fetal brain were used in this analysis. We again removed CpG sites overlapping SNPs 
within 10bp of the CpG site or at any single base extension, due to a previous analysis 
demonstrating the significant impact of these CpG sites in a functional-type enrichment analysis 
of CpG sites (McClay et al., 2015), and the fact that these sites were filtered out in the fetal brain 
study (Hannon et al., 2016). Finally we used the gometh() function in the MissMethyl R package, 
which maps CpG IDs to genes and accounts for non-uniform coverage of genes inherent to the 
450K Array (“missMethyl,” n.d.). We retained nominally significant (penrichment < 0.05) terms for 
cross-tissue overlap analyses.  
For placenta, we employed the same meQTL target filtering as described above for the other 
tissues (using meQTLs defined at FDR = 1%). However, DNAm in placenta was measured via 
WGBS, which prevented the direct utilization of the same GO enrichment pipeline via 
MissMethyl, which was designed for Illumina methylation arrays. Therefore, we adapted the 
gometh() function for WGBS data by customizing the functionality to map CpG site positions to 
genes. Specifically, we downloaded a list of RefSeq genes (hg38) from the UCSC Genome 
Browser table (Karolchik et al., 2004), and defined the promoter regions of these genes as 2000 





in the GenomicRanges R package (Lawrence et al., 2013) to find the genes (or associated 
promoters) that overlapped the placenta meQTL targets. After defining these gene lists for both 
placenta ASD meQTL targets and placenta meQTL targets generally, we used the enrichment 
test functionality of the gometh() function in MissMethyl to perform an analogous enrichment as 
done for the 450K Array-based studies that takes into account differential coverage of genes. 
Finally we again retained nominally significant terms (penrichment < 0.05) and identified different 
patterns of overlap with the respective terms from the other 3 tissues.  
3.3.7 GWAS loci expansion via meQTL target information 
We sought to demonstrate the utility of meQTL target positional information to identify 
additional genes of interest in addition to those identified by ASD GWAS SNP positions alone. 
We used the same meQTL relationships as described in the GO meQTL target enrichment 
analysis. We again downloaded a RefSeq gene list from the UCSC Genome Browser (Karolchik 
et al., 2004); this list was in build hg19 to match the meQTL positional information of the 
peripheral blood, cord blood, and fetal brain data. We used the liftOver() tool (Hinrichs et al., 
2006) to convert the hg38 positional information for the placenta DNAm data to hg19. We 
filtered this gene list to exclude long intergenic non-coding RNAs, long non-coding RNAs, 
microRNAs, and small associated RNAs. We also collapsed SNPs into bins by LD blocks 
defined via recombination hot spot data from 1000 Genomes (1000 Genomes Project Consortium 
et al., 2012, p. 0). 
3.4 Results 





We conducted a genome-wide analysis to identify meQTLs and map CpG locus methylation 
under their control, i.e. their methylation targets, in placenta tissue using unified imputed 
genome-wide genotype data and WGBS-measured DNAm data from the same individuals. Using 
a liberal significance threshold (FDR = 5%), we identified a total of 5,022,957 meQTLs and 
8,365,660 meQTL methylation targets. On average, each meQTL was associated with 
methylation levels at 96 CpG sites. Each CpG target was associated with 58 meQTL SNPs, on 
average. Using a more stringent significance threshold (FDR = 1%), we identified a total of 
4,424,678 meQTLs and 5,466,372 meQTL methylation targets. On average, each meQTL was 
associated with 82 CpG sites and each CpG target was associated with 66 meQTL SNPs. We 
observed that the degree of significance, i.e. p-values, decays with increasing physical distance 
between a meQTL and its methylation target (Supplementary Figure III-1). 
There were 2,620,313 overlapping SNPs considered for meQTL analysis in placenta, fetal brain, 
cord blood, and peripheral blood. Of these, 111,574 SNPs (4.26%) were identified as meQTLs in 
all 4 tissues, 902,884 SNPs (34.46%) were identified as meQTLs in placenta only, and 483,903 
(18.47%) SNPs were identified as meQTLs in both placenta and peripheral blood 
(Supplementary Table III-1).    
3.4.2 ASD associated SNPs, identified via GWAS, are enriched for meQTLs 
Using the most recently released autism GWAS summary statistics from the PGC-AUT 
workgroup (Grove et al., 2017) and existing meQTL maps for fetal brain, peripheral blood, 
adipose, and cord blood tissues (see Chapter 2 and (Andrews et al., 2017)) as well as our newly 
generated placenta meQTL maps, we assessed whether ASD-associated SNPs are enriched for 





1E-5 and meQTL p-value = 1.0E-08 for fetal brain or 4.8E-10 for adipose or meQTL FDR < 1% 
for cord blood, peripheral blood, and placenta), we observed significant meQTL enrichment in 
ASD SNPs in fetal brain, cord blood, peripheral blood, and placenta tissues (Table 3.1). Fetal 
brain displayed the strongest effect sizes (fold enrichment = 4.53), followed by in decreasing 
order cord blood (fold enrichment = 2.16), peripheral blood (fold enrichment = 1.39), and 
placenta (fold enrichment = 1.25). Similar results were observed using less stringent significance 
thresholds for these tissue types, although, the effect sizes decreased somewhat for fetal brain 
and placenta. In adipose tissue, significant enrichment was observed at the less stringent GWAS 
threshold (fold enrichment = 2.33, PEnrichment < 0.001) but a smaller fold change and non-
significant p-value was observed at the more stringent GWAS threshold (fold enrichment = 1.41, 
PEnrichment = 0.317).  
3.4.3 Downstream biology implicated by pathway analysis of ASD meQTL methylation targets 
We determined whether the methylation target loci controlled by ASD meQTLs are enriched for 
specific biologic pathways. We compared ASD meQTL target pathways to a background set of 
target pathways implicated for meQTLs, more generally. We identified 137, 208, 143, and 157 
gene ontology (GO) biological processes enriched, at nominal significance (p < 0.05), in ASD 
meQTL targets relative to meQTLs, generally, for fetal brain, peripheral blood, cord blood, and 
placenta, respectively (Supplementary Tables III-2 to III-5). 
A total of 6 biological processes overlapped across all 4 tissue types. These included one process 
involved in the apoptotic process, 2 processes involved in endopeptidase activity and 3 processes 
involved in mitochondrion transport. Several processes involving RNA 3’end processing and 





neuron death” overlapped fetal brain and placenta (Figure 3.2). We also observed some 
interesting GO terms that were specific to one tissue type. For example, terms such as “glial cell 
development”, “positive regulation of hormone secretion”, and “memory” were specific to fetal 
brain (Supplementary Table III-2), many Wnt singling pathways emerged in the peripheral 
blood findings (Supplementary Table III-3), and “modulation by virus of host molecular 
function” and “syncytiotrophoblast cell differentiation involved in labyrinthine layer” were 
specific to the placenta (Supplementary Table III-5). 
3.4.4 Identification of novel downstream functional candidate genes for ASD 
We next sought to identify new candidate genes for ASD, that were not identified by the GWAS 
SNP results, using our meQTL maps in fetal brain, cord and peripheral blood, and placenta 
tissues. The most recent PGC-AUT GWAS (18,381 cases and 27,969 controls) revealed 4,027 
ASD-associated (P < 1E-5) SNPs; 2,173 of those were a meQTL in all 4 - peripheral blood, cord 
blood, fetal brain and placenta - tissues (Supplementary Table III-6). We found that the 
methylation targets of these meQTL ASD-associated SNPs were often located in loci and genes 
outside of the LD block of the ASD-associated SNP itself; thus, revealing new candidate 
functional targets and genes related to ASD that were not implicated by the GWAS SNPs 
themselves. For example, one genome-wide significant ASD meQTL SNP is harbored in a locus 
where ASD-related SNPs (P < 1E-5) are located in C8orf74 but control methylation levels at a 
different locus located in PINX1 in both peripheral blood and placenta tissues (Figure 3.2). Of 
the 4 loci harboring additional genome-wide significant SNPs identified in the PGC-AUT 
GWAS analysis, one contained peripheral blood meQTLs and all 4 contained placenta meQTLs 





the other tissues we tested. In 3 of these cases (rs910805, rs71190156, and rs201910565, see 
Figures III-2, III-3 and III-5), the actual genome-wide significant SNP is a meQTL itself. For 
example, placenta meQTL maps revealed the most genome-wide significant SNP (rs910805), an 
intergenic SNP, controls methylation levels in the placenta at KIZ, KIZ-AS1, and NKX2-4 
(Figure III-2). 
3.5 Discussion 
In this work, we extended our previous framework and results integrating ASD GWAS results 
and meQTL maps to assess epigenetic targets of ASD SNPs in a new tissue type relevant to 
autism, placenta, using summary statistics from the largest ASD GWAS study to date with nearly 
triple the number of samples compared to the previous iteration (Autism Spectrum Disorders 
Working Group of The Psychiatric Genomics Consortium, 2017). We found that ASD-related 
SNPs were enriched for meQTLs from peripheral blood, cord blood, fetal brain, and placenta. 
Pathway analyses of the CpG methylation targets of ASD SNPs revealed enrichment of 
endopeptidase and mitochondrion pathways across fetal brain, blood and placenta tissues. 
However, most enriched ASD target pathways showed tissue specificity. Finally, our meQTL 
maps implicated new ASD candidate loci and genes for future follow-up studies that were 
located beyond those implicated by the SNP positions alone. 
This expansion of our previous result, which included a new tissue type and the latest GWAS 
results from a substantially larger sample size, replicated our previous finding showing an 
enrichment of peripheral blood and fetal brain meQTLs in ASD GWAS hits (Andrews et al., 
2017), and additionally demonstrated this same relationship with placenta meQTLs. We also 





previous study that utilized the previous iteration of the PGC-AUT GWAS results for analysis. 
These results broadly implicate fetal brain, cord blood, peripheral blood from early life, and the 
placenta as key tissues through which genetic control of DNAm is relevant in an ASD context. 
These findings warrant the continued investigation of DNAm signatures of ASD in these tissue 
types (i.e. differentially methylated positions or regions related to ASD), particularly at DNAm 
locations known to be controlled by ASD-related SNPs.   
Our placenta studies herein were particularly unique in that we derived placenta meQTLs using 
WGBS-measured DNAm, which offers drastically improved coverage of the DNA methylome 
over the commonly used 450K array. This fact should be taken into account when interpreting 
our results. For example, the fact that every genome-wide significant locus from the PGC-AUT 
contained a placenta meQTL is more of a reflection of the greater opportunity for SNPs to be 
called meQTLs in placenta (owing to greater number of measured CpGs in the meQTL detection 
window) than it is a greater engagement of the placenta methylome downstream of ASD SNPs. 
Similarly, our cross-tissue meQTL results revealed a great number of meQTLs that were 
identified in placenta but not seen in fetal brain, cord blood, or peripheral blood. This fact – that 
WGBS-measured DNAm leads to inherently greater meQTL findings in placenta – is necessarily 
true even given our use of strict multiple testing thresholds in the meQTL query (Ignatiadis et al., 
2016), and points to larger issues that complicate cross-tissue meQTL comparisons such as 
differing SNP and/or CpG variability thresholds used as inclusion criteria, meQTL detection 
window size, and DNAm measurement platform, as we have previously discussed (Andrews et 
al., 2017). Therefore, cross-tissue comparisons with these placenta data will be particularly of 





The use of adipose tissue meQTLs in this current study functioned as a negative control for our 
SNP-based enrichment analyses. We observed significant enrichment in adipose tissue meQTLs 
at the more liberal GWAS threshold examined to define an ASD-related SNP but not at the more 
stringent threshold of an ASD-related SNP. This pattern was not consistent with the other tissues 
we examined. Observed adipose tissue meQTL enrichment at the more liberal GWAS threshold 
may indicate a possible role for adipose tissue in ASD biology, or, more likely, a less tissue-
specific enrichment for meQTLs when including SNPs more loosely-associated with ASD. 
Therefore, characterization of meQTL relationships in an ASD context are likely more 
meaningful at the GWAS threshold where we did not observe adipose tissue meQTL enrichment 
(i.e. GWAS p-value 1E-5). In light of this, GO enrichment analyses and GWAS loci expansion 
analyses took place using meQTL relationships defined via this more stringent GWAS threshold.  
In our previous study, we reported that the CpG site targets of ASD-related SNPs were engaged 
in immune response pathways across peripheral blood, cord blood, and fetal brain (Andrews et 
al., 2017). This finding was particularly intriguing given the known comorbidity of ASD and 
immune-related phenotypes, and the fact that many gene expression and DNAm-based studies of 
ASD have identified immune response pathways. In this study, we performed similar pathway 
analyses but did not replicate the immune pathway enrichment result. One possible explanation 
for this is that the GWAS loci identified in the new large PGC-AUT meta-analyses, and used 
here, differ substantially in their CpG methylation target locations compared to the initial PGC-
AUT results that were derived using substantially fewer samples and used in our previous work. 
Instead, pathway enrichment analyses in this current study identified interesting tissue-specific 





be ASD-related via rare variant studies (Krumm et al., 2014). A placenta specific pathway 
targeted by ASD meQTLs was syncytiotrophoblast cell differentiation, an interesting finding 
given the fact that the syncytiotrophoblast layer of cells on placental villi is the only fetal tissue 
that makes contact with maternal blood (Gude, Roberts, Kalionis, & King, 2004). In other words, 
this result argues for an engagement of ASD SNPs in regulating maternal-fetal interactions 
during pregnancy, which are though to play a key role in fetal brain development (Hsiao & 
Patterson, 2012). 
Consistent with our previous immune response findings, we observed enrichment in immune-
response related pathways for fetal brain tissue (e.g. glial cell development) and virus-host 
interaction pathways in placenta. Placenta and fetal brain results are more likely to reflect causal 
mechanisms to ASD etiology given their time of collection relative to the gestational period 
(during for fetal brain and immediately following for placenta) and the frameworks connecting 
them to ASD. In contrast, cord blood and peripheral blood are mostly useful etiologically for 
their ability to serve as surrogates for less accessible tissues, though they may also reflect 
consequences of ASD (i.e instead of being causally related to ASD). The immune-response 
findings being specific to fetal brain and placenta then argue for their mechanistic, or causal role 
in ASD etiology. Future studies of ASD SNP controlled DNAm should acknowledge these 
respective roles for fetal brain and placenta vs. blood tissues, in order to aid interpretation of 
findings.    
We identified putative downstream targets for the loci containing the 5 genome-wide significant 
SNPs associated with ASD in placenta and peripheral blood tissues for follow up functional 





contain the ASD-associated SNP itself, has been previously demonstrated to contain rare CNVs 
in ASD cases (Pinto et al., 2010). We did not identify any cord blood or fetal brain meQTLs in 
these genome-wide significant loci. One possible explanation for this fact is that the placenta and 
peripheral blood datasets offered the best opportunities to identify meQTLs, owing to a large 
preponderance of measured CpG sites via WGBS in placenta, and the large sample size using for 
peripheral blood meQTL detection. Therefore, incorporation of meQTLs derived from improved 
DNAm coverage and/or larger sample sizes may also identify cord blood and fetal brain 
meQTLs in these regions. According to the current evidence, these peripheral blood and placenta 
relationships do not reflect similar relationships in the brain and so instead offer insight into 
GWAS SNP functionality in these tissues themselves. In the case of the placenta, this may still 
offer causal insights, provided they fit the in framework linking altered placenta structure and 
function to an altered maternal-fetal interface, which itself leads to altered fetal brain 
development (Hsiao & Patterson, 2012).   
Future work should continue to apply these approaches to integrate genetic and epigenetic data in 
an ASD context as both GWAS results improve and meQTL maps for different tissues become 
increasingly available to further aid in prioritization of potential functional targets of common 
genetic variants associated with ASD.  
3.6 Conclusions 
We derived a new comprehensive meQTL map in placenta tissue using unified genome-wide 
SNP and DNA methylation data from the same individuals. Using PGC-AUT GWAS results 
from the largest GWAS in autism to date, we replicate our previous finding of ASD-SNP 





enrichment for cord blood and placenta meQTLs. These findings shed light on ASD SNP 
mechanisms, specifically in their propensity to control DNAm across a range of tissue types, and 
argues for the continued investigation of the ASD-related methylation differences in these tissues 
for both mechanistic insights to and consequences of ASD. New tissue-specific and non-specific 
biological pathways, genes, and loci that are downstream targets of ASD risk SNPs enable 
prioritization of candidate genes to examine in future functional experiments to understand the 
mechanisms by which SNP variants influence autism disease risk. 
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Table 3.1: meQTL enrichment statistics for ASD GWAS SNPs across 5 tissue types 
 ASD p-value = 1E-4 ASD p-value = 1E-5 
 meQTL p-value = 1E-8 meQTL p-value = 1E-8 
Fetal 
Brain1 
3.94 (<0.001)  4.53 (<0.001) 
 meQTL p-value = 4.8E-10 meQTL p-value = 4.8E-10 
Adipose 
Tissue1 
2.33 (< 0.001) 1.41 (0.317) 
  
meQTL  
FDR = 5% 
meQTL  
FDR = 1% 
meQTL  
FDR = 5% 
meQTL  
FDR = 1% 
Peripheral 
Blood2 
1.30 (< 0.001) 1.39 (< 0.001) 1.37 (< 0.001) 1.39 ( 0.011) 
Cord 
Blood2 
2.00 (< 0.001) 2.19 (< 0.001) 1.98 (< 0.001) 2.16 (< 0.001) 
Placenta2 1.14 (< 0.001) 1.10 (0.011) 1.23 (0.002) 1.25 (0.011) 
Enrichment fold statistics and P-values based on 1,000 permutations. 1LD pruning performed with 1000 Genomes CEU samples. 2LD 













Table 3.2: Loci expansion results for AUT-PGC SNPs reaching genome-wide significance (p-value < 5E-8) in discovery sample 
and/or combined discovery and replication sample 










































































a: reached 3E-8 in combined discovery and replication sample 









Figure 3.1: meQTL target Gene ontology enrichment analysis. Venn diagram depicts number of nominally significant (p < 0.05) 






Figure 3.2: Identification of novel candidate genes for ASD through meQTL mapping in 
peripheral blood, cord blood, fetal brain, and placenta for locus on chromosome 8. Each 
tissue-specific panel presents, from bottom to top: genomic location, gene annotations, SNP 
locations, SNP-CpG associations, CpG locations. Light gray meQTL association lines denote all 
SNP to CpG associations in that tissue type. Dark meQTL association lines denote SNP-CpG 
associations for ASD-associated SNPs in PGC (P-value <= 1E-5). Data are presented for 
meQTL maps for (from top to bottom): placenta, fetal brain, cord blood, and peripheral blood.  
Please note locus coordinates differ from those in Table 2.2 because in this context they 





CHAPTER 4: PLACENTA DNA METHYLATION AND AUTISM 
SPECTRUM DISORDER 
4.1 Abstract 
Background: Epigenetic mechanisms are of increasing interest to elucidate the etiology of autism 
spectrum disorder (ASD). Previous studies examining DNA methylation (DNAm), the most well 
studied epigenetic mark, and ASD have mostly utilized brain or blood tissue for DNAm 
measurement. Placenta DNAm is not well understood in an ASD context, despite the key role the 
placenta plays in regulating the in utero environment and the prenatal window being a critical 
time period for ASD risk factors.  
Objectives: This study aims to investigate placenta methylation via comprehensive whole 
genome bisulfite sequencing (WGBS), which measures methylation at about 26 million loci, in 
order to identify A) differentially methylated regions (DMRs) and B) global methylation 
differences, related to ASD diagnosis. We conducted sex stratified analyses comparing the 
placentas from children who went on to be classified as having ASD (Nmales = 18) and who went 
on to be classified as non-typically developing (NTD; Nmales = 26, Nfemales = 24) to those from 
children who went on to classified as typically developing (TD; Nmales = 17, Nfemales = 20). 
Results: No genome-wide significant ASD-associated DMRs were identified. However, NTD 
males displayed suggestive evidence for differences in global DNA methylation patterns in CpG 
island shores (P = 0.043) and shelves (P = 0.037), and in open sea locations (P = 0.014) relative 
to TD males. No significant global methylation differences between ASD and TD males or 





Conclusions: No significant DMRs were identified in placentas obtained from women whose 
children went on to be diagnosed with ASD. Global methylation patterns did distinguish NTD 
males from TD males, but not to an extent that surpassed multiple testing correction. These 
results do not provide insight into the altered placental mechanisms that contribute to ASD 
etiology, nor do they provide placenta DNAm profiles that could serve as an ASD or NTD 
biomarker. Future studies in larger sample sizes will enable detection of autism-related 
differential methylation of smaller magnitude. These studies should be undertaken given the 
strong theoretical framework linking placenta DNAm to fetal brain developing, and the previous 
successful placenta DNAm studies in the context of ASD and related phenotypes. 
4.2 Introduction 
Autism spectrum disorder (ASD) is characterized by social, behavioral, and communication 
deficits and affects 1 in 68 children in the US (Christensen et al., 2016). ASD is known to have a 
strong genetic basis (Colvert et al., 2015; Gaugler et al., 2014; Sandin et al., 2014). Common 
variant findings are increasingly being realized through the Psychiatric Genomics Consortium 
ASD working group (PGC-AUT), with the first mega-analysis results recently being published 
(Autism Spectrum Disorders Working Group of The Psychiatric Genomics Consortium, 2017) 
and the next iteration of summary statistics recently becoming available (Grove et al., 2017). 
Most genetic findings to date have come from rare variant studies and include identification of 
inherited and de novo single nucleotide and copy number variants (CNVs) associated with ASD 
(Iossifov et al., 2014; O’Roak et al., 2014; Sanders et al., 2015).  
Increasingly, epigenetic factors have been investigated in ASD because of multiple lines of 





ASD rare variant findings (Krumm, O’Roak, Shendure, & Eichler, 2014; Pinto et al., 2014; 
Sanders et al., 2015). Second, many disorders (Rett, Angelman, Fragile X) that overlap with 
ASD phenotypically have an epigenetic basis (Budimirovic & Kaufmann, 2011; Jedele, 2007; 
Mount, Charman, Hastings, Reilly, & Cass, 2003).  
Previous studies of ASD and genome-wide DNA methylation patterns, measured in postmortem 
brain tissue because it is thought to be the affected tissue type in ASD, have implicated multiple 
genes including TSAPN32/C11orf21, ZFP57, PRRT1, and SDHAP3 (Ladd-Acosta et al., 2014; 
Nardone et al., 2014). Candidate gene approaches have found associations with MeCP2, OXTR, 
EN-2, and SHANK3 (Gregory et al., 2009; James, Shpyleva, Melnyk, Pavliv, & Pogribny, 2013; 
Nagarajan, Hogart, Gwye, Martin, & LaSalle, 2006; Zhu et al., 2014).  Another recent 
postmortem brain-based study interrogated another type of epigenetic mark, histone acetylation, 
on a genome-wide scale. The authors reported the discovery of large scale dysregulation of 
histone 3 lysine 27 acetylation (H3K27ac) in a subset of ASD cerebral cortex samples (Sun et al., 
2016). Another previous study also identified various ASD-associated changes in histone 3 
lysine 4 methylation (H3K4me3) comparing postmortem prefrontal cortex samples from ASD 
cases to controls (Shulha et al., 2012). 
Because sample sizes for brain-based studies are limited and there could be confounding issues 
related to using postmortem samples, complementary blood-based epigenetic studies of ASD 
have been undertaken as well. These studies have implicated various genes such as NFYC, 
PTPRCAP, and MBD4 (Aldinger, Plummer, & Levitt, 2013; Gregory et al., 2009; Wong et al., 
2014), There have also been ASD-based investigations of DNAm from buccal epithelium (Berko 





fathers of children with ASD (Feinberg et al., 2015). Still, in an ASD context, the accessibility of 
DNAm from peripheral tissues and the subsequent potential for epidemiological scale cohorts 
comes at the cost of a lack of direct etiologic relevance of findings. 
Given that epigenetic marks are tissue-specific, the choice of source tissue for epigenetic 
association analysis needs to be fully considered (Bakulski, Halladay, Hu, Mill, & Fallin, 2016). 
A tissue that balances etiologic relevance in an ASD context and accessibility is the placenta, 
which functions as unique maternal-fetal interface during pregnancy. The current framework 
linking placenta function to increased susceptibility to neurodevelopmental disorders involves 
the placenta’s role in regulating maternal-fetal interactions. Overall, maternal insults such as 
immune activation, malnutrition, or stress are thought to lead to altered placenta status in the 
state of cytokines, hormones and endocrine factors, and gene expression. These altered states 
then impact placental processes such as immune tolerance, the growth of the placenta into the 
uterine wall, and the production of neuroactive molecules. Finally, these affected processes result 
in several adverse events linked to the prenatal programming of disease, such as immune 
dysfunction, intrauterine growth restriction or malnutrition, hypoxia, ischemia, and altered 
neuronal development and circuit formation, each of which contribute to an increased 
susceptibility to neurodevelopmental disorders (Hsiao & Patterson, 2012). Moreover, there are 
differences in placental gene expression even in normal development between male and female 
fetuses (Buckberry, Bianco-Miotto, Bent, Dekker, & Roberts, 2014; Clifton, 2010; Cvitic et al., 
2013), a fact that is particularly intriguing with respect to ASD given its high male to female 





In keeping with this framework, several studies have identified links between altered placenta 
structure and/or function and ASD. One study based in the prospective, enriched risk birth cohort 
Markers of Autism Risk in Babies – Learning Early Signs (MARBLES), demonstrated that 
mothers with a previous child with diagnosed ASD had an 8-fold greater odds of having 
placentas (from a subsequent pregnancy) with two or more trophoblast inclusions compared to 
control mothers (Walker et al., 2013). Trophoblast inclusions are a hallmark of abnormal 
placental growth, and are characterized by the typically inner cytotrophoblast cell layer of 
placental villi enveloping the typically outer syncytiotrophoblast layer (Adler, Madankumar, 
Rosner, & Reznik, 2014). In addition to this study examining pregnancies subsequent to the 
ASD-affected child, similar relationships demonstrating an association between trophoblast 
inclusions and ASD have also come in directly comparing placentas from children who went on 
to develop ASD to those from control children (Anderson, Jacobs-Stannard, Chawarska, 
Volkmar, & Kliman, 2007). Another more recent study also linked various aspects of placenta 
histopathology to ASD. Specifically, acute placenta inflammation, chronic uteroplacental 
vasculitis, the fetal inflammatory response in the chorionic plate, and maternal vascular 
malperfusion pathology were all associated with placentas from children who went on to develop 
ASD compared to those from matched controls (Straughen et al., 2017). Finally, another paper 
demonstrated the utility of random forest-based classification of placenta chorionic surface 
vascular network structure to distinguish between placentas from high risk ASD pregnancies (i.e. 
those from mothers with a child previously diagnosed with ASD) and population-based controls 





Understanding the epigenetic features dysregulated in ASD could shed increased light on the 
placenta structure and/or functional mechanisms that impair fetal brain development. Moreover, 
placenta-based signatures of ASD could serve as a useful early biomarker for ASD that could 
guide early interventions, which have been shown to improve prognosis (Klintwall, Eldevik, & 
Eikeseth, 2015). With respect to placenta epigenetic features specifically and neurodevelopment, 
there has been a wave of studies using both candidate gene and genome-wide approaches to link 
infant-based neurobehavioral outcomes and DNAm (Lester & Marsit, 2018). There has been one 
previous study specifically examining DNAm profiles and the ASD phenotype in placenta. This 
study identified one autosomal differentially methylated region in DLL1 (Schroeder et al., 2016), 
near a putative fetal brain enhancer. This study was particularly distinguished by its used of 
sequencing-based DNAm, which allows for greater methylome coverage than Illumina array 
platforms typically used for epigenome-wide association studies. 
Our study improves upon this previous placenta DNAm and ASD study by also using placenta 
samples measured for DNAm using sequencing, but via a comprehensive technique known as 
whole genome bisulfite sequencing (WGBS) as opposed to the MethylC-seq technique used 
previously. In addition, our study makes use of a greater number of samples overall (N = 106 vs 
N = 47), and includes samples with an additional, mutually exclusive phenotype category known 
as non-typical development (NTD), allowing for a more nuanced investigation of the relationship 
between placenta DNAm and neurodevelopment more broadly. Using placental samples from an 
enriched risk birth cohort, we searched for differentially methylated regions and global 
methylation differences in placenta tissue comparing pregnancies where the children went on to 





development (NTD), to placentas from children who went on to be classified as typically 
developing (TD). We perform these analyses in a sex-stratified framework to acknowledge the 
known sexual dimorphism in placenta gene expression (Buckberry et al., 2014; Cvitic et al., 
2013) and DNAm (Gong et al., 2018; Martin et al., 2017). 
4.3 Methods 
4.3.1 EARLI Study Description 
The Early Autism Risk Longitudinal Investigation (EARLI) is a prospective, enriched-risk birth 
cohort that has been described in detail elsewhere (Newschaffer et al., 2012). The EARLI study 
was approved by Human Subjects Institutional Review Boards (IRBs) from each of the four 
study sites (Johns Hopkins University, Drexel University, University of California Davis, and 
Kaiser Permanente). Informed consent was obtained from all participating families. The 232 
mothers with a subsequent child born through this study had births between November 2009 and 
March 2012. Placental biopsy samples were collected after delivery at each clinical lab site using 
Baby Tischler Punch Biopsy Forceps. Samples were stored at ambient temperature in RNAlater 
vials (Qiagen, Cat. No. 76154) and shipped same-day to the Johns Hopkins Biological 
Repository (JHBR) in Baltimore, Maryland, for storage at -190°C until processing. After biopsy, 
the placentas were then placed flat in a bag with 10% formalin at a volume roughly equivalent to 
the size of the placenta. 
Infants were followed with extensive neurophenotyping until age three, when they obtained an 
ASD diagnosis. Children were classified as having autism spectrum disorder (ASD) if they met 
or exceeded the ASD cutoff of the Autism Diagnostic Observation Schedule (ADOS) (Lord et 





Revision (DSM-IV-TR) (“DSM-IV: Diagnostic and Statistical Manual of Mental Disorders | 
JAMA | The JAMA Network,” n.d.) criteria for Autistic Disorder or Pervasive Developmental 
Disorder – Not otherwise specified (PDD-NOS). Children were classified as having non-typical 
development (NTD) if they did not meet the criteria for ASD classification but had two or more 
Mullen Scales of Early Learning (Mullen, 1995) subtests ≥ 1.5 SD below the mean and/or one or 
more Mullen subtests ≥ 2 SD below the mean and/or ADOS ≤ 3 points below the ASD cutoff. 
Children were classified as having typical development (TD) if they did not meet the criteria for 
ASD classification and had no more than one Mullen subtest ≥ 1.5 SD below the mean and no 
Mullen subtest ≥ 2 SD below the mean and ADOS > 3 points below the ASD cutoff. 
4.3.2 Whole genome bisulfite sequencing, alignment, and quality control 
Genomic DNA (gDNA) from biopsy punches was extracted at JHBR using a QIAgen 
QIAsymphony automated workstation with the Blood 1000 protocol of the DSP DNA Midi kit 
(Cat. No. 937255) as per manufacturer’s instructions. 250ng gDNA was bisulfite treated using 
the Zymo EZ-96 DNA Methylation Kit (Cat. No. D5004), and sequencing libraries were made 
with the NEBNext Ultra DNA Library Prep Kit for Illumina. Library preparation was performed 
at the Center for Epigenetics and libraries were sequenced at ~4x coverage at the High 
Throughput Sequencing Center at the Johns Hopkins University School of Medicine using the 3 
Illumina HiSeq 2500 instruments. These low coverage measurements were ran in order to 
maximize sample numbers, exploiting known smoothing techniques to recapture higher coverage 
sequencing-based DNAm from low coverage data (Hansen, Langmead, & Irizarry, 2012). 
Initially 133 placenta samples were run on 16 flow cells; two samples failed due to a fluidics 





Raw .fastq files were aligned the human reference genome (hg38) downloaded from Ensembl 
(Aken et al., 2017) via Bismark (v0.16.3) (Krueger & Andrews, 2011) using the default 
arguments for paired-end sequencing data. M-bias plots (Hansen et al., 2012) were used to 
inform the trimming of the 5bp of both the first and second reads, and methylation status was 
called using the Bismark methylation extractor function. All subsequent analyses used R (version 
3.4.2) and the R package bsseq (version 1.13.6) (“bsseq,” n.d.). The bsseq function 
read.bismark() was used to read in Bismark output files (“cytosine report” format) and obtain 
DNAm measurements on a per-CpG site basis. A total of 29,091,077 CpG sites were measured 
with at least 1 read in 1 sample out of the total 133. Next methylation levels were smoothed 
using the BSmooth algorithm that has been previously described (Hansen et al., 2012). Briefly, 
this technique employs a local-likelihood smoothing algorithm to recapitulate higher coverage 
whole genome bisulfite sequencing data from lower coverage data, exploiting known local 
correlation structure in DNAm data. We used the BSmooth() function in the bsseq R package 
with the default arguments. 
4.3.3 Identification of differentially methylated regions  
Given the known sexual dimorphism of the placenta (Buckberry et al., 2014; Clifton, 2010; 
Cvitic et al., 2013; Gong et al., 2018; Martin et al., 2017), as well as the established sex-biased 
ratio of ASD diagnosis (Christensen et al., 2016), we elected to perform sex-stratified queries 
related to diagnosis. For males, we compared ASD cases to TD individuals, as well as NTD 
individuals to TD. For females, we only compared NTD to TD, because just a single female 
sample with available DNAm data was diagnosed with ASD. For each analysis, we limited 





males, we retained loci with ≥ 2 reads in at least 10 ASD samples and 10 TD samples, leaving a 
total of 26,988,836 DNAm sites across the 35 samples. For the NTD vs TD analysis in males, we 
retained loci with ≥ 2 reads in at least 15 NTD samples and 10 TD samples, leaving a total of 
27,010,299 DNAm sites across the 43 samples. For the NTD vs TD analysis in females, we 
retained loci with ≥ 2 reads in at least 15 NTD samples and 10 TD samples as well, leaving a 
total of 26,988,807 DNAm sites across the 44 samples. Finally, we used the BSmooth.tstat.fix() 
and dmrFinder() functions in bsseq with the default arguments to identify DMRs. Statistical 
significance was assessed by creating 1000 null sets of methylation data via scrambling sample 
labels for diagnosis and re-running the DMR-finding algorithm; p-values were calculated as the 
number of null sets in which at least 1 DMR had a ≥ ‘areaStat’ value (sum of t-statistics) and 
width (in bp) than the candidate DMR.   
4.3.4 Global methylation analysis 
In addition to searching for DMRs, we also sought to compare global methylation levels between 
each of our 3 outcome groups (ASD, NTD, and TD). To do this, we first employed a similar 
coverage-based filtering of CpG sites as performed prior to the DMR queries for the full dataset 
of 29,091,077 CpG sites and 133 samples. Specifically we limited the data to retain sites with ≥ 2 
reads in more than two-thirds of the total number of samples, leaving 26,752,597 DNAm sites. 
Next we downloaded a list of CpG islands from the UCSC Genome Browser Table (Karolchik et 
al., 2004), and defined CpG island shores as being 2000 bp upstream and downstream of these 
islands, and defined CpG island shelves as being 2000 bp flanking those shores. We used the 
function findOverlaps() in the GenomicRanges R package to classify DNAm sites into these 3 





Next we ran the clusterMaker() function in the bsseq R package to collapse loci into regions in 
an identical manner as to how they are combined for DMR finding. We computed the mean 
within each cluster for each sample. If a cluster encompassed more than one genomic region 
(such as, for example, and island and shore in the same identified cluster), we computed the 
mean within each of the genomic region. We finally collapsed across clusters, ultimately 
retaining a mean for each sample within each of the 4 genomic regions. We compared these 
values in the same stratified groups as for the DMR analysis via t-tests. 
4.4 Results 
4.4.1 Identification of specific genomic locations showing methylation differences related to ASD 
or non-typical development  
Fetal-side placenta DNAm measurement at approximately 27 million CpG sites was available for 
133 samples, of which 106 had an available diagnosis (Supplementary Table IV-1) at age 3. 
We conducted male-stratified analyses to identify DMRs associated with ASD (N = 18) or non-
typically developing (N = 26) outcomes compared to typically developing male (N = 17) 
children; no genome-wide significant differences were observed (Supplementary Figures IV-1 
to IV-6). Similarly, female-stratified analyses revealed no genome-wide significant differences 
in locus-specific methylation related to non-typically developing (N = 24) compared to typically 
developing females (N = 20) (Supplementary Figures IV-7 to IV-9).   
4.4.2 Global methylation analyses 
We next conducted sex-stratified analyses comparing overall summed mean methylation levels 
between ASD, NTD, and TD diagnostic groups in various genomic contexts including CpG 
shores, shelves, islands, and open seas. We observed suggestive evidence that non-typically 





island shores (P = 0.043), CpG island shelves (P = 0.037), and in open sea locations across the 
genome (P = 0.014; Figure 4.1 and Supplementary Table IV-2). However, these differences 
were not significant after employing multiple testing correction (pBonferroni = 0.05/12 tests = 
0.0042). Moreover, effect sizes distinguishing the NTD and TD groups were small, and global 
methylation distributions were very similar. For example, the mean methylation level for NTD 
male samples in open sea locations, globally, was 0.608, which was only slightly different from 
the open sea methylation level (0.618) in TD males (Supplementary Table IV-2). Global 
methylation levels in ASD males were not significantly different from TD males in any genomic 
context, nor were NTD and TD female methylation levels (Figure 4.1). 
4.5 Discussion 
In this study, we sought to identify differences in placenta DNA methylation related to altered 
neurodevelopment. We applied two analytic approaches. First, we performed analyses to identify 
specific genomic regions showing differences in methylation between autistic or non-typically 
developing children relative to those with typical development. Second, we examined global 
measures of methylation at pre-defined genomic regions to identify types of genomic features 
associated with autism or non-typical neurodevelopment. We did not identify any DMRs or 
global methylation differences that were significant after multiple testing correction.   
Despite many previous studies linking placenta DNAm to infant neurobehavior (Lester & Marsit, 
2018) and one study to ASD (Schroeder et al., 2016), we did not identify any genome-wide 
significant DMRs separating ASD and ASD-related diagnostic groups from TD children. We 
chose to employ sex-stratified association analyses in light of the strong ASD male-to-female-





approach resulted in sample sizes of at most 26 samples per diagnostic outcome (TD male 
group). Thus, even though we have one of the largest placenta WGBS sample sizes, we may lack 
the statistical power to detect DMRs at effect sizes in placenta relevant to ASD. Differences 
between our analytic approach and a previous study of placenta DNAm and ASD that identified 
a methylation difference using a similar sample size (n=24 ASD and 23 TD kids) in a similar 
enriched birth cohort as EARLI may explain the different findings. For example, the previous 
study did not perform sex-stratified analyses and also did not test explicitly for DMRs but rather 
for average methylation differences between ASD and TD samples in both partially methylated 
domains (PMDs) and highly-methylated domains, or HMDs (Schroeder et al., 2016).  
Additionally, we did not employ any direct correction for cell type heterogeneity given the lack 
of a current placenta cell type DNAm reference panel as has been developed for a variety of 
other tissues (Bakulski, Feinberg, et al., 2016; Guintivano, Aryee, & Kaminsky, 2013; Reinius et 
al., 2012; Teschendorff et al., 2016), and the lack of many methodological approaches for 
reference-free based correction in sequencing-based DNAm (Teschendorff & Zheng, 2017). 
Both of these limitations represent key areas of future research that should be pursued. Though 
customarily thought to be critical to avoid Type I error, lack of adjustment for cell type 
heterogeneity can result in decreased power in association studies as well (Teschendorff & 
Zheng, 2017), and may have impaired our ability to detect genome-wide significant DMRs.  
We did identify suggestive global methylation differences between NTD and TD samples in 
males only. While our DMR analysis chiefly aims to identify regions of 1-2 Kb in length, this 
approach tests DNAm over much larger regions (for examples, all clusters contained in CpG 





In this manner, this analysis was more consistent with the previous ASD-placenta DNAm study 
that examined PMDs and HMDs that are, on average, an order of magnitude larger than these 
sought-after DMRs (Schroeder et al., 2013). However, suggestive differences in global 
methylation patterns between NTD and TD males did not surpass multiple testing correction and 
were characterized by very small effect sizes as far as mean differences between groups and 
overall differences of distributions. Moreover, these findings are limited somewhat by the lack of 
a “dose-response” type relationship in ASD samples, such as a stronger degree of 
hypomethylation relative to TD samples in the more severe phenotype of ASD. Instead, we often 
observed an opposite effect size in the ASD to TD comparison to what we saw in the NTD to TD 
comparison. Still, it is theoretically possible that these hypomethylation effects are specific to the 
NTD diagnosis and this finding should be investigated further. 
Future analyses of placenta DNAm and ASD should continue to pursue measurement of DNAm 
via WGBS, despite lack of significant findings in this study. Additional WGBS samples can be 
combined with the samples used in this study to better exploit the unbiased assessment of the 
placenta DNA methylome. Additionally, better leveraging of the PMD/HMD distinction can be 
made for association analyses. Specifically, it has been observed that greater inter-individual 
variability is present in placenta PMDs compared to HMDs (Schroeder et al., 2013, 2016). 
Therefore, placental DNAm association analyses, especially those of limited sample sizes 
needing to overcome multiple testing burden from a large number of interrogated loci presented 
by WGBS, can limit initial discovery regions to PMDs, as their greater variability dictates an 
increased likelihood to display phenotypic-related differences. However, this approach does not 





despite the fact that the one significant difference observed between ASD and TD samples in the 
previous placenta DNAm-ASD study was in a HMD (Schroeder et al., 2016). Finally, future 
studies should also look to more explicitly incorporate exposure information during pregnancy 
and maternal characteristics to discovery placenta DNAm signatures of ASD. For example, it is 
possible that placenta DNAm patterns differ according to ASD diagnosis only in the presence of 
particular environmental exposures that affect the maternal-fetal interface. In this manner, 
placenta DNAm offers interesting potential to discover the joint effect of genetic and 
environmental risk factors on ASD.  
4.6 Conclusions 
This study fails to identify significant DMRs or global methylation differences in placentas from 
children later diagnosed with ASD or NTD from those with TD. Given the strong theoretical 
framework linking placenta DNAm, placenta structure and function, and altered fetal brain 
development, as well as previous studies successfully identifying placenta DNAm signatures of 
infant neurobehavior and ASD, additional studies of placenta DNAm and ASD are still 
warranted, albeit with larger sample sizes than those used in this study. 
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Figure 4.1: Global methylation analysis, stratified by genomic feature, in placenta. Boxplots 
depict distribution of DNAm each diagnostic group of samples, stratified by sex. Number of 
clusters included in each genomic feature are also shown via ‘n’ (see Methods). P-values for t-
tests comparing different groups. Panel A) CpG islands Panel B) CpG island shores Panel C) 
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5.1 Abstract 
Background: The placenta undergoes vast epigenomic reprogramming.  In normal development, 
there are sex-specific differences in placenta function and responses to nutritional, stress-related, 
or environmental insults. While a few gene expression studies have interrogated the mechanism 
of these sex differences, previous studies of placenta DNA methylation have been limited by 
either limited methylome coverage or small sample size. To address these limitations, we use a 
comprehensive measurement of methylation (whole-genome bisulfite sequencing) on 37 (Nmales 
= 17, Nfemales = 20) fetal side placenta samples and search for differentially methylated regions 
(DMRs) according to fetal sex.  
Results: We identified one genome wide significant (ppermutation = 0.015) DMR where males 
exhibited on average 15% higher methylation levels in a CpG island promoter of ZNF300, a gene 
previously associated with cell proliferation and tumorogenesis. This fetal sex DMR is placenta-
specific, and is consistently replicated with similar magnitude in 7 additional sets of samples 
(made up of 6 independent studies), including full term and preterm placenta datasets and mixed 
cell and single cell type datasets, and persists in different disease states. Females can be 





have lower methylation levels.  Methylation levels in this DMR are associated with placenta 
perimeter (P = 0.044), area (P = 0.009) and maximum diameters (P = 0.059); these placenta 
morphology findings appear to be predominantly among females. Finally, there is suggestive 
evidence that ZNF300 DMR methylation levels mediate chromosome 5 and chromosome X SNP 
influences on these morphological features. 
Conclusions: Placenta methylation levels at the ZNF300 promoter are differential by sex and 
associated with placenta morphological features. Both of these findings are driven by a subset of 
female samples that have lower ZNF300 methylation levels than males.  
Keywords: placenta, DNA methylation, fetal sex, whole genome bisulfite sequencing 
5.2 Introduction 
It is well established that there are sex biases in phenotypes across the life course. For example, 
males are 20% more likely to have a poorer outcome in pregnancies complicated by 
preeclampsia, preterm delivery, and intrauterine growth restriction (IUGR) (Vatten & Skjaerven, 
2004). And later in life, males are more likely to be diagnosed with autism spectrum disorder 
(ASD) (Christensen et al., 2016), schizophrenia (Aleman, Kahn, & Selten, 2003), and 
cardiovascular outcomes (Bots, Peters, & Woodward, 2017), and females are more likely to be 
diagnosed with autoimmune disorders (Ngo, Steyn, & McCombe, 2014). Moreover, it is 
increasingly appreciated that the developmental and/or gestational period is critical to the 
programming of disease late in life – the “developmental origins of health and disease” construct 
(Wadhwa, Buss, Entringer, & Swanson, 2009). The placenta is a key organ during fetal 
development, providing a critical interface between the mother and fetus, and regulating the 





together, these notions suggest that there are sex-specific placental functions that can ultimately 
contribute to skewed sex ratios for adverse health outcomes.  
Male-female differences have been demonstrated during the gestational period, particularly for 
adaptations to adverse insults or environments (Clifton, 2010). For example, female growth has 
been shown to be reduced in the presence of mild maternal asthma; growth can be returned to 
normal levels with use of inhaled steroids (Murphy et al., 2003). Alternatively males continue 
normal growth in the presence of maternal asthma and only exhibit signs of affected growth 
when the asthma reaches acute levels (Murphy, Gibson, Talbot, & Clifton, 2005). Similarly, 
female fetuses in pregnancies complicated by preeclampsia have shown to exhibit reduced 
growth, while males tend to grow normally (Stark, Clifton, & Wright, 2009). Such findings have 
led to hypotheses regarding the differential nature of responses to perturbations during pregnancy 
by sex: that males aim to maintain growth in the presence of an initial adverse insult, leaving less 
reserve capacity to handle an additional adverse event. In contrast, females reduce growth in the 
presence of a poor intrauterine environment, allowing for increased ability to address further 
adverse events (Clifton, 2010).  It is also postulated that females tend to be more at risk for 
adverse outcomes when perturbations occur in the peri-conception or early gestational periods, 
affecting trophoblast differentiation. In contrast, male fetuses are more vulnerable in mid-to late 
gestation, when exposures will affect expansion and function of the definitive placenta as well as 
nutrient transport (Kalisch-Smith, Simmons, Dickinson, & Moritz, 2017). Finally, placenta 
immune function displays evidence for sex-specific effects as well; for example mouse studies 





displaying greater inflammation and macrophage activation than females (Kim, Young, Grattan, 
& Jasoni, 2014; Tarrade, Panchenko, Junien, & Gabory, 2015).  
Beyond these observations, little is understood about the mechanism of sex differences in the 
placenta. Some gene expression studies have provided suggestions; for example a study 
investigating sorted placenta cell types found pathways such as graft vs. host disease, immune 
function, and inflammation to be enriched in genes differentially expressed by sex (Cvitic et al., 
2013). Another meta-analysis of placenta microarray data discovered pathways such as cell 
growth, proliferation, and hormonal function (Buckberry, Bianco-Miotto, Bent, Dekker, & 
Roberts, 2014). Additional insights into mechanisms of sex-specific function may also come 
from investigating epigenetic data, or specifically DNA methylation (DNAm). Sex-related 
mechanisms may be particularly illuminated through the placenta methylome given previous 
studies highlighting its role in various phenotypes such as preeclampsia (Kulkarni, Chavan-
Gautam, Mehendale, Yadav, & Joshi, 2011; Yuen, Peñaherrera, von Dadelszen, McFadden, & 
Robinson, 2010) and IUGR (Roifman et al., 2016), its sensitivity to environmental exposures 
during the prenatal period (Maccani et al., 2015; Maccani, Koestler, Houseman, Marsit, & 
Kelsey, 2013; Mohanty et al., 2015; Suter et al., 2011), and its dynamic nature across gestation 
(Novakovic et al., 2011). Moreover, there have been many recent studies successfully 
demonstrating autosomal DNAm differences across a variety of tissue types, such as peripheral 
blood (Inoshita et al., 2015; Price et al., 2013; Singmann et al., 2015; Suderman et al., 2017), 
cord blood (Yousefi et al., 2015), pancreas (Hall et al., 2014), prefrontal cortex (Xu et al., 2014), 
and two recent studies in placenta (Gong et al., 2018; Martin et al., 2017). This first of these 





in a small for gestational age cohort, implicating similar pathways to those found by gene 
expression studies such as immune function, growth/transcription factor signaling, and transport 
across cell membranes. However, that study measured DNAm via the Illumina 450k microarray 
(Martin et al., 2017). While this platform is the standard measurement tool for DNAm studies, it 
is still limited in its coverage of the DNA methylome. The second placenta study addressed these 
concerns by measuring placenta DNAm via the gold standard technique of whole genome 
bisulfite sequencing (WGBS), but only studied 4 samples (2 female, 2 male). Beyond sex 
chromosomes, they observed one autosomal differentially methylated region in the gene body of 
CSMD1, and this was not observed in 8 other tissues, suggesting that it is placenta-specific 
(Gong et al., 2018). 
In this manuscript, we measure placenta DNAm via WGBS on a much larger set of samples 
(Nmales = 17, Nfemales = 20) to identify autosomal differential methylation corresponding to fetal 
sex. We identify a genome-wide significant differentially methylated region (DMR) in the 
promoter of ZNF300. We demonstrate the persistence of this hit in numerous publically available 
datasets, describe potential evidence for local and X chromosome genetic variants controlling 
DNAm levels in this region, and describe how both of these molecular features are associated 
with placenta morphology.  
5.3 Methods 
5.3.1 EARLI study description  
The Early Autism Risk Longitudinal Investigation (EARLI) is a prospective, enriched-risk birth 
cohort that has been described in detail elsewhere (Newschaffer et al., 2012). The EARLI study 





study sites (Johns Hopkins University, Drexel University, University of California Davis, and 
Kaiser Permanente). Informed consent was obtained from all participating families. The 232 
mothers with a subsequent child born through this study had births between November 2009 and 
March 2012. Placental biopsy samples were collected after delivery at each clinical lab site using 
Baby Tischler Punch Biopsy Forceps. Samples were stored at ambient temperature in RNAlater 
vials (Qiagen, Cat. No. 76154) and shipped same-day to the Johns Hopkins Biological 
Repository (JHBR) in Baltimore, Maryland, for storage at -190°C until processing. After biopsy, 
the placentas were then placed flat in a bag with 10% formalin at a volume roughly equivalent to 
the size of the placenta. These bags were then shipped to Placenta Analytics, LLC, where they 
underwent extensive morphological and surface imaging testing.  
Infants were followed with extensive neurophenotyping until age three, when a diagnosis of 
ASD could reliably be made. Children were classified as having autism spectrum disorder (ASD) 
if they met or exceeded the ASD cutoff of the Autism Diagnostic Observation Schedule (ADOS) 
(Lord et al., 2000) and met the Diagnostic and Statistical Manual of Mental Disorders, 4th 
edition, Text Revision (DSM-IV-TR) (“DSM-IV: Diagnostic and Statistical Manual of Mental 
Disorders | JAMA | The JAMA Network,” n.d.) criteria for Autistic Disorder or Pervasive 
Developmental Disorder – Not otherwise specified (PDD-NOS). Children were classified as 
having non-typical development (NTD) if they did not meet the criteria for ASD classification 
but had two or more Mullen Scales of Early Learning (Mullen, 1995) subtests ≥ 1.5 SD below 
the mean and/or one or more Mullen subtests ≥ 2 SD below the mean and/or ADOS ≤ 3 points 
below the ASD cutoff. Children were classified as having typical development (TD) if they did 





below the mean and no Mullen subtest ≥ 2 SD below the mean and ADOS > 3 points below the 
ASD cutoff.  
5.3.2 Whole genome bisulfite sequencing processing, alignment, and quality control 
Genomic DNA (gDNA) from biopsy punches was extracted at JHBR using a QIAgen 
QIAsymphony automated workstation with the Blood 1000 protocol of the DSP DNA Midi kit 
(Cat. No. 937255) as per manufacturer’s instructions. 250ng gDNA was bisulfite treated using 
the Zymo EZ-96 DNA Methylation Kit (Cat. No. D5004), and sequencing libraries were made 
with the NEBNext Ultra DNA Library Prep Kit for Illumina. Library preparation was performed 
at the Center for Epigenetics and libraries were sequenced at ~4x coverage at the High 
Throughput Sequencing Center at the Johns Hopkins University School of Medicine using the 3 
Illumina HiSeq 2500 instruments. Initially 133 placenta samples were run on 16 flow cells; two 
samples failed due to a fluidics error and were re-run using a 17th flow cell.  
Raw .fastq files were aligned the human reference genome (hg38) downloaded from Ensembl 
(Aken et al., 2017) via Bismark (v0.16.3) (Krueger & Andrews, 2011) using the default 
arguments for paired-end sequencing data. M-bias plots (Hansen, Langmead, & Irizarry, 2012) 
were used to inform the trimming of the 5bp of both the first and second reads, and methylation 
status was called using the Bismark methylation extractor function. All subsequent analyses used 
R (version 3.4.2) and the R package bsseq (version 1.13.6) (“bsseq,” n.d.). The bsseq function 
read.bismark() was used to read in Bismark output files (“cytosine report” format) and obtain 
DNAm measurements on a per-CpG site basis. A total of 29,091,077 CpG sites were measured 
with at least 1 read in 1 sample out of the total 133. Next methylation levels were smoothed 





this technique employs a local-likelihood smoothing algorithm to recapitulate higher coverage 
whole genome bisulfite sequencing data from lower coverage data, exploiting known local 
correlation structure in DNAm data. We used the BSmooth() function in the bsseq R package 
with the default arguments.    
5.3.3 Identification of differentially methylated regions 
To characterize normal placentas, we limited our initial discovery sample to 37 samples (Nmales = 
17, Nfemales = 20) with a classification of TD at 3 years of age. We removed CpGs with little or no 
coverage in a large proportion of samples to avoid detection of DMRs in these regions, as they 
are likely to be false positives (“bsseq,” n.d.). Specifically we limited DNAm data to sites at 
which at least 8 males and 10 females had ≥ 2 reads at each CpG site, and also removed sex 
chromosome CpGs, leaving a total of 26,157,032 CpG sites. Finally we used the 
BSmooth.tstat.fix() and dmrFinder() functions in bsseq with the default arguments to identify 
DMRs. Statistical significance was assessed by creating 1000 null sets of methylation data via 
scrambling sample labels for fetal sex and re-running the DMR-finding algorithm; p-values were 
calculated as the number of null sets in which at least 1 DMR had a ≥ ‘areaStat’ value (sum of t-
statistics) and width (in bp) than the candidate DMR.   
5.3.4 Placenta replication data sets 
After identifying a genome-wide significant DMR near ZNF300, we sought to examine the 
extent to which this difference replicated in additional datasets. First, we examined the DMR in 
the 50 EARLI WGBS samples classified as NTD (Nmales = 26, Nfemales = 24), termed Placenta 
Replication 1 (PR 1). Next we downloaded the manifest for the Illumina HumanMethylation450 





available, and found that 10 450K probes overlapped with the ZNF300 DMR coordinates. 
Therefore, we first downloaded 3 full term, mixed cell placenta datasets (matching the type of 
data we had for EARLI) from the Gene Expression Omnibus (GEO) (Edgar, Domrachev, & 
Lash, 2002) (GSE75248, GSE71678, and GSE75196), and obtained an additional dataset of this 
kind (Roifman et al., 2016) from the study authors; these were termed PRs 2-5 respectively. Next 
to investigate if this DMR was present earlier in the gestational period, we downloaded the 
preterm samples from an additional dataset (GSE57767), which we termed PR 6. Finally, to 
preclude the possibility that this DMR was driven by cell type heterogeneity (Jaffe & Irizarry, 
2014), we downloaded an additional 450k dataset of a single placenta cell type, villous 
cytotrophoblasts (GSE593208), which we termed PR 7.     
For 450k datasets for which raw data were available (PRs 2-5 and 7), we implemented the 
following processing and QC steps: functional normalization (Fortin et al., 2014), removal of 
samples with low overall intensity (median methylated or unmethylated signal < 11) or with a 
detection p-value > 0.01 in more than 1% of probes, and removal of probes described as 
ambiguously mapping (Chen et al., 2013), or with a detection p-value > 0.01 in more than 10% 
of samples. For PR 6, for which raw data were not available, we performed quantile 
normalization (Touleimat & Tost, 2012) and removed ambiguously mapping probes.  
5.3.5 Additional tissue replication data sets 
We also sought to discover the extent to which the genome-wide significant placenta DMR was 
present in different tissue types; we examined 450k data from cord blood, fetal brain, and 
peripheral blood. The cord blood data were obtained from EARLI samples; processing and 





methylation values for fetal brain data were downloaded from GEO (GSE58885). Peripheral 
blood data from 3-5 year old children were used from the Study to Explore Early Development; 
processing and quality control has also been previously described (Andrews et al., 2017).  
5.3.6 Genotype processing and methylation quantitative trait loci query 
We were first interested in quantifying the relationship of chromosome 5 SNPs to the ZNF300 
DMR methylation levels. Genotype processing and QC for EARLI autosomal SNPs has been 
previously described (Andrews et al., 2017). Imputed genotype data were available on 682,195 
SNPS for 121 of the 133 samples on which WGBS data existed. We imposed a 5% MAF 
threshold and removed duplicate positions, which limited the number of SNPs to 451,693, and 
then lifted the data from hg19 to hg38 (to match genome build on which WGBS alignment was 
performed) using the liftOver software (Hinrichs et al., 2006), yielding a final count of 451,680 
SNPs on chromosome 5. We were also interest in quantifying X chromosome SNP relationships 
to the DMR methylation levels. We measured 108,563 SNPs using the Illumina Omni5 plus 
exome array, which included 105,121 SNPs from the non-pseudoautosomal (nonPAR) region 
and 3,442 SNPs from the pseudoautosomal (PAR) region. Imposing a 5% MAF threshold 
yielded a total of 47,399 SNPs (44,992 nonPAR and 2,407 PAR), and lifting genome builds left a 
final total of 47,265 SNPs.  
To perform the methylation quantitative trait loci (meQTL) queries, we regressed the mean 
methylation level in the ZNF300 DMR onto each genotype (using an additive model) adjusting 
for the first four principal components of ancestry and gestational age. For the X chromosome 





meta-analyzed those results together using the METAL software (Willer, Li, & Abecasis, 2010) 
under the default conditions.  
5.3.7 Morphology mediation analyses 
We regressed mean ZNF300 methylation levels onto each morphological feature, adjusting for 
gestational age and birthweight; we did this analysis first in all samples on which DNAm and 
morphology data were available (N = 56), and then repeated the analyses in males (N = 34) and 
females (N = 22) separately. Finally, to explore the possibility that the suggestive genotype 
effects of meQTLs influenced these morphology phenotypes through ZNF300 DNAm, we 
employed a causal inference testing (CIT), or mediation analysis, approach as we previously 
implemented for rheumatoid arthritis and child allergy (Hong et al., 2015; Liu et al., 2013). 
Briefly, this method conducts a series of regressions to establish the genotypic effect on a 
phenotype that acts through methylation, exploiting the implicit nature of the SNP effect to 
precede all other effects temporally. These regressions are: 
1) Regression of phenotype (Y) onto methylation (M): Y and M are associated but no 
causality established 
2) Regression of methylation (M) onto genotype (G): G is causally associated with M 
3) Regression of Y onto G: G is causally associated with Y 
4) Regression of Y onto G, adjusting for M: Attenuation of beta coefficient indicates that 
the causal effect of G on Y is mediated by M 
We conducted a series of CIT procedures using all SNPs from the chromosome 5 and 
chromosome X meQTL queries that passed a suggestive significance threshold of p ≤ 1E-4 (n = 





phenotypes. For each regression, we included the total number of samples which had 
measurements for the form of data included in that regression. For regression 1, this was 56 
samples. For regression 2, this was 121 samples. For regressions 3 and 4, this was 51 samples. 
For all regressions involving X chromosome genotype data, we conducted analyses separately in 
males and females and then meta-analyzed the results as done for the meQTL query. 
5.4 Results 
5.4.1 Whole genome bisulfite sequencing study of fetal sex and replication 
A single DMR met a genome-wide permutation-base p-value threshold < 0.05: a 1597 bp region 
on chromosome 5 (ppermutation = 0.015; Supplementary Figure V-1). This DMR is characterized 
by 15% hypermethylation on average in male compared to female placentas (Figure 5.1A), and 
is not driven by fetal sex-related coverage of the region (Figure 5.1B).  It encompasses a roughly 
1.5 Kb region in a CpG island promoter of the ZNF300, and overlaps placenta-specific DNaseI 
hypersensitive sites identified in both male and female samples (Figure 5.1C). The DMR also 
overlaps 56 transcription factor binding sites (TFBSs), 53 of which map to the promoter region 
of the ZNF300. However, this number of TFBSs does not greatly distinguish ZNF300 from other 
genes in the genome, as roughly 30% of genes exhibit higher numbers of promoter-targeting 
TFBSs (Supplementary Figure V-2).   
We next sought to examine the extent to which the ZNF300 fetal sex DMR replicated in 
additional datasets.  First we examined EARLI placentas from independent children who went on 
to be classified as non-typically developing (Nmales = 26, Nfemales = 24); these samples also 
showed a sex DMR at ZNF300, with a mean male-female difference (MD) of 0.12 (Placenta 





additional datasets, using multiple probes on the array that overlapped the DMR region. Four 
datasets from full term, mixed cell samples replicated the sex DMR, with MD values between 
0.12 and 0.22 (PR 2-5 – Figure 5.2B-E). A separate dataset of preterm, mixed cell samples 
showed a MD value of 0.16 (PR 6 – Figure 5.2F). Finally, a sample of preterm placentas using a 
single placenta cell type (villous cytotrophoblasts) replicated with a MD value of 0.25 (PR 7 – 
Figure 5.2G). In addition to demonstrating the robustness of this DMR to gestational period (PR 
6 & 7) and potential confounding by cell type heterogeneity (PR 7), these replication sets also 
demonstrate the persistence of this DMR in different disease states. This persistence is true of 
early life phenotypes such as preeclampsia (cases and controls – PR 4; cases only – PR 6) and 
intrauterine growth restriction (PR 5), as well as later in life phenotypes such as non-typical 
neurodevelopment (PR 1).  
5.4.2 Non-placenta tissues 
Differential methylation by sex was not observed at ZNF300 in cord blood samples, fetal brain or 
peripheral blood samples. Mean differences between males and females were 0.004, 0.016, and 
0.01, respectively (Figure 5.3).  
5.4.3 Growth relationship with placenta DNAm at ZNF300 
This promoter region of ZNF300 had previously been identified for differential placenta DNAm 
related IUGR (Roifman et al., 2016). Specifically, in monochorionic IUGR discordant twin 
samples, placentas from IUGR samples were hypermethylated in this region. In our EARLI 
samples, and one of the publically available replication samples (PR 3), we derived a small-for-
gestational age (SGA) phenotype as a proxy for IUGR, based on birthweight and gestational age. 





samples but was seen when looking at females only. In males, the opposite effect of 
hypomethylation was seen for the SGA samples (Supplementary Figure V-3A-C). In PR3, 
hypomethylation of SGA samples was seen when looking across all samples and in males only, 
whereas no relationship was seen in females only (Supplementary Figure V-3D-F).    
5.4.4 The association between ZNF300 methylation levels and placenta morphological features 
We sought to understand the potential relationship between methylation levels in the ZNF300 
DMR and placenta morphological features, specifically placenta weight and placenta perimeter, 
area, and max diameter as determined by 2D fetal surface imaging. Across male and female 
samples on which methylation and morphology data were both available (N = 56), average 
methylation levels in the DMR were significantly associated with placenta perimeter (p = 0.044), 
area (p = 0.009), and max diameter (p = 0.059), but not weight (p =0.714), adjusted for birth 
weight and gestational age (Figure 5.4). Sex-stratified analyses revealed that this association was 
driven by female samples (Supplementary Figure V-4).  The ZNF300 methylation association 
to placenta morphology was not seen in males.  
5.4.5 Integrating genotype, ZNF300 methylation levels, and placenta morphology 
Finally, we sought to integrate genotype, methylation, and morphology information to 
investigate the potential role of ZNF300 methylation levels as a mediator of cis (chromosome 5) 
or trans (chromosome X) SNP effects on morphology. 17 SNPs were suggestively associated (p 
≤ 1E-4) with ZNF300 methylation levels (6 from chromosome 5 and 11 from chromosome X; 
Supplementary Figure V-5). Of these, one SNP on chromosome 5 and 7 SNPs on chromosome 





max diameter that was partially mediated through ZNF300 methylation levels (Figure 5 and 
Supplementary Figures V-6 to V-9).  
5.5 Discussion 
This study uses WGBS-measured DNAm data from fetal side placenta samples to identify a 
DMR associated with fetal sex harbored in a CpG island promoter region of ZNF300. Additional 
datasets demonstrate the replication of this DMR across multiple studies at a very similar 
magnitude (~15% higher methylation in males), and provide evidence for the persistence of the 
DMR at different gestational periods, in a single placenta cell type, and in different disease 
states. The DMR is placenta-specific, cannot be attributed to potential confounding variables 
such as gestational age, mode of delivery, or race, and does not share a significant degree of 
homology with sex chromosome sequences. Suggestive evidence exists for genetic drivers of 
ZNF300 methylation levels, which in turn are related to placenta morphology.  
Interestingly, the ZNF300 sex DMR is characterized by greater variability in female samples 
than males, as female samples cluster into a group with DNAm levels similar to those of males 
and another group with lower methylation levels who drive differential mean DNAm levels. 
Lower DNAm levels in the identified region are associated with smaller placenta perimeters, 
areas, and maximum diameters, but not placenta weights. This finding is driven by a female 
samples, and potentially reflects mediation of SNP influences on placenta morphology by 
DNAm.  
The chief strength of our finding is the extensive replication of the DMR across 7 different data 
sets, including 6 independent studies. To our knowledge, this is the strongest body of evidence 





In addition, two lines of evidence indicate that the DMR is placenta-specific. First, direct lookup 
of the identified ZNF300 region in DNAm isolated from cord blood, peripheral blood, and fetal 
tissues showed no relationship to sex. Second, the vast majority of previous studies of autosomal 
DNAm differences related to sex in other tissues, such as across peripheral blood (Inoshita et al., 
2015; Price et al., 2013; Suderman et al., 2017), cord blood (Yousefi et al., 2015), pancreas (Hall 
et al., 2014), and brain (Xu et al., 2014) did not report ZNF300 differences. One study in 
peripheral blood did report 5 Bonferroni significant ZNF300 sites in their initial discovery phase, 
but only replicated the result in 1 of their 3 replication cohorts, and only for 2 sites (Singmann et 
al., 2015).  
ZNF300 functions as a transcriptional repressor, and hypermethylation in the promoter of this 
gene has been previously associated with decreased gene expression (Zhao et al., 2014). 
Expression of the ZNF300 has been previously associated with tumorogenesis in HeLa cells 
(Wang et al., 2012), but knockdown of ZNF300 has been previously associated with cell 
proliferation in K562 cells (Cai et al., 2014). Our results indicated that placenta cells (chiefly 
whichever cell types drive this methylation association) tend to mimic K562 cells in their 
ZNF300 functionality, as hypomethylated female samples (thus those with increased ZNF300 
expression) tended to have placentas characterized by smaller areas, perimeters, and max 
diameters, indicating a decreased proliferative capacity.  
A previous study of placenta DNAm also identified the ZNF300 promoter region as being 
differentially methylation in monochorionic twin samples discordant for IUGR (Roifman et al., 
2016). Using SGA as a surrogate for IUGR, we did not replicate this finding using EARLI 





number of SGA samples and should be investigated further, particularly in light of our findings 
relating DNAm in this region to placenta morphology. Of note is that while we observed 
hypermethylation at ZNF300 in SGA samples (consistent in direction with IUGR as reported in 
the previous paper), when limiting analyses to females only, we also found lower DNAm levels 
in this region to be associated with smaller placenta areas, even though it has been previously 
reported that small placenta size is associated with IUGR in women with low pregnancy-
associated plasma protein-A (Proctor et al., 2009).  
The hypomethylated female samples represented one mode of female samples in the identified 
ZNF300 region. While this group drove the differential methylation and morphology findings, 
the other group of females had methylation levels that tended to cluster with male samples. In 
other words, females were characterized by a greater degree of DNAm variability in this region 
compared to males, and this region may have well been discovered by screens for sex-specific 
differential DNAm variability. The notion of greater DNAm variability in female samples, 
especially in this case where there are downstream morphological consequences, is particularly 
intriguing in the context of the placenta. It has been theorized that faster male growth during 
gestation comes at the risk of decreased plasticity or robustness to perturbations or adverse 
conditions during pregnancy (Clifton, 2010; Eriksson, Kajantie, Osmond, Thornburg, & Barker, 
2010). The greater distribution of placenta ZNF300 methylation levels and their linked 
morphological phenotypes that was observed in females in our study is congruent with this 
notion of female adaptability. Furthermore, there was a strong association between ZNF300 
methylation levels and these phenotypes when limiting analyses to females only, while no 





Future work should continue to investigate sex-related mean differences in DNAm as we did 
here in light of our small discovery sample size (N = 37). However, given the nature of the 
ZNF300 DMR discovered in our study, sex-focused studies of placenta DNAm should screen for 
differential variability as well. Future work specific to the ZNF300 DMR should first aim to 
better characterize the source(s) of this methylation difference. One potential area of 
investigation could be the role of sex hormones; this path is particularly intriguing given 
previous findings linking peripheral blood-derived DNAm sex differences in early life and sex 
hormone levels (Suderman et al., 2017). We also demonstrated suggestive evidence for local and 
more distant genetic effects on ZNF300 DNAm levels; these findings should be confirmed in 
greater sample sizes of joint genotype and DNAm data than were available herein (N = 121).  
Our evidence demonstrating the association between ZNF300 DNAm levels and placenta 
morphological phenotypes, including the suggestive genotype relationships acting through 
methylation to influence placenta morphology, should also be confirmed in greater sample sizes.  
This work should include efforts to obtain more direct evidence for the presence of this DMR 
during the gestational period, to better argue for its functional relevance. Finally, specific 
investigations to characterize the biomodality of female ZNF300 DNAm levels should be 
conducted to understand the factors driving females to cluster in one group vs. another, to what 
extent this grouping characterizes DNAm levels across the genome, and to discover if these two 
groups differ in early and/or later in life health outcomes.  
5.6 Conclusions 
We demonstrate a sex-related DMR identified in placenta samples that is harbored in a CpG 





different studies with a similar magnitude, and is robust to gestational period, cell type 
heterogeneity, and disease state. Female samples with lower DNAm levels in this region have 
smaller placenta areas, perimeters, and maximum diameters than females with DNAm levels 
similar to males. These DNAm influences on placenta morphology may be mediating local and 
more distant (X chromosome) genetic effects. This DMR provides insight into potential 
molecular mechanisms of known sex differences in placenta structure and function. We argue for 
the further characterization of this DMR for its role in contributing to sex-biased phenotypes 
later in life.    
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Figure 5.1: Differential placenta methylation by fetal sex identified at ZNF300 CpG island 
promoter. Panel A) Percent methylation (y-axis) plotted against genomic position (x-axis). 
Dashed lines represent individual samples and solid lines represent average for male (blue) and 
female (yellow) samples, respectively. Vertical dashed lines denote actual DMR start and stop 
coordinates. Panel B) Read counts divided by average coverage across all autosomal loci (y-
axis) vs. genomic position (x-axis). No differences exist between males and females in the DMR 
region. Panel C) Overlap of DMR with Gene track, CpG islands (UCSC Table Brower) and 
DNaseHS sites. Latter regions were downloaded from ENCODE for a male (GSM2400398) and 






Figure 5.2: Replication of male hypermethylation at ZNF300 CpG island promoter. Panel 
A) EARLI WGBS non-typically developing samples. Panels B-G: 450k replication datasets 
including preterm (Panels F & G) and single cell type (Panel G) datasets. 450k coverage 






Figure 5.3: Attempted replication of ZNF300 DMR in additional tissue types. Panel A) 
Cord blood samples from EARLI study Panel B) Fetal brain Panel C) Peripheral blood from 3-5 










Figure 5.4: Relationship between mean methylation levels at ZNF300 DMR and placenta morphological features. Mean DNAm 
levels in DMR (y-axis) vs. placental weight, perimeter, area, and maximum diameter (left to right, x-axis). P-values shown are for the 






Figure 5.5: Mediation analysis demonstrating relationship between a chromosome X SNP, 
mean ZNF300 DMR methylation levels, and placenta area. Panel A) Association between 
placenta area and average DNAm in DMR (p = 0.009); causality cannot be established. Panel B) 
Causal relationship between chromosome X SNP and average DNAm in DMR (p = 6.18E-5). 
Panel C) Causal relationship between chromosome X SNP and placenta area (p = 0.028). Panel 
D) Attenuation of SNP linear regression beta coefficient upon inclusion of DMR methylation 






CHAPTER 6: GENERAL DISCUSSION AND CONCLUDING REMARKS 
6.1 Major Findings 
The work in this dissertation provides mechanistic insights into autism spectrum disorder (ASD) 
and sexual dimorphism during pregnancy that can be gained through epigenetic data, in 
particular its integration with genotype data, across tissue types. 
First, we integrated methylation quantitative trait loci (meQTL) information across fetal brain, 
peripheral blood, and cord blood with a recent iteration of GWAS summary statistics from the 
ASD subgroup of the Psychiatric Genomics Consortium (PGC-AUT) to better understand ASD 
genetic signals. We found that ASD-related SNPs were enriched for fetal brain (OR = 3.55, 
Penrichment < 0.001) and peripheral blood meQTLs (OR = 1.58, Penrichment < 0.001). Additionally, 
the CpG sites associated with ASD-related SNPs were preferentially engaged in immune 
response pathways across fetal brain, cord blood, and peripheral blood. This finding is 
particularly interesting given that it is consistent with previous gene expression studies of ASD 
but that it reveals pathways that are not implicated by ASD genetic findings. Finally, we showed, 
in general, how mapping of the CpG targets of ASD-associated SNPs can expand the biological 
insights gleaned through GWAS analysis. 
Next, we focused on ASD studies of DNA methylation data from the placenta, which is an 
understudied but key tissue of interest in an ASD context. First, we repeated our previous 
integrative genotype-DNAm studies to include placenta meQTLs. Using a new iteration of the 
GWAS summary statistics from the PGC-AUT, we found ASD-related SNPs to be enriched for 
placenta meQTLs (fold enrichment = 1.25, pEnrichment = 0.011), replicated our previous findings of 





pEnrichment = 0.011) meQTLs, and also demonstrated enrichment for cord blood (FE = 2.16, 
pEnrichment < 0.001) meQTLs. While we did not replicate our previously observed enrichment for 
immune response pathways in ASD SNP-associated CpG sites across tissue types, tissue-specific 
pathways revealed interesting associations. These included Wnt signaling in peripheral blood, 
glial cell development in fetal brain, and virus-host interaction and syncytiotrophoblast cell 
development in placenta. Finally, all five genome-wide significant SNP loci identified by the 
PGC-AUT display evidence for meQTLs in placenta and/or peripheral blood, which expand loci 
to include additional gene targets and shed light on the tissue-specific functionality of these 
SNPs.  
Our second investigation of placenta DNAm in an ASD context involved queries for 
differentially methylated regions (DMRs) and global methylation differences related to ASD 
diagnosis. In sex-stratified analyses, no significant DMRs were identified, though we did find 
suggestive evidence that global placenta DNAm patterns in children who went on to be classified 
as non-typically developing differed from those of children who went on to be classified as 
typically developing in CpG island shores (p = 0.043), CpG island shelves (p = 0.037), and open 
sea regions (p = 0.014). However, these differences were small in magnitude and did not remain 
significant after multiple testing correction. 
Lastly we sought to discover fetal-sex-related differences in placenta DNAm, in an effort to 
contribute to research seeking to understand the mechanisms of sexual dimorphism during the 
gestational period. A CpG-island promoter region of ZNF300 was found be approximately 15% 
hypermethylated in male placentas compared to female placentas. ZNF300 has been previously 





sex-related differentially methylated region (DMR) is placenta-specific, and replicated in 7 
additional groups of samples, including 6 cohorts independent from the discovery sample. 
Replication sets demonstrated the persistence of this DMR at different points in the gestational 
period, in a single placenta cell type (villous cytotrophoblasts) and in different disease states 
(preeclampsia, intrauterine growth restriction, etc.) Female samples in the DMR region were 
characterized by two groups, one that exhibited DNAm levels similar to males, and the other that 
exhibited lower DNAm levels and who drives the differential methylation result. This later group 
was also characterized by smaller placenta area, perimeter, and maximum diameters as 
determined via 2D fetal surface imaging. Finally, suggestive evidence indicates that these 
methylation to placenta morphology relationships actually mediate local (chromosome 5) and 
distant (chromosome X) genetic relationships on placenta morphology that act through ZNF300 
DNAm. 
These studies demonstrate the value of epigenetic data for insights into normal development and 
adverse health outcomes in early life, particularly when used in conjunction with paired genotype 
data. Moreover, the inherent nature of epigenetic marks to vary across tissue types was exploited 
to illustrate useful mechanisms that both span across tissues and that are tissue-specific. 
6.2 Strengths and Limitations 
The first two studies comprise the first genome-wide integration of genetic and epigenetic data in 
an ASD context that has been performed to date. While our studies are inspired by similar 
integrative studies that have been done for bipolar disorder and schizophrenia, our work is 
distinguished by the focus on both SNP-based and CpG-based enrichment analyses. Previous 





associated SNPs. Our studies additionally enumerated the biological pathways engaged by ASD-
controlled CpG sites, demonstrating additional value to be gained from genotype-epigenotype 
integration.  
Another unique strength of the first two studies was the use of DNAm across tissue types. This 
approach treats a commonly considered challenge to studying epigenetic marks in life – that they 
inherently vary by tissue type – as an opportunity  to gain both cross-tissue and tissue-specific 
insights. For example, in the first study, the CpG-based enrichment analyses revealed immune 
response pathways to be engaged by ASD SNPs through DNAm across fetal brain, cord, blood, 
and peripheral blood. In the second study, though many cross-tissue pathways were not 
discovered, the use of multiple tissue types allowed for tissue-specific patterns to be elucidated. 
In peripheral blood, Wnt signaling pathways were specifically enriched in CpG sites controlled 
by ASD SNPs. But this enrichment was not seen in cord blood, fetal brain, and placenta. The use 
of multiple tissue types additionally added strength to our SNP-based enrichment analyses by 
allowing for a rigorously designed comparison in which our SNP enrichment approach could be 
tested in a positive control tissue (fetal brain in both studies) and a negative control tissue (lung 
in the first study and adipose tissue in the second study). The results in these control tissues 
confirmed the validity of our methodological pipeline and defined a spectrum of results against 
which our placenta and blood tissues of interest could be evaluated.  
They key insight from these two analyses is that all conclusions made from these studies are ones 
that are only achieved through the integration of genetic and epigenetic data, and not possible to 





demonstrated in these studies can be readily used in the context of any phenotype and tissue, as 
they only require a list of GWAS summary statistics and meQTL maps for the tissue of interest.  
These cross-tissue meQTL studies did present inherent challenges. Most previous meQTL 
studies only analyzed a single tissue type from a single study; harmonizing specific meQTL and 
CpG targets across tissue types and across different studies required deeper attention to SNP and 
methylation measurement tools used, thresholds for calling a meQTL, and available power. 
Factors such as available SNPs to be tested, available CpG sites to be tested, and meQTL 
detection windows in meQTL discovery can all create differential opportunity for a SNP to be 
called a meQTL and a CpG site to be deemed as associated with a SNP. For example, placenta 
DNAm was measured via whole genome bisulfite sequencing (WGBS), which measures 
upwards of 28 million CpG sites in the human methylome. In contrast, meQTL lists for all other 
tissues were generated using DNAm measured via the Illumina 450K Array, which queries only 
480,000 CpG sites in the methylome. Even within 450K studies, differences between tissues can 
exist in terms of SNP minor allele frequency and CpG site variability thresholds for inclusion 
into the meQTL query, quality control procedures, etc. These differences dictate that a SNP truly 
being a meQTL in one tissue and not another cannot be distinguished from a SNP only having an 
opportunity to be statistically classified as a meQTL in one tissue, but not the other. These 
concerns apply to classifying a CpG site as SNP-controlled in multiple tissues as well. 
While the main purpose of these studies was to integrate genotype and DNA data, the fetal sex 
study was primarily a DNAm-only analysis, one that was characterized by the use of a 
comprehensive, gold standard assessment of the placenta methylome via WGBS. The chief 





discovered ZNF300 DMR. Overall the DMR persists with a consistent direction and similar 
magnitude in seven additional groups of samples, including an independent set of samples from 
the same Early Autism Risk Longitudinal Investigation, and six others from separate publically 
available datasets. These replication sets additionally demonstrate the robustness of the finding 
to different disease states, points in the gestational period, and potential confounding via cell 
type heterogeneity (Jaffe & Irizarry, 2014). Taken together, these facts dictate that this ZNF300 
DMR in placenta is the strongest evidence achieved to data for an autosomal DNAm difference 
related to sex, across any tissue. This study also strongly characterizes the nature and sources of 
this DMR by incorporating additional forms of data. For example, lookup of the ZNF300 region 
in additional tissue types (including cord blood from the same individuals) allowed for the DMR 
to be classified as placenta-specific. Incorporation of placenta morphology data allowed for the 
downstream consequences of this DMR to begin to be elucidated and increased insight into how 
this DMR could mechanistically contribute to male-female differences during gestation. Finally, 
incorporation of paired genotype data allowed for insights into how the DMR could be 
genetically programed by local and distant SNP effects, and how ZNF300 DNAm mediates these 
effects on placenta morphology.     
This fetal sex study does suffer from a small sample size in the initial discovery phase (N = 37). 
This number dictated that the study could not adequately take advantage of the unique presence 
of WGBS-measured DNAm and was likely underpowered for association analysis. This study 
also did not employ direct correction for cell type heterogeneity given the lack of a current 
placenta cell type DNAm reference panel as has been developed for a variety of other tissues 





et al., 2016), and the lack of many methodological approaches for reference-free based correction 
in sequencing-based DNAm (Jaffe & Irizarry, 2014; Teschendorff & Zheng, 2017). It is unlikely 
that cell type heterogeneity drove the ZNF300 finding given that it was unrelated to gestational 
age (of which cell type is a known surrogate) and the DMR was present when looking at DNAm 
from a single placenta cell type. However, lack of correction for cell type heterogeneity could 
have further underpowered our analyses and prevented us from discovering additional genome-
wide significant loci (Teschendorff & Zheng, 2017). The limitations also apply to our WGBS 
study searching for DMRs related to ASD diagnosis.  
Another limitation of the fetal sex study is the lack of direct evidence for the discovered DMR to 
influence ZNF300 gene expression. Functional work has been performed to demonstrate the 
(expected) inverse association between ZNF300 promoter methylation levels and corresponding 
gene expression levels, but this work was done in liver tissue, not placenta. Genotype-DNAm 
and genotype-DNAm-morphology studies also suffered from a key challenge in data integration 
efforts – available samples with all forms of data. In the analysis looking for genetic drivers of 
ZNF300 methylation levels, only 121 samples were available, a number that left us 
underpowered to detect typical GWAS-level effect sizes. By contrast, the most recent PGC-AUT 
GWAS results were generated from 10,000 to 20,000 individuals (Grove et al., 2017). These 
concerns were exacerbated when limited to samples on which placenta morphology data were 
available as well.  
6.3 Public Health Significance 
The investigations integrating genetic and epigenetic data in an ASD context are of primary 





global analyses that argue for the value of specific tissues in ASD epigenetic research. In the first 
study, peripheral blood shared the same SNP and CpG-based inferences as fetal brain, albeit at 
different effect sizes. This fact argues for blood-based epigenetic research as a surrogate for less 
accessible brain-based results for ASD. This conclusion should be limited to methylation 
signatures under some genetic control, since this was the focus of our study. But it may offer an 
exciting opportunity to investigate DNAm in an ASD context at scale, given that peripheral 
blood DNAm can be collected on very large groups of people.  
Interestingly, in the second study, while the SNP-based enrichment results showed blood-brain 
concordance as we observed previously, CpG-based enrichment results pointed to tissue-specific 
pathways.  This reopens the question about whether peripheral epigenetic signals can serve as a 
proxy for brain, but does indicate value in understanding how a peripheral tissue is contributing 
to or reflective of disease etiology. Indeed, if the timing of DNAm collection is after disease 
onset (as it was in these studies for peripheral blood), these relationships can be indicative of 
direct genotype to disease relationships, which itself manifests in epigenetic changes (Ladd-
Acosta & Fallin, 2016).  
For more affected tissues where DNAm collection precedes ASD onset, such as fetal brain and 
placenta, our genotype-epigenotype analyses primarily illuminated genotype to disease 
relationships mediated by DNAm. Particularly in the second study, our analyses illuminated 
mechanistic relationships linking specific (genome-wide significant) ASD SNPs to specific CpG 
sites and genes, identifying possible intervention targets and providing mechanistic insights into 
the functions of GWAS-associated SNPs (Ladd-Acosta & Fallin, 2016). Of particular interest in 





insights both if functions are common across tissues and if they are tissue-specific. The insights 
offered by GWAS can be enhanced if we consider their potential impact in a variety of contexts, 
starting with tissue type but also including factors such as specific windows in the life course and 
the presence of certain environmental exposures.   
The fetal sex studies offer etiologic insights as well, potentially across a broad spectrum of 
phenotypes with sex-biased prevalence that occur across the life course. These include early life 
phenotypes such as preeclampsia and intrauterine growth restriction (Vatten & Skjaerven, 2004), 
but also later in life phenotypes like ASD (Christensen et al., 2016), schizophrenia (Aleman, 
Kahn, & Selten, 2003), cardiovascular outcomes (Bots, Peters, & Woodward, 2017), and 
autoimmune disorders (Ngo, Steyn, & McCombe, 2014). Our result, showing a fetal sex-related 
methylation difference related to placenta morphology, offers potential clues towards the 
developmental origins of this sexual dimorphism, as governed by the placenta.   
Female samples in the identified DMR region were characterized by two groups: those that had 
methylation levels similar to males, and those had lower methylation levels. This latter group 
drove the differential methylation result, and also exhibited placentas that were smaller in area, 
perimeter, and maximum diameter. Though future work is necessary, it is possible that these two 
groups of females differ significantly in terms of their prognosis for early and later in life adverse 
health outcomes. Therefore, DNAm levels at this ZNF300 region could be used to identify at risk 
populations and potentially inform treatment options. For example, if this dichotomy of females 
was found to correlate to adverse neurodevelopmental outcomes, placenta DNAm levels at 
ZNF300 could guide early interventions.  





A key area of future research for our studies integrating genetic and epigenetic data in an ASD 
context is to repeat analyses as ASD GWAS results are increasingly refined, and as meQTL 
information for additional tissue types becomes available. It is with this basis that the second 
study of this dissertation was developed; this work incorporated a more recent iteration of the 
GWAS summary statistics from the PGC-AUT, and an additional tissue of interest, the placenta. 
This iteration offered five genome-wide significant loci and therefore was of most value in the 
GWAS loci expansion analysis, which demonstrated meQTL relationships for all of these SNPs. 
Functional follow-up of these SNPs to understand their mechanistic role in ASD is likely to be 
undertaken, and these investigations can be informed by the nature of genetic control of DNAm 
that these SNPs exhibit in placenta and peripheral blood.  
As the field of epigenetic epidemiology advances, it will be important to gain additional 
coverage of the DNAm methylome in large groups of samples across different tissue types. We 
discovered that all five genome-wide significant loci identified in the PGC-AUT displayed 
evidence for controlling nearby placenta DNAm levels, which were measured via WGBS. This is 
likely not a consequence of a unique engagement by the placenta methylome of ASD SNPs, but 
rather a function of the significantly greater opportunity of SNPs to be called a placenta meQTL. 
Therefore, WGBS-level DNAm in additional tissues such as fetal brain, peripheral blood, and 
cord blood, can offer both comprehensive assessment of meQTLs and more unbiased cross-
tissue comparison. If possible, meQTL queries should be done on multiple tissue samples from 
the same group of individuals, using identical parameters for the meQTL queries. These efforts 
can minimize common issues that complicate comparing meQTLs identified in different studies. 





discover DMRs and global methylation differences related to ASD; our placenta WGBS ASD 
study suffered from small sample size because we conducted sex-stratified analyses.     
Discovery of the fetal sex ZNF300 DMR in placenta offers multiple avenues for future research. 
Given the extent of replication that was observed, and future efforts should focus on identifying 
sources of the DMR and its downstream morphological and phenotypic consequences. First, 
ZNF300 promoter DNAm levels should be confirmed for their role in dictating ZNF300 
expression. While an inverse relationship is canonical and has been demonstrated in liver cells, 
rigorous functional work in placenta should be established. Next, additional samples must be 
generated on which genotype, DNAm, and placenta morphology data all are available. These 
data will be useful to better understand the interplay of these factors in establishing the 
suggestive genotype to ZNF300 DNAm to placenta morphology relationship discovered herein. 
Moreover, it will be increasingly necessary to integrate these data to understand placenta 
function more broadly. 
Other follow up efforts to the ZNF300 finding must focus on the observed bimodality in female 
samples. First, this clustering of females samples should be interpreted as differential variability 
compared to male samples, not simply as a sex-specific differences in mean values. It is possible 
that the female placenta methylome is broadly characterized as more variable than that of males. 
Therefore, methodologies should be developed to identify differentially variable regions in 
sequencing-based DNAm data and should be applied in this context. Currently, such methods are 
optimized for DNA methylation array data. Next, the sources of the ZNF300 female bimodality 
should be enumerated. It is possible that one group of female samples shared a common 





should be investigated further, though they require a unique study setting in which both placenta 
DNAm and rich maternal exposure and/or behavior history during pregnancy is available. 
Finally, it is of great interest to characterize the effects of lower ZNF300 methylation levels in 
females, and their subsequent decreased placenta areas, on health outcomes in pregnancy and 
over the life course. Such investigations will require paired DNAm and placenta morphology 
data, along with potentially long term prospective follow up.  
The work in this dissertation provides demonstrates the value of epigenetic factors in discovering 
insights into ASD and sexual dimorphism during pregnancy. These findings were both enhanced 
and characterized in key ways by using many techniques to incorporate genetic data in 
conjunction with epigenetic data, and by exploiting DNAm data from a variety of tissue types. 
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Supplementary Figure I-1: The relationship between degree of significance and distance 
between SNP and CpG site on chromosome 21. Degree of significance (y-axis) defined by -
log10 p-value. Only meQTLs present at FDR = 5% are shown. The degree of significance decays 
with increasing distance. Left panel shows relationship for SEED peripheral blood data and right 










Supplementary Figure I-2: Gene Ontology enrichment analysis for meQTL targets in peripheral blood. Gene Ontology (GO) 
enrichment analysis via the ‘gometh’ function in the MissMethyl R package. The results for the “biological processes” group were 
pruned to remove overlapping terms using the REVIGO software. Results shown for meQTL targets of ASD-related (PGC p-value < 
1E-4) SNPs and their proxies (r2) against a background of all meQTL targets (n = 201 vs n = 59,308; Panels A+B) and for meQTL 
targets against a background of all CpG sties tested (n = 59,308 vs n = 290,066; Panels C+D). meQTL targets all defined via meQTL 
p-value threshold = FDR 5%. Panels A+C) The top 10  biological process by GO enrichment p-value after REVIGO pruning. Panel 
B+D) A multi-dimensional scaling projection of the semantic similarity in nominally significant (enrichment p-value < 0.05) GO 
terms produced by REVIGO. Clusters are identified via labeling of the terms with both the least redundancy and highest degree of 
enrichment (‘dispensability’ value < 0.15). Color reflect degree of significance and increasing size reflects greater frequency of term 






Supplementary Figure I-3: Gene Ontology enrichment analysis for meQTL targets in cord blood. Gene Ontology (GO) 
enrichment analysis via the ‘gometh’ function in the MissMethyl R package. The results for the “biological processes” group were 
pruned to remove overlapping terms using the REVIGO software. Results shown for meQTL targets of ASD-related (PGC p-value < 
1E-4) SNPs and their proxies (r2) against a background of all meQTL targets (n = 66 vs n = 22,803; Panels A+B) and for meQTL 
targets against a background of all CpG sties tested (n = 22,803 vs n = 289,645; Panels C+D). meQTL targets all defined via meQTL 
p-value threshold = FDR 5%. Panels A+C) The top 10  biological process by GO enrichment p-value after REVIGO pruning. Panel 
B+D) A multi-dimensional scaling projection of the semantic similarity in nominally significant (enrichment p-value < 0.05) GO 
terms produced by REVIGO. Clusters are identified via labeling of the terms with both the least redundancy and highest degree of 
enrichment (‘dispensability’ value < 0.15). Color reflect degree of significance and increasing size reflects greater frequency of term 






Supplementary Figure I-4: Gene Ontology enrichment analysis for meQTL targets in fetal brain. Gene Ontology (GO) 
enrichment analysis via the ‘gometh’ function in the MissMethyl R package. The results for the “biological processes” group were 
pruned to remove overlapping terms using the REVIGO software. Results shown for meQTL targets of ASD-related (PGC p-value < 
1E-4) SNPs and their proxies (r2) against a background of all meQTL targets (n = 53 vs n = 7,863; Panels A+B) and for meQTL 
targets against a background of all CpG sties tested (n = 7,863 vs n = 314,554; Panels C+D). meQTL targets all defined via meQTL 
p-value threshold = FDR 5%. Panels A+C) The top 10 biological process by GO enrichment p-value after REVIGO pruning. Panel 
B+D) A multi-dimensional scaling projection of the semantic similarity in nominally significant (enrichment p-value < 0.05) GO 
terms produced by REVIGO. Clusters are identified via labeling of the terms with both the least redundancy and highest degree of 
enrichment (‘dispensability’ value < 0.15). Color reflect degree of significance and increasing size reflects greater frequency of term 
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% of Total Independent 
Sites 
1    125,869 4.65% 6,640 4.15% 
2    407,722 15.08% 22,135 13.83% 
3    30,691 1.14% 1,354 0.85% 
4    722,703 26.73% 42,561 26.58% 
5    528 0.02% 18 0.01% 
6    6,299 0.23% 333 0.21% 
7    4,940 0.18% 237 0.15% 
8    1,405,261 51.97% 86,821 54.23% 
   SUM 2,704,013  160,099  
Results are shown for meQTLs associated at FDR = 5% threshold in blood and cord blood datasets and threshold of 1E-8 in fetal 
brain. 
Only SNPs that were included in all three tissues in their respective meQTL queries are included in this analyis (n = 2,704,013). 
Independent sites were constructed by grouping SNPs into bins defined by recombination hot spot data from 1000 Genomes (see 
Methods). 
For example, scenario 1 lists that there are a total of 125,869 SNPs that are meQTLs in blood, cord blood, and fetal brain, which fall 





















SNPs % of Total SNPs 
Independent 
Sites 
% of Total Independent 
Sites 
1    5 0.46% 2 0.80% 
2    74 6.76% 18 7.23% 
3    0 0.00% 0 0.00% 
4    195 17.82% 28 11.24% 
5    19 1.74% 8 3.21% 
6    75 6.86% 13 5.22% 
7    0 0.00% 0 0.00% 
8    726 66.36% 180 72.29% 
   SUM 1094  249  
Results are shown for meQTLs associated at FDR = 5% threshold in blood and cord blood datasets and threshold of 1E-8 in fetal 
brain. 
All ASD-related (p< 1E-04) SNPs in PGC, regardless of if they were tested in the respective meQTL studies, are included in this 
analysis. 
Independent sites were constructed by grouping SNPs into bins defined by recombination hot spot data from 1000 Genomes (see 
Methods). 











Supplementary Data II-1: Peripheral blood meQTLs identified at FDR = 5%.  






















Supplementary Data II-2: Cord blood meQTLs identified at FDR = 5%.  





















Supplementary Data II-3: Marginally significant Gene Ontology Terms post REVIGO comparing ASD-related meQTL 
targets to meQTL targets generally in peripheral blood. P.DE refers to p-value for enrichment as computed by gometh() function 
in MissMethyl R package. Scaled Rank is computed as rank divided by the total number of terms in the list (n = 95). 
GO ID Term P.DE Rank ScaledRank 
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II 0.000123 1 0.01 
GO:0002505 antigen processing and presentation of polysaccharide antigen via MHC class II 0.000192 2 0.02 
GO:0002506 polysaccharide assembly with MHC class II protein complex 0.000192 3 0.03 
GO:0071823 protein-carbohydrate complex subunit organization 0.000192 4 0.04 
GO:0031295 T cell costimulation 0.000816 5 0.05 
GO:0002396 MHC protein complex assembly 0.001139 6 0.06 
GO:0060333 interferon-gamma-mediated signaling pathway 0.001607 7 0.07 
GO:0050851 antigen receptor-mediated signaling pathway 0.002121 8 0.08 
GO:0046887 positive regulation of hormone secretion 0.0043 9 0.09 
GO:0001783 B cell apoptotic process 0.006717 10 0.11 
GO:0030166 proteoglycan biosynthetic process 0.006887 11 0.12 
GO:1902775 mitochondrial large ribosomal subunit assembly 0.007342 12 0.13 
GO:0034341 response to interferon-gamma 0.007598 13 0.14 
GO:0045338 farnesyl diphosphate metabolic process 0.010001 14 0.15 
GO:1902856 negative regulation of nonmotile primary cilium assembly 0.010681 15 0.16 
GO:0006369 termination of RNA polymerase II transcription 0.010682 16 0.17 
GO:0032625 interleukin-21 production 0.012311 17 0.18 
GO:0072619 interleukin-21 secretion 0.012311 18 0.19 
GO:1901899 positive regulation of relaxation of cardiac muscle 0.013317 19 0.2 
GO:1902570 protein localization to nucleolus 0.013546 20 0.21 
GO:0031099 regeneration 0.013974 21 0.22 
GO:0016337 single organismal cell-cell adhesion 0.014138 22 0.23 





GO:0048024 regulation of mRNA splicing, via spliceosome 0.016621 24 0.25 
GO:0002339 B cell selection 0.016698 25 0.26 
GO:0061470 T follicular helper cell differentiation 0.017096 26 0.27 
GO:0031635 adenylate cyclase-inhibiting opioid receptor signaling pathway 0.018049 27 0.28 
GO:0051012 microtubule sliding 0.019357 28 0.29 
GO:0044060 regulation of endocrine process 0.019483 29 0.31 
GO:0042461 photoreceptor cell development 0.021344 30 0.32 
GO:0045218 zonula adherens maintenance 0.022584 31 0.33 
GO:0098602 single organism cell adhesion 0.023398 32 0.34 
GO:0030299 intestinal cholesterol absorption 0.023474 33 0.35 
GO:0048597 post-embryonic camera-type eye morphogenesis 0.023496 34 0.36 
GO:0010899 regulation of phosphatidylcholine catabolic process 0.023678 35 0.37 
GO:1900155 negative regulation of bone trabecula formation 0.024242 36 0.38 
GO:0014717 regulation of satellite cell activation involved in skeletal muscle regeneration 0.024316 37 0.39 
GO:0010046 response to mycotoxin 0.025255 38 0.4 
GO:1902572 negative regulation of serine-type peptidase activity 0.025549 39 0.41 
GO:1901509 regulation of endothelial tube morphogenesis 0.026235 40 0.42 
GO:0030091 protein repair 0.026842 41 0.43 
GO:0044272 sulfur compound biosynthetic process 0.027027 42 0.44 
GO:0032844 regulation of homeostatic process 0.027254 43 0.45 
GO:1903361 protein localization to basolateral plasma membrane 0.027412 44 0.46 
GO:0097021 lymphocyte migration into lymphoid organs 0.028288 45 0.47 
GO:1902571 regulation of serine-type peptidase activity 0.028416 46 0.48 
GO:0006285 base-excision repair, AP site formation 0.028604 47 0.49 
GO:0006029 proteoglycan metabolic process 0.029195 48 0.51 
GO:0030263 apoptotic chromosome condensation 0.029381 49 0.52 
GO:0042117 monocyte activation 0.030469 50 0.53 





GO:0043606 formamide metabolic process 0.030471 52 0.55 
GO:0032940 secretion by cell 0.030778 53 0.56 
GO:0070544 histone H3-K36 demethylation 0.031005 54 0.57 
GO:0016075 rRNA catabolic process 0.031544 55 0.58 
GO:0048852 diencephalon morphogenesis 0.032019 56 0.59 
GO:0061146 Peyer's patch morphogenesis 0.032314 57 0.6 
GO:0036124 histone H3-K9 trimethylation 0.032359 58 0.61 
GO:0042159 lipoprotein catabolic process 0.03293 59 0.62 
GO:0036301 macrophage colony-stimulating factor production 0.033104 60 0.63 
GO:1901256 regulation of macrophage colony-stimulating factor production 0.033104 61 0.64 
GO:0002440 production of molecular mediator of immune response 0.033722 62 0.65 
GO:0009223 pyrimidine deoxyribonucleotide catabolic process 0.034189 63 0.66 
GO:0008635 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c 0.034482 64 0.67 
GO:0046349 amino sugar biosynthetic process 0.034833 65 0.68 
GO:1901565 organonitrogen compound catabolic process 0.036166 66 0.69 
GO:0006024 glycosaminoglycan biosynthetic process 0.037186 67 0.71 
GO:0045471 response to ethanol 0.037351 68 0.72 
GO:0031124 mRNA 3'-end processing 0.037546 69 0.73 
GO:0006641 triglyceride metabolic process 0.038112 70 0.74 
GO:0006987 activation of signaling protein activity involved in unfolded protein response 0.038374 71 0.75 
GO:0010225 response to UV-C 0.038784 72 0.76 
GO:0030202 heparin metabolic process 0.038807 73 0.77 
GO:0030210 heparin biosynthetic process 0.038807 74 0.78 
GO:1900745 positive regulation of p38MAPK cascade 0.041265 75 0.79 
GO:0032471 negative regulation of endoplasmic reticulum calcium ion concentration 0.041845 76 0.8 
GO:0006488 dolichol-linked oligosaccharide biosynthetic process 0.042594 77 0.81 
GO:0006490 oligosaccharide-lipid intermediate biosynthetic process 0.042594 78 0.82 





GO:0030521 androgen receptor signaling pathway 0.043956 80 0.84 
GO:0002407 dendritic cell chemotaxis 0.044505 81 0.85 
GO:0042118 endothelial cell activation 0.044915 82 0.86 
GO:0000185 activation of MAPKKK activity 0.045366 83 0.87 
GO:0014719 skeletal muscle satellite cell activation 0.04705 84 0.88 
GO:0006353 DNA-templated transcription, termination 0.047062 85 0.89 
GO:0051597 response to methylmercury 0.047182 86 0.91 
GO:0032211 negative regulation of telomere maintenance via telomerase 0.047797 87 0.92 
GO:0006638 neutral lipid metabolic process 0.047806 88 0.93 
GO:0000027 ribosomal large subunit assembly 0.047898 89 0.94 
GO:0009064 glutamine family amino acid metabolic process 0.048245 90 0.95 
GO:0006002 fructose 6-phosphate metabolic process 0.048597 91 0.96 
GO:0015942 formate metabolic process 0.048828 92 0.97 
GO:1900121 negative regulation of receptor binding 0.049665 93 0.98 
GO:0001704 formation of primary germ layer 0.049838 94 0.99 







Supplementary Data II-4: Marginally significant Gene Ontology Terms post REVIGO comparing ASD-related meQTL 
targets to meQTL targets generally in cord blood. P.DE refers to p-value for enrichment as computed by gometh() function in 





GO ID Term P.DE Rank ScaledRank 
GO:0031295 T cell costimulation 3.66E-05 1 0.01 
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response 6.16E-05 2 0.03 
GO:0046887 positive regulation of hormone secretion 6.42E-05 3 0.04 
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II 8.99E-05 4 0.05 
GO:0071346 cellular response to interferon-gamma 0.000185 5 0.07 
GO:0042088 T-helper 1 type immune response 0.000269 6 0.08 
GO:2001179 regulation of interleukin-10 secretion 0.000286 7 0.09 
GO:0034341 response to interferon-gamma 0.000305 8 0.11 
GO:0016337 single organismal cell-cell adhesion 0.000444 9 0.12 
GO:0050851 antigen receptor-mediated signaling pathway 0.000534 10 0.13 
GO:0032689 negative regulation of interferon-gamma production 0.000684 11 0.14 
GO:0098602 single organism cell adhesion 0.000803 12 0.16 
GO:0051294 establishment of spindle orientation 0.000914 13 0.17 
GO:0016045 detection of bacterium 0.001086 14 0.18 
GO:0051046 regulation of secretion 0.001438 15 0.2 
GO:0030155 regulation of cell adhesion 0.001603 16 0.21 
GO:0002440 production of molecular mediator of immune response 0.00192 17 0.22 
GO:0032673 regulation of interleukin-4 production 0.001953 18 0.24 
GO:0032613 interleukin-10 production 0.002202 19 0.25 
GO:0009595 detection of biotic stimulus 0.002516 20 0.26 
GO:0098609 cell-cell adhesion 0.002522 21 0.28 
GO:0032633 interleukin-4 production 0.002656 22 0.29 
GO:0046903 secretion 0.003056 23 0.3 
GO:0002437 inflammatory response to antigenic stimulus 0.003388 24 0.32 
GO:0007163 establishment or maintenance of cell polarity 0.004132 25 0.33 
GO:0055082 cellular chemical homeostasis 0.00453 26 0.34 





GO:0001775 cell activation 0.005234 28 0.37 
GO:0051012 microtubule sliding 0.005393 29 0.38 
GO:1902856 negative regulation of nonmotile primary cilium assembly 0.005393 30 0.39 
GO:1902572 negative regulation of serine-type peptidase activity 0.006425 31 0.41 
GO:0045785 positive regulation of cell adhesion 0.007128 32 0.42 
GO:0030091 protein repair 0.007384 33 0.43 
GO:0014717 regulation of satellite cell activation involved in skeletal muscle regeneration 0.008105 34 0.45 
GO:1901899 positive regulation of relaxation of cardiac muscle 0.008212 35 0.46 
GO:1902571 regulation of serine-type peptidase activity 0.008889 36 0.47 
GO:0007267 cell-cell signaling 0.009077 37 0.49 
GO:0045217 cell-cell junction maintenance 0.010775 38 0.5 
GO:0010817 regulation of hormone levels 0.01084 39 0.51 
GO:0021853 cerebral cortex GABAergic interneuron migration 0.012358 40 0.53 
GO:0000394 RNA splicing, via endonucleolytic cleavage and ligation 0.013606 41 0.54 
GO:1903361 protein localization to basolateral plasma membrane 0.014024 42 0.55 
GO:0032609 interferon-gamma production 0.014738 43 0.57 
GO:0002505 antigen processing and presentation of polysaccharide antigen via MHC class II 0.01674 44 0.58 
GO:0002506 polysaccharide assembly with MHC class II protein complex 0.01674 45 0.59 
GO:0071823 protein-carbohydrate complex subunit organization 0.01674 46 0.61 
GO:0097021 lymphocyte migration into lymphoid organs 0.01725 47 0.62 
GO:0014719 skeletal muscle satellite cell activation 0.020694 48 0.63 
GO:0051262 protein tetramerization 0.022051 49 0.64 
GO:0071322 cellular response to carbohydrate stimulus 0.023286 50 0.66 
GO:0070208 protein heterotrimerization 0.02422 51 0.67 
GO:0043586 tongue development 0.024362 52 0.68 
GO:0061146 Peyer's patch morphogenesis 0.024482 53 0.7 
GO:0003416 endochondral bone growth 0.024653 54 0.71 





GO:0097154 GABAergic neuron differentiation 0.026122 56 0.74 
GO:0002396 MHC protein complex assembly 0.027389 57 0.75 
GO:0050663 cytokine secretion 0.029522 58 0.76 
GO:0007155 cell adhesion 0.030223 59 0.78 
GO:0048025 negative regulation of mRNA splicing,  via spliceosome 0.030285 60 0.79 
GO:0050930 induction of positive chemotaxis 0.030321 61 0.8 
GO:0051641 cellular localization 0.030578 62 0.82 
GO:0022610 biological adhesion 0.030893 63 0.83 
GO:0006688 glycosphingolipid biosynthetic process 0.031241 64 0.84 
GO:0006887 exocytosis 0.031749 65 0.86 
GO:0060716 labyrinthine layer blood vessel development 0.032733 66 0.87 
GO:0050482 arachidonic acid secretion 0.033411 67 0.88 
GO:0043954 cellular component maintenance 0.036598 68 0.89 
GO:0010649 regulation of cell communication by electrical coupling 0.037733 69 0.91 
GO:0032844 regulation of homeostatic process 0.041279 70 0.92 
GO:0048537 mucosal-associated lymphoid tissue development 0.041796 71 0.93 
GO:0097503 sialylation 0.044311 72 0.95 
GO:0032846 positive regulation of homeostatic process 0.045836 73 0.96 
GO:0010882 regulation of cardiac muscle contraction by calcium ion signaling 0.047684 74 0.97 
GO:1902116 negative regulation of organelle assembly 0.048363 75 0.99 











Supplementary Data II-5: Marginally significant Gene Ontology Terms post REVIGO comparing ASD-related meQTL 
targets to meQTL targets generally in fetal brain. P.DE refers to p-value for enrichment as computed by gometh() function in 
MissMethyl R package. Scaled Rank is computed as rank divided by the total number of terms in the list (n = 47). 
GO ID Term P.DE Rank ScaledRank 
GO:0002480 antigen processing and presentation of exogenous peptide antigen via MHC class I,  TAP-independent 0.000194 1 0.02 
GO:0009595 detection of biotic stimulus 0.000284 2 0.04 
GO:0016045 detection of bacterium 0.000284 3 0.06 
GO:0071346 cellular response to interferon-gamma 0.000338 4 0.09 
GO:0034341 response to interferon-gamma 0.000473 5 0.11 
GO:0019884 antigen processing and presentation of exogenous antigen 0.000658 6 0.13 
GO:0019882 antigen processing and presentation 0.001485 7 0.15 
GO:0032649 regulation of interferon-gamma production 0.001906 8 0.17 
GO:0032609 interferon-gamma production 0.002266 9 0.19 
GO:0035709 memory T cell activation 0.003379 10 0.21 
GO:2000568 positive regulation of memory T cell activation 0.003379 11 0.23 
GO:0019236 response to pheromone 0.003461 12 0.26 
GO:0002440 production of molecular mediator of immune response 0.004663 13 0.28 
GO:1901899 positive regulation of relaxation of cardiac muscle 0.005371 14 0.3 
GO:0043586 tongue development 0.007629 15 0.32 
GO:0042088 T-helper 1 type immune response 0.00818 16 0.34 
GO:1901844 regulation of cell communication by electrical coupling involved in cardiac conduction 0.009813 17 0.36 
GO:0002486 
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway,  
TAP-independent 
0.010066 18 0.38 
GO:0006388 tRNA splicing,  via endonucleolytic cleavage and ligation 0.011328 19 0.4 





GO:0042270 protection from natural killer cell mediated cytotoxicity 0.01277 21 0.45 
GO:0051481 negative regulation of cytosolic calcium ion concentration 0.013208 22 0.47 
GO:0048172 regulation of short-term neuronal synaptic plasticity 0.015344 23 0.49 
GO:0002369 T cell cytokine production 0.016892 24 0.51 
GO:0003416 endochondral bone growth 0.017508 25 0.53 
GO:0060314 regulation of ryanodine-sensitive calcium-release channel activity 0.019026 26 0.55 
GO:0022409 positive regulation of cell-cell adhesion 0.020701 27 0.57 
GO:0032633 interleukin-4 production 0.021045 28 0.6 
GO:0032673 regulation of interleukin-4 production 0.021045 29 0.62 
GO:0031342 negative regulation of cell killing 0.021288 30 0.64 
GO:0010644 cell communication by electrical coupling 0.021313 31 0.66 
GO:0035774 positive regulation of insulin secretion involved in cellular response to glucose stimulus 0.023315 32 0.68 
GO:0070296 sarcoplasmic reticulum calcium ion transport 0.023996 33 0.7 
GO:0008380 RNA splicing 0.024102 34 0.72 
GO:0032613 interleukin-10 production 0.026464 35 0.74 
GO:0001825 blastocyst formation 0.029925 36 0.77 
GO:0019731 antibacterial humoral response 0.030731 37 0.79 
GO:0002437 inflammatory response to antigenic stimulus 0.031129 38 0.81 
GO:0019883 antigen processing and presentation of endogenous antigen 0.033044 39 0.83 
GO:0019730 antimicrobial humoral response 0.033445 40 0.85 
GO:0051606 detection of stimulus 0.035732 41 0.87 
GO:0002704 negative regulation of leukocyte mediated immunity 0.03729 42 0.89 
GO:0006397 mRNA processing 0.037962 43 0.91 
GO:0002228 natural killer cell mediated immunity 0.039409 44 0.94 
GO:0009617 response to bacterium 0.046842 45 0.96 
GO:0071593 lymphocyte aggregation 0.04887 46 0.98 






Supplementary Data II-6: meQTL evidence for every ASD-associated (PGC p-value < 1E-4) locus. 






















Supplementary Data II-7: Enrichment Statistics comparing meQTL targets of cross-disorder PGC SNPs to meQTL targets of 
non cross disorder PGC associated SNPs. Each cell represents the results of a Fisher's  exact test examining the tendency of meQTL 
targets of significant (p <= 1E-4) SNPs (or their proxies) from the PGC cross disorder mega-analysis to overlap various functional 
regions compared to CpG sites that were also meQTL targets but not of signficant PGC cross disorder SNPs or their proxies. Green 
chromatin marks denote those typically associated with transcriptionally active chromatin; red marks denote those typically associated 
with inactive chromatin. We report the enrichment fold statistic or odds ratio and p-value. Values in parentheses in column headers 
denote the number of meQTL targets of significant PGC cross-disorder SNPs or their proxies in that tissue or that overlap in those two 
tissues (at FDR = 5% p-value for blood, cord blood, and lung and p-value = 1E-8 for fetal brain). 


















Supplementary Data II-8: Enrichment Statistics comparing meQTL targets to non-meQTL targets. Each cell represents the 
results of a Fisher's exact test examining the tendency of meQTL targets in several groups to overlap various functional regions 
compared to non-meQTL targets. Green chromatin marks denote those typically associated with transcriptionally active chromatin; 
red marks denote those typically associated with inactive chromatin. We report the enrichment fold statistic or odds ratio and p-value. 
Values in parentheses in column headers denote the number of meQTL targets in that tissue or that overlap in those two tissues (at 
FDR = 5% p-value for blood, cord blood, and lung and p-value = 1E-8 for fetal brain). 




















Table III-1: Summary of meQTL evidence across tissue type. The number of SNPs and independent sites that fall under each 
category of cross-tissue meQTL presence. Results are shown for meQTLs associated at FDR = 1% threshold in blood, cord blood, and 
placenta datasets and threshold of 1E-8 in fetal brain. Only SNPs that were included in all three tissues in their respective meQTL 
queries are included in this analysis (n = 2,620,313). Independent sites were constructed by grouping SNPs into bins defined by 
recombination hot spot data from 1000 Genomes (see Methods). For example, scenario 1 lists that there are a total of 111,574 SNPs 









SNPs % of Total SNPs 
Independent 
Sites 
% of Total Independent 
Sites 
1     111,574 4.26% 5,809 3.70% 
2     289,240 11.04% 14,744 9.40% 
3     32,409 1.24% 1,381 0.88% 
4     5,067 0.19% 397 0.25% 
5     37,567 1.43% 2,659 1.70% 
6     483,903 18.47% 25,747 16.42% 
7     3,243 0.12% 201 0.13% 
8     129,549 4.94% 9,613 6.13% 
9     494 0.02% 26 0.02% 
10     4,130 0.16% 201 0.13% 
11     62 0.00% 3 0.00% 
12     1,059 0.04% 73 0.05% 
13     5,959 0.23% 274 0.17% 
14     902,884 34.46% 48,387 30.85% 
15     1,418 0.05% 95 0.06% 
16     611,755 23.35% 47,230 30.11% 
 






Table III-2: Marginally significant Gene Ontology Terms post REVIGO comparing ASD-
related meQTL targets to meQTL targets generally in fetal brain. P.DE refers to p-value for 
enrichment as computed by gometh() function in MissMethyl R package. 
GO ID Term P.DE 
GO:0000459 exonucleolytic trimming involved in rRNA processing 0.001391 
GO:0000467 
exonucleolytic trimming to generate mature 3'-end of 5.8S rRNA from 
tricistronic rRNA transcript (SSU-rRNA,  5.8S rRNA, LSU-rRNA) 
0.001391 
GO:1990000 amyloid fibril formation 0.001479 
GO:0048143 astrocyte activation 0.001479 
GO:1903748 
negative regulation of establishment of protein localization to 
mitochondrion 
0.001479 
GO:0090258 negative regulation of mitochondrial fission 0.001479 
GO:1902988 neurofibrillary tangle assembly 0.001479 
GO:1905689 positive regulation of diacylglycerol kinase activity 0.001479 
GO:1902474 positive regulation of protein localization to synapse 0.001479 
GO:1905687 regulation of diacylglycerol kinase activity 0.001479 
GO:1902473 regulation of protein localization to synapse 0.001479 
GO:0019518 L-threonine catabolic process to glycine 0.002113 
GO:0006567 threonine catabolic process 0.002113 
GO:0031125 rRNA 3'-end processing 0.002559 
GO:0048312 intracellular distribution of mitochondria 0.003157 
GO:0072386 plus-end-directed organelle transport along microtubule 0.003259 
GO:0032930 positive regulation of superoxide anion generation 0.003557 
GO:0006566 threonine metabolic process 0.00389 
GO:0048311 mitochondrion distribution 0.004695 
GO:0010917 negative regulation of mitochondrial membrane potential 0.004979 
GO:0019896 axonal transport of mitochondrion 0.005077 
GO:0043628 ncRNA 3'-end processing 0.005654 
GO:0045837 negative regulation of membrane potential 0.005889 
GO:0032928 regulation of superoxide anion generation 0.00625 
GO:0001774 microglial cell activation 0.006514 
GO:0006544 glycine metabolic process 0.006532 
GO:0051654 establishment of mitochondrion localization 0.008162 
GO:0034643 establishment of mitochondrion localization,  microtubule-mediated 0.008162 
GO:0047497 mitochondrion transport along microtubule 0.008162 
GO:0007194 negative regulation of adenylate cyclase activity 0.008186 
GO:0090140 regulation of mitochondrial fission 0.008634 
GO:0090503 RNA phosphodiester bond hydrolysis,  exonucleolytic 0.008766 





GO:0031116 positive regulation of microtubule polymerization 0.009138 
GO:0031112 positive regulation of microtubule polymerization or depolymerization 0.009138 
GO:0031280 negative regulation of cyclase activity 0.009578 
GO:0014002 astrocyte development 0.009962 
GO:0000469 cleavage involved in rRNA processing 0.010114 
GO:0045936 negative regulation of phosphate metabolic process 0.010192 
GO:0010563 negative regulation of phosphorus metabolic process 0.010192 
GO:0051350 negative regulation of lyase activity 0.010646 
GO:0000466 
maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA,  5.8S 
rRNA,  LSU-rRNA) 
0.010703 
GO:0045773 positive regulation of axon extension 0.010922 
GO:0090322 regulation of superoxide metabolic process 0.011023 
GO:0035418 protein localization to synapse 0.011712 
GO:0048708 astrocyte differentiation 0.011882 
GO:0042554 superoxide anion generation 0.012275 
GO:0051646 mitochondrion localization 0.012275 
GO:0042116 macrophage activation 0.012587 
GO:0030818 negative regulation of cAMP biosynthetic process 0.012637 
GO:0070841 inclusion body assembly 0.012642 
GO:0007214 gamma-aminobutyric acid signaling pathway 0.012721 
GO:0031113 regulation of microtubule polymerization 0.013371 
GO:0030815 negative regulation of cAMP metabolic process 0.013622 
GO:0031122 cytoplasmic microtubule organization 0.013756 
GO:0000266 mitochondrial fission 0.013822 
GO:0050853 B cell receptor signaling pathway 0.013887 
GO:0030803 negative regulation of cyclic nucleotide biosynthetic process 0.014024 
GO:0030809 negative regulation of nucleotide biosynthetic process 0.014024 
GO:1900372 negative regulation of purine nucleotide biosynthetic process 0.014024 
GO:0000460 maturation of 5.8S rRNA 0.014332 
GO:0009069 serine family amino acid metabolic process 0.014558 
GO:0030800 negative regulation of cyclic nucleotide metabolic process 0.015008 
GO:0010823 negative regulation of mitochondrion organization 0.016394 
GO:0098930 axonal transport 0.016464 
GO:0050772 positive regulation of axonogenesis 0.01682 
GO:0031110 regulation of microtubule polymerization or depolymerization 0.017216 
GO:0008088 axo-dendritic transport 0.017388 
GO:0046785 microtubule polymerization 0.01814 
GO:0043086 negative regulation of catalytic activity 0.019029 





GO:0050848 regulation of calcium-mediated signaling 0.01963 
GO:0070201 regulation of establishment of protein localization 0.021081 
GO:0006801 superoxide metabolic process 0.021298 
GO:0009066 aspartate family amino acid metabolic process 0.021939 
GO:0032024 positive regulation of insulin secretion 0.022385 
GO:0009892 negative regulation of metabolic process 0.023193 
GO:0090277 positive regulation of peptide hormone secretion 0.023352 
GO:1900543 negative regulation of purine nucleotide metabolic process 0.023682 
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway 0.024375 
GO:0045980 negative regulation of nucleotide metabolic process 0.024684 
GO:0030516 regulation of axon extension 0.02492 
GO:0031109 microtubule polymerization or depolymerization 0.025531 
GO:0051881 regulation of mitochondrial membrane potential 0.026349 
GO:0038083 peptidyl-tyrosine autophosphorylation 0.026561 
GO:0021782 glial cell development 0.028007 
GO:0032880 regulation of protein localization 0.028023 
GO:0061387 regulation of extent of cell growth 0.028897 
GO:0048675 axon extension 0.029531 
GO:0045761 regulation of adenylate cyclase activity 0.029783 
GO:0046887 positive regulation of hormone secretion 0.029899 
GO:1903828 negative regulation of cellular protein localization 0.030214 
GO:0007613 memory 0.031193 
GO:0099111 microtubule-based transport 0.032655 
GO:0010970 transport along microtubule 0.032655 
GO:1903747 regulation of establishment of protein localization to mitochondrion 0.033539 
GO:0010770 positive regulation of cell morphogenesis involved in differentiation 0.033557 
GO:1901606 alpha-amino acid catabolic process 0.034177 
GO:0044092 negative regulation of molecular function 0.034199 
GO:1901216 positive regulation of neuron death 0.03447 
GO:0006919 
activation of cysteine-type endopeptidase activity involved in apoptotic 
process 
0.035086 
GO:2000379 positive regulation of reactive oxygen species metabolic process 0.035188 
GO:1900034 regulation of cellular response to heat 0.035714 
GO:0031279 regulation of cyclase activity 0.035981 
GO:0006796 phosphate-containing compound metabolic process 0.035984 
GO:0051339 regulation of lyase activity 0.036125 
GO:0009063 cellular amino acid catabolic process 0.036205 





GO:0030817 regulation of cAMP biosynthetic process 0.036764 
GO:0006793 phosphorus metabolic process 0.03795 
GO:0030705 cytoskeleton-dependent intracellular transport 0.038996 
GO:0031047 gene silencing by RNA 0.039264 
GO:0031123 RNA 3'-end processing 0.039891 
GO:0009190 cyclic nucleotide biosynthetic process 0.040056 
GO:0052652 cyclic purine nucleotide metabolic process 0.040056 
GO:0030802 regulation of cyclic nucleotide biosynthetic process 0.040056 
GO:0030808 regulation of nucleotide biosynthetic process 0.040056 
GO:1900371 regulation of purine nucleotide biosynthetic process 0.040056 
GO:0030814 regulation of cAMP metabolic process 0.04146 
GO:0019722 calcium-mediated signaling 0.041882 
GO:0070507 regulation of microtubule cytoskeleton organization 0.042236 
GO:2001020 regulation of response to DNA damage stimulus 0.04225 
GO:0050770 regulation of axonogenesis 0.042585 
GO:0032273 positive regulation of protein polymerization 0.04261 
GO:0043280 
positive regulation of cysteine-type endopeptidase activity involved in 
apoptotic process 
0.044364 
GO:0030799 regulation of cyclic nucleotide metabolic process 0.044738 
GO:0072655 establishment of protein localization to mitochondrion 0.045406 
GO:2001056 positive regulation of cysteine-type endopeptidase activity 0.045423 
GO:1990138 neuron projection extension 0.045583 
GO:0010001 glial cell differentiation 0.046054 
GO:0046058 cAMP metabolic process 0.046621 
GO:0007188 
adenylate cyclase-modulating G-protein coupled receptor signaling 
pathway 
0.047007 
GO:0070585 protein localization to mitochondrion 0.047026 
GO:0030307 positive regulation of cell growth 0.047315 
GO:0010950 positive regulation of endopeptidase activity 0.047851 
GO:0048639 positive regulation of developmental growth 0.049279 











Table III-3: Marginally significant Gene Ontology Terms post REVIGO comparing ASD-
related meQTL targets to meQTL targets generally in peripheral blood. P.DE refers to p-
value for enrichment as computed by gometh() function in MissMethyl R package. 
GO ID Term P.DE 
GO:0010976 positive regulation of neuron projection development 0.002244 
GO:1903944 negative regulation of hepatocyte apoptotic process 0.002667 
GO:1901740 negative regulation of myoblast fusion 0.002667 
GO:1903943 regulation of hepatocyte apoptotic process 0.002667 
GO:1905474 canonical Wnt signaling pathway involved in stem cell proliferation 0.00345 
GO:0060064 Spemann organizer formation at the anterior end of the primitive streak 0.00345 
GO:1904744 positive regulation of telomeric DNA binding 0.003606 
GO:0030307 positive regulation of cell growth 0.003877 
GO:1990138 neuron projection extension 0.004527 
GO:0045338 farnesyl diphosphate metabolic process 0.004586 
GO:0044108 cellular alcohol biosynthetic process 0.004586 
GO:0044107 cellular alcohol metabolic process 0.004586 
GO:0006696 ergosterol biosynthetic process 0.004586 
GO:0008204 ergosterol metabolic process 0.004586 
GO:0016129 phytosteroid biosynthetic process 0.004586 
GO:0016128 phytosteroid metabolic process 0.004586 
GO:0032413 negative regulation of ion transmembrane transporter activity 0.005059 
GO:0035934 corticosterone secretion 0.005255 
GO:2000852 regulation of corticosterone secretion 0.005255 
GO:0048639 positive regulation of developmental growth 0.005342 
GO:1904063 negative regulation of cation transmembrane transport 0.005813 
GO:0019518 L-threonine catabolic process to glycine 0.005905 
GO:0006567 threonine catabolic process 0.005905 
GO:0034242 negative regulation of syncytium formation by plasma membrane fusion 0.006124 
GO:0045666 positive regulation of neuron differentiation 0.006242 
GO:1905689 positive regulation of diacylglycerol kinase activity 0.006458 
GO:1905687 regulation of diacylglycerol kinase activity 0.006458 





GO:0071376 cellular response to corticotropin-releasing hormone stimulus 0.006867 
GO:0043435 response to corticotropin-releasing hormone 0.006867 
GO:0060061 Spemann organizer formation 0.006881 
GO:0031346 positive regulation of cell projection organization 0.006986 
GO:2001288 positive regulation of caveolin-mediated endocytosis 0.007227 
GO:1904751 positive regulation of protein localization to nucleolus 0.007547 
GO:0048697 positive regulation of collateral sprouting in absence of injury 0.007722 
GO:0048696 regulation of collateral sprouting in absence of injury 0.007722 
GO:0032410 negative regulation of transporter activity 0.007849 
GO:0051458 corticotropin secretion 0.007862 
GO:1902988 neurofibrillary tangle assembly 0.008241 
GO:0045008 depyrimidination 0.008417 
GO:0006285 base-excision repair,  AP site formation 0.008742 
GO:0034766 negative regulation of ion transmembrane transport 0.009037 
GO:0044338 
canonical Wnt signaling pathway involved in mesenchymal stem cell 
differentiation 
0.009238 
GO:0006566 threonine metabolic process 0.009529 
GO:0000459 exonucleolytic trimming involved in rRNA processing 0.009643 
GO:0000467 
exonucleolytic trimming to generate mature 3'-end of 5.8S rRNA from 
tricistronic rRNA transcript (SSU-rRNA,  5.8S rRNA,  LSU-rRNA) 
0.009643 
GO:1904742 regulation of telomeric DNA binding 0.009767 
GO:1990000 amyloid fibril formation 0.010146 
GO:1904954 
canonical Wnt signaling pathway involved in midbrain dopaminergic 
neuron differentiation 
0.010299 
GO:0048588 developmental cell growth 0.010354 
GO:0034763 negative regulation of transmembrane transport 0.010617 
GO:0048143 astrocyte activation 0.010981 
GO:0031125 rRNA 3'-end processing 0.011038 
GO:1904749 regulation of protein localization to nucleolus 0.011184 
GO:0097384 cellular lipid biosynthetic process 0.011208 





GO:0072126 positive regulation of glomerular mesangial cell proliferation 0.011449 
GO:1902570 protein localization to nucleolus 0.012034 
GO:0048312 intracellular distribution of mitochondria 0.012359 
GO:0044339 canonical Wnt signaling pathway involved in osteoblast differentiation 0.012709 
GO:0060560 developmental growth involved in morphogenesis 0.013214 
GO:0050772 positive regulation of axonogenesis 0.013303 
GO:0014732 skeletal muscle atrophy 0.013363 
GO:0014891 striated muscle atrophy 0.013363 
GO:0045927 positive regulation of growth 0.01396 
GO:2000347 positive regulation of hepatocyte proliferation 0.014205 
GO:0090258 negative regulation of mitochondrial fission 0.014302 
GO:2001286 regulation of caveolin-mediated endocytosis 0.014647 
GO:0030516 regulation of axon extension 0.014911 
GO:1903748 
negative regulation of establishment of protein localization to 
mitochondrion 
0.015266 
GO:0014842 regulation of skeletal muscle satellite cell proliferation 0.015531 
GO:0010975 regulation of neuron projection development 0.01572 
GO:0009223 pyrimidine deoxyribonucleotide catabolic process 0.015729 
GO:0045761 regulation of adenylate cyclase activity 0.016017 
GO:0048669 collateral sprouting in absence of injury 0.016873 
GO:0030091 protein repair 0.01693 
GO:0090193 positive regulation of glomerulus development 0.01712 
GO:1901724 positive regulation of cell proliferation involved in kidney development 0.017182 
GO:0044340 canonical Wnt signaling pathway involved in regulation of cell proliferation 0.017339 
GO:0048311 mitochondrion distribution 0.017531 
GO:0014866 skeletal myofibril assembly 0.017545 
GO:0010720 positive regulation of cell development 0.017596 
GO:0043628 ncRNA 3'-end processing 0.018464 
GO:0072386 plus-end-directed organelle transport along microtubule 0.018529 
GO:0006244 pyrimidine nucleotide catabolic process 0.018637 
GO:0014841 skeletal muscle satellite cell proliferation 0.018905 





GO:0051962 positive regulation of nervous system development 0.019615 
GO:0031279 regulation of cyclase activity 0.020282 
GO:0061387 regulation of extent of cell growth 0.020375 
GO:0014857 regulation of skeletal muscle cell proliferation 0.020672 
GO:0051339 regulation of lyase activity 0.020767 
GO:2000009 negative regulation of protein localization to cell surface 0.020881 
GO:1902306 negative regulation of sodium ion transmembrane transport 0.02129 
GO:2000650 negative regulation of sodium ion transmembrane transporter activity 0.02129 
GO:0035933 glucocorticoid secretion 0.021527 
GO:2000849 regulation of glucocorticoid secretion 0.021527 
GO:0032211 negative regulation of telomere maintenance via telomerase 0.021735 
GO:0072124 regulation of glomerular mesangial cell proliferation 0.021807 
GO:0071732 cellular response to nitric oxide 0.022146 
GO:0019896 axonal transport of mitochondrion 0.022424 
GO:0043981 histone H4-K5 acetylation 0.022479 
GO:0043982 histone H4-K8 acetylation 0.022479 
GO:0048666 neuron development 0.022945 
GO:0048675 axon extension 0.023532 
GO:0010579 
positive regulation of adenylate cyclase activity involved in G-protein 
coupled receptor signaling pathway 
0.023714 
GO:0010578 
regulation of adenylate cyclase activity involved in G-protein coupled 
receptor signaling pathway 
0.023714 
GO:0072584 caveolin-mediated endocytosis 0.023727 
GO:0014856 skeletal muscle cell proliferation 0.024029 
GO:0006883 cellular sodium ion homeostasis 0.024351 
GO:0048638 regulation of developmental growth 0.024425 
GO:0010917 negative regulation of mitochondrial membrane potential 0.02462 
GO:0043271 negative regulation of ion transport 0.024625 
GO:0060174 limb bud formation 0.024744 
GO:0014889 muscle atrophy 0.025036 
GO:0010766 negative regulation of sodium ion transport 0.025336 





GO:1902474 positive regulation of protein localization to synapse 0.02546 
GO:1902473 regulation of protein localization to synapse 0.02546 
GO:0097284 hepatocyte apoptotic process 0.025485 
GO:0071731 response to nitric oxide 0.025686 
GO:2000345 regulation of hepatocyte proliferation 0.025919 
GO:0032930 positive regulation of superoxide anion generation 0.026001 
GO:0009264 deoxyribonucleotide catabolic process 0.026022 
GO:0046386 deoxyribose phosphate catabolic process 0.026022 
GO:0048672 positive regulation of collateral sprouting 0.02606 
GO:0090192 regulation of glomerulus development 0.02742 
GO:0048843 negative regulation of axon extension involved in axon guidance 0.027571 
GO:0009219 pyrimidine deoxyribonucleotide metabolic process 0.027646 
GO:0043280 
positive regulation of cysteine-type endopeptidase activity involved in 
apoptotic process 
0.027707 
GO:0032928 regulation of superoxide anion generation 0.029548 
GO:0006544 glycine metabolic process 0.029966 
GO:0045837 negative regulation of membrane potential 0.030087 
GO:1902170 cellular response to reactive nitrogen species 0.030179 
GO:2001056 positive regulation of cysteine-type endopeptidase activity 0.030342 
GO:1902668 negative regulation of axon guidance 0.030382 
GO:0010832 negative regulation of myotube differentiation 0.030754 
GO:0043984 histone H4-K16 acetylation 0.030825 
GO:1901722 regulation of cell proliferation involved in kidney development 0.030939 
GO:1904953 
Wnt signaling pathway involved in midbrain dopaminergic neuron 
differentiation 
0.032022 
GO:0051974 negative regulation of telomerase activity 0.032037 
GO:0060544 regulation of necroptotic process 0.032064 
GO:0000466 
maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S 
rRNA,  LSU-rRNA) 
0.03232 
GO:0001774 microglial cell activation 0.032607 
GO:0051129 negative regulation of cellular component organization 0.032883 





GO:0072575 epithelial cell proliferation involved in liver morphogenesis 0.03364 
GO:0072574 hepatocyte proliferation 0.03364 
GO:0006171 cAMP biosynthetic process 0.033713 
GO:1901739 regulation of myoblast fusion 0.033936 
GO:1903828 negative regulation of cellular protein localization 0.034803 
GO:1903427 negative regulation of reactive oxygen species biosynthetic process 0.035122 
GO:0048589 developmental growth 0.035222 
GO:0010950 positive regulation of endopeptidase activity 0.035271 
GO:1901017 negative regulation of potassium ion transmembrane transporter activity 0.0356 
GO:0035930 corticosteroid hormone secretion 0.035966 
GO:2000846 regulation of corticosteroid hormone secretion 0.035966 
GO:0008299 isoprenoid biosynthetic process 0.036425 
GO:0007567 parturition 0.037001 
GO:0034643 establishment of mitochondrion localization,  microtubule-mediated 0.037073 
GO:0047497 mitochondrion transport along microtubule 0.037073 
GO:0001704 formation of primary germ layer 0.037562 
GO:0009068 aspartate family amino acid catabolic process 0.037635 
GO:0072576 liver morphogenesis 0.037735 
GO:0072497 mesenchymal stem cell differentiation 0.038203 
GO:1901020 negative regulation of calcium ion transmembrane transporter activity 0.038871 
GO:0010667 negative regulation of cardiac muscle cell apoptotic process 0.039004 
GO:0072109 glomerular mesangium development 0.03921 
GO:1904357 negative regulation of telomere maintenance via telomere lengthening 0.039571 
GO:0051654 establishment of mitochondrion localization 0.039936 
GO:0030802 regulation of cyclic nucleotide biosynthetic process 0.039972 
GO:0031344 regulation of cell projection organization 0.040585 
GO:0043501 skeletal muscle adaptation 0.040741 
GO:0010770 positive regulation of cell morphogenesis involved in differentiation 0.041136 
GO:0030814 regulation of cAMP metabolic process 0.041718 





GO:0000460 maturation of 5.8S rRNA 0.041969 
GO:0009950 dorsal/ventral axis specification 0.042 
GO:0009890 negative regulation of biosynthetic process 0.042137 
GO:0090503 RNA phosphodiester bond hydrolysis,  exonucleolytic 0.042248 
GO:0010664 negative regulation of striated muscle cell apoptotic process 0.042319 
GO:0090322 regulation of superoxide metabolic process 0.042876 
GO:2000377 regulation of reactive oxygen species metabolic process 0.043127 
GO:0045664 regulation of neuron differentiation 0.043179 
GO:0010952 positive regulation of peptidase activity 0.043389 
GO:0000469 cleavage involved in rRNA processing 0.04405 
GO:0009190 cyclic nucleotide biosynthetic process 0.044074 
GO:0052652 cyclic purine nucleotide metabolic process 0.044074 
GO:1901380 negative regulation of potassium ion transmembrane transport 0.044086 
GO:0070198 protein localization to chromosome,  telomeric region 0.04426 
GO:2000831 regulation of steroid hormone secretion 0.044276 
GO:0035929 steroid hormone secretion 0.044276 
GO:0072111 cell proliferation involved in kidney development 0.045288 
GO:0031116 positive regulation of microtubule polymerization 0.045883 
GO:0008361 regulation of cell size 0.046025 
GO:1900371 regulation of purine nucleotide biosynthetic process 0.046116 
GO:0009394 2'-deoxyribonucleotide metabolic process 0.04653 
GO:0019692 deoxyribose phosphate metabolic process 0.04653 
GO:0042554 superoxide anion generation 0.04658 
GO:0090140 regulation of mitochondrial fission 0.046653 
GO:0030808 regulation of nucleotide biosynthetic process 0.046927 
GO:0001558 regulation of cell growth 0.047192 
GO:1903861 positive regulation of dendrite extension 0.047624 
GO:0048841 regulation of axon extension involved in axon guidance 0.047822 
GO:0007188 
adenylate cyclase-modulating G-protein coupled receptor signaling 
pathway 
0.048497 





GO:1903055 positive regulation of extracellular matrix organization 0.049434 





























Table III-4: Marginally significant Gene Ontology Terms post REVIGO comparing ASD-
related meQTL targets to meQTL targets generally in cord blood. P.DE refers to p-value for 
enrichment as computed by gometh() function in MissMethyl R package. 
GO ID Term P.DE 
GO:0044108 cellular alcohol biosynthetic process 0.002662 
GO:0044107 cellular alcohol metabolic process 0.002662 
GO:0006696 ergosterol biosynthetic process 0.002662 
GO:0008204 ergosterol metabolic process 0.002662 
GO:0045338 farnesyl diphosphate metabolic process 0.002662 
GO:0016129 phytosteroid biosynthetic process 0.002662 
GO:0016128 phytosteroid metabolic process 0.002662 
GO:0043280 
positive regulation of cysteine-type endopeptidase activity involved in 
apoptotic process 
0.003229 
GO:2001056 positive regulation of cysteine-type endopeptidase activity 0.003486 
GO:1990138 neuron projection extension 0.003623 
GO:1902988 neurofibrillary tangle assembly 0.003711 
GO:1905689 positive regulation of diacylglycerol kinase activity 0.003711 
GO:1905687 regulation of diacylglycerol kinase activity 0.003711 
GO:0010950 positive regulation of endopeptidase activity 0.003917 
GO:2001288 positive regulation of caveolin-mediated endocytosis 0.004093 
GO:0097384 cellular lipid biosynthetic process 0.004192 
GO:0090258 negative regulation of mitochondrial fission 0.004346 
GO:2001286 regulation of caveolin-mediated endocytosis 0.004803 
GO:0051345 positive regulation of hydrolase activity 0.004888 
GO:0010952 positive regulation of peptidase activity 0.004905 
GO:0048639 positive regulation of developmental growth 0.005188 
GO:1990000 amyloid fibril formation 0.005378 
GO:0006883 cellular sodium ion homeostasis 0.005816 
GO:1903748 
negative regulation of establishment of protein localization to 
mitochondrion 
0.005872 
GO:0030307 positive regulation of cell growth 0.005999 
GO:0048143 astrocyte activation 0.006494 
GO:1903828 negative regulation of cellular protein localization 0.006535 
GO:0072386 plus-end-directed organelle transport along microtubule 0.007035 
GO:0043981 histone H4-K5 acetylation 0.00733 
GO:0043982 histone H4-K8 acetylation 0.00733 
GO:0043281 
regulation of cysteine-type endopeptidase activity involved in apoptotic 
process 
0.00772 





GO:0048588 developmental cell growth 0.007756 
GO:0019896 axonal transport of mitochondrion 0.007856 
GO:1902474 positive regulation of protein localization to synapse 0.008461 
GO:1902473 regulation of protein localization to synapse 0.008461 
GO:0051654 establishment of mitochondrion localization 0.008538 
GO:0034643 establishment of mitochondrion localization,  microtubule-mediated 0.008538 
GO:0047497 mitochondrion transport along microtubule 0.008538 
GO:0060560 developmental growth involved in morphogenesis 0.008583 
GO:2000116 regulation of cysteine-type endopeptidase activity 0.008616 
GO:2000009 negative regulation of protein localization to cell surface 0.009069 
GO:0065009 regulation of molecular function 0.009501 
GO:0048312 intracellular distribution of mitochondria 0.009524 
GO:1901017 negative regulation of potassium ion transmembrane transporter activity 0.010909 
GO:0010917 negative regulation of mitochondrial membrane potential 0.01134 
GO:0001774 microglial cell activation 0.011414 
GO:0045927 positive regulation of growth 0.011608 
GO:0048311 mitochondrion distribution 0.012047 
GO:1902306 negative regulation of sodium ion transmembrane transport 0.01231 
GO:2000650 negative regulation of sodium ion transmembrane transporter activity 0.01231 
GO:0010766 negative regulation of sodium ion transport 0.012836 
GO:0051336 regulation of hydrolase activity 0.012927 
GO:0072584 caveolin-mediated endocytosis 0.013271 
GO:0048638 regulation of developmental growth 0.014013 
GO:1903861 positive regulation of dendrite extension 0.014028 
GO:1903859 regulation of dendrite extension 0.014028 
GO:0010976 positive regulation of neuron projection development 0.014505 
GO:0045837 negative regulation of membrane potential 0.014517 
GO:0008299 isoprenoid biosynthetic process 0.01462 
GO:1901380 negative regulation of potassium ion transmembrane transport 0.015179 
GO:0090140 regulation of mitochondrial fission 0.015355 
GO:0032930 positive regulation of superoxide anion generation 0.015883 
GO:0032928 regulation of superoxide anion generation 0.016347 
GO:0050790 regulation of catalytic activity 0.016587 
GO:0097484 dendrite extension 0.016698 
GO:0098930 axonal transport 0.017406 
GO:0014002 astrocyte development 0.018291 
GO:0070841 inclusion body assembly 0.018339 





GO:0051646 mitochondrion localization 0.0205 
GO:0043267 negative regulation of potassium ion transport 0.021921 
GO:0045862 positive regulation of proteolysis 0.022254 
GO:0043085 positive regulation of catalytic activity 0.022919 
GO:0045666 positive regulation of neuron differentiation 0.023435 
GO:0052547 regulation of peptidase activity 0.023626 
GO:0042554 superoxide anion generation 0.024071 
GO:0007194 negative regulation of adenylate cyclase activity 0.024392 
GO:0031280 negative regulation of cyclase activity 0.024392 
GO:0031116 positive regulation of microtubule polymerization 0.02496 
GO:0007214 gamma-aminobutyric acid signaling pathway 0.025053 
GO:0032467 positive regulation of cytokinesis 0.025339 
GO:2000008 regulation of protein localization to cell surface 0.02547 
GO:0008088 axo-dendritic transport 0.025526 
GO:0010823 negative regulation of mitochondrion organization 0.025551 
GO:0055078 sodium ion homeostasis 0.025642 
GO:0000266 mitochondrial fission 0.025833 
GO:0060306 regulation of membrane repolarization 0.026395 
GO:0090322 regulation of superoxide metabolic process 0.026451 
GO:0051350 negative regulation of lyase activity 0.027288 
GO:0050853 B cell receptor signaling pathway 0.027829 
GO:0086009 membrane repolarization 0.028288 
GO:0031346 positive regulation of cell projection organization 0.028524 
GO:0042116 macrophage activation 0.028561 
GO:0006695 cholesterol biosynthetic process 0.029215 
GO:1902653 secondary alcohol biosynthetic process 0.029215 
GO:0070936 protein K48-linked ubiquitination 0.029337 
GO:1901016 regulation of potassium ion transmembrane transporter activity 0.029455 
GO:0050769 positive regulation of neurogenesis 0.030632 
GO:0032880 regulation of protein localization 0.030752 
GO:0086005 ventricular cardiac muscle cell action potential 0.031326 
GO:0031112 positive regulation of microtubule polymerization or depolymerization 0.031797 
GO:0003254 regulation of membrane depolarization 0.03187 
GO:0045773 positive regulation of axon extension 0.032106 
GO:0044092 negative regulation of molecular function 0.03228 
GO:0006513 protein monoubiquitination 0.032499 
GO:0030818 negative regulation of cAMP biosynthetic process 0.0326 
GO:0030803 negative regulation of cyclic nucleotide biosynthetic process 0.0326 





GO:0031113 regulation of microtubule polymerization 0.03442 
GO:0030809 negative regulation of nucleotide biosynthetic process 0.034587 
GO:1900372 negative regulation of purine nucleotide biosynthetic process 0.034587 
GO:0030815 negative regulation of cAMP metabolic process 0.034826 
GO:0030800 negative regulation of cyclic nucleotide metabolic process 0.034826 
GO:0072384 organelle transport along microtubule 0.035202 
GO:0016126 sterol biosynthetic process 0.036787 
GO:0043967 histone H4 acetylation 0.037702 
GO:0034394 protein localization to cell surface 0.037777 
GO:0035418 protein localization to synapse 0.038496 
GO:0044093 positive regulation of molecular function 0.03893 
GO:0001706 endoderm formation 0.038982 
GO:2000649 regulation of sodium ion transmembrane transporter activity 0.039899 
GO:0032413 negative regulation of ion transmembrane transporter activity 0.040227 
GO:0045934 
negative regulation of nucleobase-containing compound metabolic 
process 
0.041205 
GO:0010975 regulation of neuron projection development 0.041796 
GO:0042391 regulation of membrane potential 0.041935 
GO:0010720 positive regulation of cell development 0.042406 
GO:0022604 regulation of cell morphogenesis 0.042883 
GO:1904063 negative regulation of cation transmembrane transport 0.042933 
GO:0051962 positive regulation of nervous system development 0.043027 
GO:0048708 astrocyte differentiation 0.043568 
GO:0086002 cardiac muscle cell action potential involved in contraction 0.044143 
GO:0031122 cytoplasmic microtubule organization 0.044494 
GO:1902305 regulation of sodium ion transmembrane transport 0.044882 
GO:0051781 positive regulation of cell division 0.045409 
GO:0050772 positive regulation of axonogenesis 0.045825 
GO:0016049 cell growth 0.045833 
GO:0051881 regulation of mitochondrial membrane potential 0.046107 
GO:0046785 microtubule polymerization 0.046366 
GO:0030104 water homeostasis 0.046827 
GO:0050848 regulation of calcium-mediated signaling 0.047181 
GO:0006801 superoxide metabolic process 0.049141 







Table III-5: Marginally significant Gene Ontology Terms post REVIGO comparing ASD-
related meQTL targets to meQTL targets generally in placenta. P.DE refers to p-value for 
enrichment as computed by gometh() function in MissMethyl R package. 
GO ID Term P.DE 
GO:1904744 positive regulation of telomeric DNA binding 0.000407 
GO:0039506 modulation by virus of host molecular function 0.00054 
GO:0039507 suppression by virus of host molecular function 0.00054 
GO:0039513 suppression by virus of host catalytic activity 0.00054 
GO:0039516 modulation by virus of host catalytic activity 0.00054 
GO:0039650 
suppression by virus of host cysteine-type endopeptidase activity 
involved in apoptotic process 
0.00054 
GO:0052053 negative regulation by symbiont of host catalytic activity 0.00054 
GO:0052055 modulation by symbiont of host molecular function 0.00054 
GO:0052056 negative regulation by symbiont of host molecular function 0.00054 
GO:0052148 modulation by symbiont of host catalytic activity 0.00054 
GO:0052199 
negative regulation of catalytic activity in other organism involved in 
symbiotic interaction 
0.00054 
GO:0098939 dendritic transport of mitochondrion 0.000664 
GO:0098972 anterograde dendritic transport of mitochondrion 0.000664 
GO:0005979 regulation of glycogen biosynthetic process 0.001391 
GO:0010962 regulation of glucan biosynthetic process 0.001391 
GO:0019050 suppression by virus of host apoptotic process 0.00161 
GO:0039526 modulation by virus of host apoptotic process 0.00161 
GO:0032885 regulation of polysaccharide biosynthetic process 0.002221 
GO:0033668 negative regulation by symbiont of host apoptotic process 0.002259 
GO:0052041 negative regulation by symbiont of host programmed cell death 0.002259 
GO:0052490 
negative regulation by organism of programmed cell death in other 
organism involved in symbiotic interaction 
0.002259 
GO:0070873 regulation of glycogen metabolic process 0.002439 
GO:1904742 regulation of telomeric DNA binding 0.002984 
GO:0032881 regulation of polysaccharide metabolic process 0.003495 
GO:0052203 




syncytiotrophoblast cell differentiation involved in labyrinthine layer 
development 
0.003696 
GO:0045494 photoreceptor cell maintenance 0.003762 
GO:0052150 modulation by symbiont of host apoptotic process 0.004051 
GO:0005978 glycogen biosynthetic process 0.00425 





GO:0090503 RNA phosphodiester bond hydrolysis,  exonucleolytic 0.004558 
GO:0006397 mRNA processing 0.004727 
GO:1903527 positive regulation of membrane tubulation 0.00522 
GO:0046677 response to antibiotic 0.005269 
GO:0098935 dendritic transport 0.005487 
GO:0098937 anterograde dendritic transport 0.005487 
GO:0090282 
positive regulation of transcription involved in G2/M transition of 
mitotic cell cycle 
0.005825 
GO:0006396 RNA processing 0.005891 
GO:2001288 positive regulation of caveolin-mediated endocytosis 0.005944 
GO:0000377 
RNA splicing, via transesterification reactions with bulged adenosine 
as nucleophile 
0.006155 
GO:0000398 mRNA splicing, via spliceosome 0.006155 
GO:0000375 RNA splicing, via transesterification reactions 0.006285 
GO:0071931 
positive regulation of transcription involved in G1/S transition of 
mitotic cell cycle 
0.006339 
GO:0044531 modulation of programmed cell death in other organism 0.00718 
GO:0044532 modulation of apoptotic process in other organism 0.00718 
GO:0052040 modulation by symbiont of host programmed cell death 0.00718 
GO:0052248 




modulation by organism of apoptotic process in other organism 
involved in symbiotic interaction 
0.00718 
GO:0000117 
regulation of transcription involved in G2/M transition of mitotic cell 
cycle 
0.007233 
GO:0000738 DNA catabolic process, exonucleolytic 0.007283 
GO:0033692 cellular polysaccharide biosynthetic process 0.007979 
GO:0000245 spliceosomal complex assembly 0.008353 
GO:0035063 nuclear speck organization 0.008601 
GO:1904751 positive regulation of protein localization to nucleolus 0.009986 
GO:0044362 negative regulation of molecular function in other organism 0.010107 
GO:0052204 
negative regulation of molecular function in other organism involved 
in symbiotic interaction 
0.010107 
GO:1901216 positive regulation of neuron death 0.010112 
GO:0000271 polysaccharide biosynthetic process 0.010769 
GO:0016052 carbohydrate catabolic process 0.011035 
GO:1903525 regulation of membrane tubulation 0.011163 
GO:0034637 cellular carbohydrate biosynthetic process 0.011268 
GO:0051725 protein de-ADP-ribosylation 0.011689 





GO:0005977 glycogen metabolic process 0.012354 
GO:0006073 cellular glucan metabolic process 0.012354 
GO:0044042 glucan metabolic process 0.012354 
GO:0051168 nuclear export 0.012871 
GO:1904749 regulation of protein localization to nucleolus 0.012892 
GO:0001895 retina homeostasis 0.012915 
GO:0044359 modulation of molecular function in other organism 0.013661 
GO:0052205 
modulation of molecular function in other organism involved in 
symbiotic interaction 
0.013661 
GO:2001286 regulation of caveolin-mediated endocytosis 0.013777 
GO:0036462 TRAIL-activated apoptotic signaling pathway 0.013832 
GO:0008380 RNA splicing 0.014365 
GO:0005981 regulation of glycogen catabolic process 0.0144 
GO:0019318 hexose metabolic process 0.014588 
GO:0097202 activation of cysteine-type endopeptidase activity 0.01512 
GO:0043255 regulation of carbohydrate biosynthetic process 0.015464 
GO:0006285 base-excision repair, AP site formation 0.015553 
GO:0045008 depyrimidination 0.015553 
GO:0043696 dedifferentiation 0.015942 
GO:0043697 cell dedifferentiation 0.015942 
GO:1903729 regulation of plasma membrane organization 0.016129 
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway 0.016191 
GO:0006112 energy reserve metabolic process 0.016881 
GO:0043470 regulation of carbohydrate catabolic process 0.017704 
GO:0071550 death-inducing signaling complex assembly 0.017706 
GO:0044264 cellular polysaccharide metabolic process 0.018014 
GO:0031125 rRNA 3'-end processing 0.018147 
GO:1902459 positive regulation of stem cell population maintenance 0.018827 
GO:1902570 protein localization to nucleolus 0.020274 
GO:0010906 regulation of glucose metabolic process 0.020515 
GO:0022613 ribonucleoprotein complex biogenesis 0.020953 
GO:0097296 
activation of cysteine-type endopeptidase activity involved in 
apoptotic signaling pathway 
0.021103 
GO:2000650 
negative regulation of sodium ion transmembrane transporter 
activity 
0.021334 
GO:0006883 cellular sodium ion homeostasis 0.022645 
GO:0032025 response to cobalt ion 0.022887 
GO:0071803 positive regulation of podosome assembly 0.023113 
GO:0043471 regulation of cellular carbohydrate catabolic process 0.023152 





GO:0006913 nucleocytoplasmic transport 0.023804 
GO:0006304 DNA modification 0.024163 
GO:1902306 negative regulation of sodium ion transmembrane transport 0.024837 
GO:0051169 nuclear transport 0.024896 
GO:0005996 monosaccharide metabolic process 0.025243 
GO:0045651 positive regulation of macrophage differentiation 0.025616 
GO:2000009 negative regulation of protein localization to cell surface 0.026107 
GO:0019317 fucose catabolic process 0.027106 
GO:0042354 L-fucose metabolic process 0.027106 
GO:0042355 L-fucose catabolic process 0.027106 
GO:0051974 negative regulation of telomerase activity 0.028299 
GO:0009223 pyrimidine deoxyribonucleotide catabolic process 0.028442 
GO:0061000 negative regulation of dendritic spine development 0.028721 
GO:0072584 caveolin-mediated endocytosis 0.02935 
GO:0034643 establishment of mitochondrion localization,  microtubule-mediated 0.030167 
GO:0047497 mitochondrion transport along microtubule 0.030167 
GO:0010766 negative regulation of sodium ion transport 0.030171 
GO:0006353, 
termination 
DNA-templated transcription, termination 0.030285 
GO:0006493 protein O-linked glycosylation 0.030557 
GO:0051654 establishment of mitochondrion localization 0.031091 
GO:0031123 RNA 3'-end processing 0.031568 
GO:2001269 
positive regulation of cysteine-type endopeptidase activity involved 
in apoptotic signaling pathway 
0.032691 
GO:0043280 
positive regulation of cysteine-type endopeptidase activity involved 
in apoptotic process 
0.033074 
GO:0045649 regulation of macrophage differentiation 0.033708 
GO:0016071 mRNA metabolic process 0.034377 
GO:1901017 
negative regulation of potassium ion transmembrane transporter 
activity 
0.034678 
GO:0030575 nuclear body organization 0.034893 
GO:1901380 negative regulation of potassium ion transmembrane transport 0.035096 
GO:0006244 pyrimidine nucleotide catabolic process 0.0352 
GO:0010675 regulation of cellular carbohydrate metabolic process 0.035527 
GO:0071801 regulation of podosome assembly 0.035967 
GO:0006004 fucose metabolic process 0.036858 
GO:0051345 positive regulation of hydrolase activity 0.03714 
GO:0051302 regulation of cell division 0.037586 
GO:0045725 positive regulation of glycogen biosynthetic process 0.037904 





GO:2001236 regulation of extrinsic apoptotic signaling pathway 0.038191 
GO:2001056 positive regulation of cysteine-type endopeptidase activity 0.038616 
GO:0090501 RNA phosphodiester bond hydrolysis 0.04007 
GO:0043467 regulation of generation of precursor metabolites and energy 0.040456 
GO:0060041 retina development in camera-type eye 0.040989 
GO:0009219 pyrimidine deoxyribonucleotide metabolic process 0.041415 
GO:0043628 ncRNA 3'-end processing 0.043752 
GO:0006486 protein glycosylation 0.043774 
GO:0043413 macromolecule glycosylation 0.043774 
GO:0016338 
calcium-independent cell-cell adhesion via plasma membrane cell-
adhesion molecules 
0.047051 
GO:0070875 positive regulation of glycogen metabolic process 0.047427 
GO:0034138 toll-like receptor 3 signaling pathway 0.047653 
GO:0070085 glycosylation 0.047803 
GO:0010977 negative regulation of neuron projection development 0.048276 
GO:0010950 positive regulation of endopeptidase activity 0.048306 
GO:1901099 negative regulation of signal transduction in absence of ligand 0.048537 
GO:2001240 
negative regulation of extrinsic apoptotic signaling pathway in 
absence of ligand 
0.048537 
GO:2000036 regulation of stem cell population maintenance 0.048947 
GO:0097320 plasma membrane tubulation 0.049208 
GO:0045821 positive regulation of glycolytic process 0.049741 
















Table III-6: Summary of evidence for PGC-AUT GWAS results being meQTLs across 4 tissue types. The number of ASD 
related (p-value <= 1E-5) SNPs and independent sites (defined via LD blocks) that fall under each category of cross-tissue meQTL. 
Results are shown for meQTLs associated at FDR = 1% threshold in blood, cord blood, and placenta datasets and threshold of 1E-8 in 
fetal brain. All SNPs in PGC, regardless of if they were tested in the respective meQTL studies, are included in this analysis. 
Independent sites were constructed by grouping SNPs into bins defined by recombination hot spot data from 1000 Genomes (see 
Materials and Methods). For example, scenario 1 lists that there are a total of 2173 SNPs that are meQTLs in blood, cord blood, and 







SNPs % of Total SNPs 
Independent 
Sites 
% of Total Independent 
Sites 
1     2173 53.96% 16 12.40% 
2     90 2.23% 10 7.75% 
3     8 0.20% 2 1.55% 
4     1 0.02% 0 0.00% 
5     0 0.00% 0 0.00% 
6     69 1.71% 9 6.98% 
7     29 0.72% 0 0.00% 
8     14 0.35% 4 3.10% 
9     684 16.99% 2 1.55% 
10     88 2.19% 4 3.10% 
11     3 0.07% 0 0.00% 
12     4 0.10% 0 0.00% 
13     23 0.57% 1 0.78% 
14     593 14.73% 35 27.13% 
15     9 0.22% 0 0.00% 
16     239 5.93% 46 35.66% 
 









Figure III-1: The relationship between significance level and SNP and CpG site distance on chromosome 21. Degree of 
significance (y-axis) defined by -log10 p-value. The degree of significance decays with increasing distance. Points are colored by 
status as a meQTL or a false positive as determined by IHW (Ignatiadis, Klaus, Zaugg, & Huber, 2016). Panel A) FDR = 5%. Panel 







Figure III-2:  Identification of ASD candidate genes through meQTL mapping in 
peripheral blood and placenta for an ASD GWAS locus identified on chromosome 20. Each 
tissue-specific panel presents, from bottom to top: genomic location, gene annotations, SNP 
locations, SNP-CpG associations, CpG locations. Light gray meQTL association lines denote all 
SNP to CpG associations in that tissue type. Dark meQTL association lines denote SNP-CpG 
associations for ASD-associated SNPs in PGC (P-value <= 1e-05). Red lines denote SNP-CpG 
associations for genome-wide significant SNP (rs910805) harbored in this locus. Data are 
presented for meQTL maps for (from top to bottom): placenta and peripheral blood.  Please note 
locus coordinates differ from those in Table 2.2 because in this context they encompass the 












Figure III-3: Mapping potential functional loci for follow up studies in placenta tissue for 
the PGC-AUT GWAS identified SNP at the MACROD2 locus on chromosome 20. The 
panels present, from bottom to top: genomic location, gene annotations, SNP locations, SNP-
CpG associations, CpG locations. Light gray meQTL association lines denote all SNP to CpG 
associations in that tissue type. Dark meQTL association lines denote SNP-CpG associations for 
ASD-associated SNPs in PGC (P-value <= 1e-05). Red lines denote SNP-CpG associations for 
genome-wide significant SNP (rs71190156) harbored in this locus. Please note locus coordinates 
differ from those in Table 2.2 because in this context they encompass the locations of meQTL 














Figure III-4: Mapping potential functional loci for follow up studies in placenta tissue for 
the PGC-AUT GWAS identified SNP at the SRPK2 locus on chromosome 7. The panels 
show, from bottom to top: genomic location, gene annotations, SNP locations, SNP-CpG 
associations, CpG locations. Light gray meQTL association lines denote all SNP to CpG 
associations in that tissue type. Dark meQTL association lines denote SNP-CpG associations for 
ASD-associated SNPs in PGC (P-value <= 1e-05).   Please note locus coordinates differ from 







Figure III-5: Mapping potential functional loci for follow up studies in placenta tissue for 
the PGC-AUT GWAS identified SNP at a genomic region on chromosome 1. The panels 
present, from bottom to top: genomic location, gene annotations, SNP locations, SNP-CpG 
associations, CpG locations. Light gray meQTL association lines denote all SNP to CpG 
associations in that tissue type. Dark meQTL association lines denote SNP-CpG associations for 
ASD-associated SNPs in PGC (P-value <= 1e-05). Red lines denote SNP-CpG associations for 
genome-wide significant SNP (rs201910565) harbored in this locus. Please note locus 
coordinates differ from those in Table 2.2 because  they encompass the locations of meQTL 















Table IV-1: Demographics table for WGBS samples included in ASD DMR and global methylation analyses. 
  Males (n = 61) 
p-value 
Females (n = 45) 
p-value 






Mean (range) 0.821a,2 
Weeks 
39.05 (35.99 - 
41.00) 





  40.01 








0.126b,2 N (%) 0.00659b,2 
White 11 (0.61) 12 (0.46) 12 (0.71)   0 6 (0.25) 13 (0.65)   
Black 5 (0.28) 6 (0.23) 1 (0.06)   0 5 (0.21) 0   
Asian 0 4 (0.15) 0   0 1 (0.04) 2 (0.1)   
Other/Missing 2 (0.11) 4 (0.15) 4 (0.24)   1 (1.00) 12 (0.5) 5 (0.25)   
Mode of 
delivery N (%) 
0.638b,1; 
0.837b,2 N (%) 0.03b,2 
Vaginal 8 (0.44) 15 (0.58) 9 (0.53)   0 12 (0.5) 14 (0.70)   
C-section 7 (0.39) 10 (0.38) 4 (0.24)   0 10 (0.42) 1 (0.05)   
Missing 3 (0.17) 1 (0.04) 4 (0.24)   1 (1.00) 2 (0.08) 5 (0.25)   










Table IV-2: Summary statistics for sex-stratified diagnostic groups for region-specific 









TD-Males 0.211 0.221 0.223 0.224 0.225 0.255 
NTD-Males 0.199 0.214 0.221 0.221 0.227 0.241 
ASD-Males 0.211 0.222 0.226 0.226 0.232 0.235 
TD-Females 0.210 0.219 0.222 0.223 0.225 0.238 









TD-Males 0.583 0.590 0.595 0.596 0.600 0.619 
NTD-Males1 0.564 0.585 0.592 0.590 0.598 0.604 
ASD-Males 0.583 0.592 0.597 0.596 0.599 0.609 
TD-Females 0.565 0.583 0.591 0.590 0.598 0.606 









TD-Males 0.707 0.712 0.717 0.718 0.724 0.735 
NTD-Males2 0.684 0.707 0.715 0.712 0.719 0.731 
ASD-Males 0.707 0.711 0.714 0.717 0.724 0.728 
TD-Females 0.682 0.704 0.714 0.713 0.724 0.732 









TD-Males 0.602 0.612 0.617 0.618 0.623 0.640 
NTD-Males3 0.555 0.602 0.611 0.608 0.617 0.632 
ASD-Males 0.597 0.609 0.613 0.615 0.620 0.632 
TD-Females 0.573 0.600 0.619 0.613 0.626 0.642 
NTD-Females 0.584 0.602 0.612 0.612 0.622 0.637 
a: 2000 bp downstream and upstream of islands; b: 2000 bp downstream and upstream of shores; 
c: measured CpG sites not in islands, shores, or shelves 1: nominally different from TD-males (t-
test p-value = 0.043); 2: nominally different from TD-males (t-test p-value = 0.037); 3: 







Figure IV-1: Top-ranked DMR for comparison of ASD (n = 18) to TD (n = 17) in males. 
Top panel: Percent methylation vs genomic position. Dashed black vertical lines represent actual 
DMR coordinates. Dashed lines represent individual samples and solid lines represent the 
average of samples of each respective diagnosis. Bottom panel: Y-axis is ratio of reads at 
measured CpG sites divided by average coverage across the whole genome, x-axis is genomic 









Figure IV-2: Second-ranked DMR for comparison of ASD (n = 18) to TD (n = 17) in males. 
Top panel: Percent methylation vs genomic position. Dashed black vertical lines represent actual 
DMR coordinates. Dashed lines represent individual samples and solid lines represent the 
average of samples of each respective diagnosis. Middle panel: Y-axis is ratio of reads at 
measured CpG sites divided by average coverage across the whole genome, x-axis is genomic 
position. This plot explores possibility of copy number differences by diagnosis. Bottom panel: 
Overlap of DMR with Gene track, CpG islands (UCSC Table Brower) and DNaseHS sites. 
Latter regions were downloaded from ENCODE for a male (GSM2400398) and female 






Figure IV-3: Third-ranked DMR for comparison of ASD (n = 18) to TD (n = 17) in males. 
Top panel: Percent methylation vs genomic position. Dashed black vertical lines represent actual 
DMR coordinates. Dashed lines represent individual samples and solid lines represent the 
average of samples of each respective diagnosis. Middle panel: Y-axis is ratio of reads at 
measured CpG sites divided by average coverage across the whole genome, x-axis is genomic 
position. This plot explores possibility of copy number differences by diagnosis. Bottom panel: 
Overlap of DMR with Gene track, CpG islands (UCSC Table Brower) and DNaseHS sites. 
Latter regions were downloaded from ENCODE for a male (GSM2400398) and female 





Figure IV-4: Top-ranked DMR for comparison of NTD (n = 26) to TD (n = 17) in males. 
Top panel: Percent methylation vs genomic position. Dashed black vertical lines represent actual 
DMR coordinates. Dashed lines represent individual samples and solid lines represent the 
average of samples of each respective diagnosis. Middle panel: Y-axis is ratio of reads at 
measured CpG sites divided by average coverage across the whole genome, x-axis is genomic 
position. This plot explores possibility of copy number differences by diagnosis. Bottom panel: 
Overlap of DMR with Gene track, CpG islands (UCSC Table Brower) and DNaseHS sites. 
Latter regions were downloaded from ENCODE for a male (GSM2400398) and female 








Figure IV-5: Second-ranked DMR for comparison of NTD (n = 26) to TD (n = 17) in males. 
Top panel: Percent methylation vs genomic position. Dashed black vertical lines represent actual 
DMR coordinates. Dashed lines represent individual samples and solid lines represent the 
average of samples of each respective diagnosis. Middle panel: Y-axis is ratio of reads at 
measured CpG sites divided by average coverage across the whole genome, x-axis is genomic 
position. This plot explores possibility of copy number differences by diagnosis. Bottom panel: 
Overlap of DMR with Gene track, CpG islands (UCSC Table Brower) and DNaseHS sites. 
Latter regions were downloaded from ENCODE for a male (GSM2400398) and female 







Figure IV-6: Third-ranked DMR for comparison of NTD (n = 26) to TD (n = 17) in males. 
Top panel: Percent methylation vs genomic position. Dashed black vertical lines represent actual 
DMR coordinates. Dashed lines represent individual samples and solid lines represent the 
average of samples of each respective diagnosis. Middle panel: Y-axis is ratio of reads at 
measured CpG sites divided by average coverage across the whole genome, x-axis is genomic 
position. This plot explores possibility of copy number differences by diagnosis. Bottom panel: 
Overlap of DMR with Gene track, CpG islands (UCSC Table Brower) and DNaseHS sites. 
Latter regions were downloaded from ENCODE for a male (GSM2400398) and female 






Figure IV-7: Top-ranked DMR for comparison of NTD (n = 24) to TD (n = 20) in females. 
Top panel: Percent methylation vs genomic position. Dashed black vertical lines represent actual 
DMR coordinates. Dashed lines represent individual samples and solid lines represent the 
average of samples of each respective diagnosis. Middle panel: Y-axis is ratio of reads at 
measured CpG sites divided by average coverage across the whole genome, x-axis is genomic 
position. This plot explores possibility of copy number differences by diagnosis. Bottom panel: 
Overlap of DMR with Gene track, CpG islands (UCSC Table Brower) and DNaseHS sites. 
Latter regions were downloaded from ENCODE for a male (GSM2400398) and female 






Figure IV-8: Second-ranked DMR for comparison of NTD (n = 24) to TD (n = 20) in 
females. Top panel: Percent methylation vs genomic position. Dashed black vertical lines 
represent actual DMR coordinates. Dashed lines represent individual samples and solid lines 
represent the average of samples of each respective diagnosis. Bottom panel: Y-axis is ratio of 
reads at measured CpG sites divided by average coverage across the whole genome, x-axis is 






Figure IV-9: Third-ranked DMR for comparison of NTD (n = 24) to TD (n = 20) in females. 
Top panel: Percent methylation vs genomic position. Dashed black vertical lines represent actual 
DMR coordinates. Dashed lines represent individual samples and solid lines represent the 
average of samples of each respective diagnosis. Middle panel: Y-axis is ratio of reads at 
measured CpG sites divided by average coverage across the whole genome, x-axis is genomic 
position. This plot explores possibility of copy number differences by diagnosis. Bottom panel: 
Overlap of DMR with Gene track, CpG islands (UCSC Table Brower) and DNaseHS sites. 
Latter regions were downloaded from ENCODE for a male (GSM2400398) and female 







Supplementary Table V-1: Sample characteristics for all 133 EARLI WGBS samples 
 Males (n=76) Females (n=57) p-value 
Diagnosis N (%) N (%) 0.004
1 
Typically Developing 17 (0.22) 20 (0.35)  
Non-Typically Developing 26 (0.34) 24 (0.42)  
Autism Spectrum Disorder 18 (0.24) 1 (0.02)  
Lost to follow up 15 (0.20) 12 (0.21)  
Gestational Age Mean (range) Mean (range) 0.604
2 
Weeks 
39.28 (35.99 - 
42.43) 
39.41 (33.86 - 
41.57)  
Race N (%) N (%) 0.467
1 
White 43 (0.57) 26 (0.46)  
Black 6 (0.08) 4 (0.07)  
Asian 12 (0.16) 8 (0.14)  
Other/Missing 15 (0.20) 19 (0.33)  
Mode of delivery N (%) N (%) 0.290
1 
Vaginal 38 (0.50) 30 (0.53)  
C-section 26 (0.34) 12 (0.21)  
Missing 12 (0.16) 15 (0.26)  
 
1: chi-square test p-value 














Supplementary Table V-2: BLAT results for ZNF300 DMR region. Results include BLAT results for reference sequence in DMR 
region and for source sequence of 9 450k probes that overlap this region.  
450k Probes Overlapping ZNF300 DMR 
ACTIONS QUERY SCORE START END QSIZE IDENTITY CHRO STRAND START END SPAN 
--------------- ----- ---------------- ------ ------ ------ -------- ----- ------ --------- ---------- ------- 
browser details cg19486756 50 1 50 50 100.00% 5 - 1.5E+08 1.5E+08 50 
browser details cg12346881 50 1 50 50 100.00% 5 - 1.5E+08 1.5E+08 50 
browser details cg04675542 50 1 50 50 100.00% 5 + 1.5E+08 1.5E+08 50 
browser details cg02343823 50 1 50 50 100.00% 5 - 1.5E+08 1.5E+08 50 
browser details cg08580836 50 1 50 50 100.00% 5 - 1.5E+08 1.5E+08 50 
browser details cg08580836 32 12 46 50 97.10% 6 + 1086171 1200162 113992 
browser details cg19014419 50 1 50 50 100.00% 5 + 1.5E+08 1.5E+08 50 
browser details cg11291313 50 1 50 50 100.00% 5 - 1.5E+08 1.5E+08 50 
browser details cg18237551 50 1 50 50 100.00% 5 - 1.5E+08 1.5E+08 50 
browser details cg21228005 50 1 50 50 100.00% 5 + 1.5E+08 1.5E+08 50 
                        
chr5:150904274-150905870 under hg38 
ACTIONS QUERY SCORE START END QSIZE IDENTITY CHRO STRAND START END SPAN 
--------------- --------- ------------ ------ ------ ------ ------- ------- --- ----------- ---------- ------- 
browser details hg38_dna 1597 1 1597 1597 100.00% 5 + 1.51E+08 1.51E+08 1597 
browser details hg38_dna 269 463 869 1597 83.50% 5 + 1.51E+08 1.51E+08 403 
browser details hg38_dna 30 1170 1254 1597 96.90% 1 + 1.54E+08 1.54E+08 233 
browser details hg38_dna 28 1199 1244 1597 66.70% 1 + 50659355 50659384 30 
browser details hg38_dna 26 1352 1381 1597 96.50% 10 + 461616 461660 45 
browser details hg38_dna 26 1352 1381 1597 96.50% 10 + 746531 746575 45 
browser details hg38_dna 26 810 836 1597 100.00% 1 + 1.94E+08 1.94E+08 483 
browser details hg38_dna 23 1182 1204 1597 100.00% 11 - 12070379 12070401 23 





browser details hg38_dna 22 405 426 1597 100.00% 7 - 37414236 37414257 22 
browser details hg38_dna 22 1182 1203 1597 100.00% 12 - 1E+08 1E+08 22 
browser details hg38_dna 22 244 265 1597 100.00% 1 - 22907061 22907082 22 
browser details hg38_dna 21 182 202 1597 100.00% 12 - 70460496 70460516 21 





















Supplementary Table V-3: Association metrics for mean ZNF300 methylation levels and 
potential key confounders. P-values shown are for linear regression of mean across 45 CpG 
sites in ZNF300 DMR vs gestational age, the first 5 principal components from genotype data, 
and mode of delivery (vaginal vs C-section).  
E(MDMRmean)= α+ β1GestationalAge+ɛ  
 Coefficient (95% Confidence Interval) p-value 
Gestational Age 0.0025 (-0.0260, 0.0309) 0.861 
E(MDMRmean)= α+ β2PC1+ β2PC2+ β3PC3+ β4PC4+ β5PC5+ɛ 
 Coefficient (95% Confidence Interval) p-value 
PC1 -1.52 (-7.95, 4.91) 0.631 
PC2 -2.09 (-9.05, 4.87) 0.541 
PC3 1.29 (-12.34, 14.93) 0.846 
PC4 -14.80 (-71.92, 42.31) 0.598 
PC5 -2.73 (-13.71, 8.26) 0.613 
E(MDMRmean)= α+ β1ModeofDelivery+ɛ  
 Coefficient (95% Confidence Interval) p-value 





















Supplementary Figure V-1: Genome-wide results for DMR identification via BSmooth. Y-
axis depicts width (bp) of null (black dots) or candidate (green dots) DMRs. X-axis depicts area 
statistics (sum of t-statistics in DMR) of null or candidate DMRs. Null DMRs are those 









Supplementary Figure V-2: Distribution of promoter-mapping TFBSs across the genome. 













Supplementary Figure V-3: Attempted replication of Roifman et al. finding relating ZNF300 promoter methylation to IUGR. 
Panel A: Percent methylation (y-axis) vs genomic position (x-axis) for WGBS EARLI samples (n = 74), samples colored by SGA 
(red, n = 6) and non-SGA (blue, n=68) status. Panel B: Same as A), but males only (nSGA = 3, ntotal = 34). Panel C: Same as A), but 
females only (nSGA = 3, ntotal = 34). Panel D: Percent methylation (y-axis) vs genomic position (x-axis) for 450K PR3 (GSE71678) 
samples (n = 338), samples colored by SGA (red, n = 19) and non-SGA (blue, n = 319) status. Panel E: Same as D), but males only 











Supplementary Figure V-4: Relationship between mean methylation levels at ZNF300 DMR and placenta morphological 
features in males and females separately. Mean DNAm levels in DMR (y-axis) vs. placental weight, perimeter, area, and maximum 
diameter (left to right, x-axis). P-values shown are for the regression of average DNAm in DMR onto each feature, adjusted for 






Supplementary Figure V-5: Manhattan plots for methylation quantitative trait loci query for SNPs related to mean ZNF300 









Supplementary Figure V-6: Full mediation analysis (SNP  Methylation  Placenta weight) results for chromosome 5 and 
chromosome X SNPs suggestively associated with ZNF300 methylation levels. Points shown indicate regression coefficients for 
SNP terms in a model with the morphological phenotype as an outcome regressed onto the SNP, birthweight and gestational age 
without (black points) and with (gray points) including average methylation in the ZNF300 DMR region. P-values and error bars are 






Supplementary Figure V-7: Full mediation analysis (SNP  Methylation  Placenta perimeter) results for chromosome 5 and 
chromosome X SNPs suggestively associated with ZNF300 methylation levels. Points shown indicate regression coefficients for 
SNP terms in a model with the morphological phenotype as an outcome regressed onto the SNP, birthweight and gestational age 
without (black points) and with (gray points) including average methylation in the ZNF300 DMR region. P-values and error bars are 






Supplementary Figure V-8: Full mediation analysis (SNP  Methylation  Placenta area) results for chromosome 5 and 
chromosome X SNPs suggestively associated with ZNF300 methylation levels. Points shown indicate regression coefficients for 
SNP terms in a model with the morphological phenotype as an outcome regressed onto the SNP, birthweight and gestational age 
without (black points) and with (gray points) including average methylation in the ZNF300 DMR region. P-values and error bars are 






Supplementary Figure V-9: Full mediation analysis (SNP  Methylation  Placenta maximum diameter) results for 
chromosome 5 and chromosome X SNPs suggestively associated with ZNF300 methylation levels. Points shown indicate 
regression coefficients for SNP terms in a model with the morphological phenotype as an outcome regressed onto the SNP, 
birthweight and gestational age without (black points) and with (gray points) including average methylation in the ZNF300 DMR 
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